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Pax6 is a member of a highly evolutionarily conserved family of transcription
factors. These genes are characterised by the presence of a 'paired-type' DNA
binding domain. Pax6 is developmentally regulated and is required for the normal
embryonic development of the central nervous system, eye and pancreas. In adults it
is thought to be involved in the correct function of the pancreas and cerebellum,
although its precise mechanism of action is not as yet fully understood.
In order to better understand Pax6 function I generated a novel tool - a 'Pax6
reporter' transgenic mouse that expresses GFP under the control of Pax6 regulatory
elements. The transgenic mouse was generated from a modified yeast artificial
chromosome (YAC) that contains the human PAX6 gene and has been previously
demonstrated to rescue loss of endogenous Pax6 in Pax6seysey mice.
The key advantages of a YAC addition transgenic include that it is already known
that Pax6 regulatory elements are present over a 200Kb region and inserting a
reporter gene into the endogenous Pax6 would not be independent of the endogenous
locus.
An expression cassette encoding GFP and an IRES-neoR vector were inserted into
the YAC in frame with the normal PAX6 translation start point in exon 4. preserving
the rest of the PAX6 locus. This put GFP and neomycin under the control of the
PAX6 regulatory elements. The modified YAC was then injected into fertilised
mouse oocytes to generate nine lines of transgenic mice.
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Once generated the expression pattern in each line was analysed at a range of
developmental stages by imaging appropriate sections of agarose embedded mouse
embryos. This confirmed that the expression was the same as the previously reported
Pax6 expression pattern. In addition, the copy number and extent of the YAC




BAC Bacterial artificial chromosome
CAT chloramphenicol acetyltransferase
CHEF Alternating Contour-Clamped Homogeneous Electric Field
CNS Central Nervous System
DNA Deoxyribonucleic Acid
E Embryonic Age (E0.5 is defined here as the day of discovering
vaginal plug)
EDTA Ethylenediaminetetraacetic acid
ES Embryonic Stem Cells
EtBr Ethidium Bromide
FACS Fluorescence Activated Cell Sorting
GFP Green Fluorescent Protein
hAP human placental alkaline phosphatase
HRP horseradish peroxidase
IRES Internal Ribosome Entry Site
LacZ Bacterial gene that encodes the protein P-galactosidase
LoxP Locus of crossover of PI
mRNA Messenger Ribonucleic Acid
neoR Neomycin Resistance
PAC PI-derived artificial chromosome
PCR Polymerase Chain Reaction
PFG Pulse Field Gel
PFGE Pulse Field Gel Electrophoresis
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Chapter 1. General Introduction-
Development of the brain
The vertebrate brain develops from the planar sheet of proliferating neuroepithelial
cells arising from the embryonic ectoderm germ layer, the neural plate. The process
of neurulation converts the neural plate into the neural tube. Briefly, folds arise in the
neural plate, appose and later fuse to form the neural tube. The process extends
rostrally and caudally in a zipper-like fashion. Some cells break off and become
neural crest cells that later contribute to the peripheral nervous system. A series of
ring-like constrictions appear in the neural tube and mark the approximate
boundaries between the primordia of the major brain regions: the forebrain
(prosencephalon), midbrain (mesencephalon), and hindbrain (rhombencephalon).
Further subdivision generates a series of segment-like swellings or neuromeres,
within each of these regions. Caudal to the hindbrain the neural tube remains a
uniformly narrow cylinder, the precursor of the spinal cord. Concurrent with
subdivision, the neural tube undergoes pronounced bending. These flexures result in
previously distant parts of the neural tube coming into close contact, see Figures 1.1
and 1.2.
The forebrain comprises two regions, the telencephalon and the diencephalon. The
telencephalic vesicles appear as two dorsolateral expansions of the primary forebrain.
These continue to enlarge disproportionately to the rest of the developing brain. The
diencephalic structures (such as the thalamus and hypothalamus) form from an
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Figure 1.1. Diagram of the mouse brain viewed from the side around mid





Figure 1.2 Schematic diagrams of the telencephalon during development. Both
diagrams are from around birth. (A) The X shows the locations of the three
sections in (B).The figures are adapted from Zaki et al., (2003).
The developing telencephalon can be divided into two areas. The dorsal
telencephalon is referred to as the pallium (this gives rise to the glutamatergic
cortical structures) and the ventral telencephalon as the subpallium (this gives rises to
the GABAergic basal ganglia). Both of these areas can be further subdivided. The
pallium can be divided into four areas. The medial pallium which gives rise to the
archicortex, including the hippocampus; the dorsal pallium where the neocortex
forms; the lateral pallium which generates the olfactory cortex and the ventral
pallium from which the claustroamygdaloid complex is generated. The subpallium
can be subdivided into two distinct domains, the lateral (LGE) and medial (MGE)
ganglionic eminences. The LGE can be further subdivided into the dorsal and lateral
ganglionic eminences. See Figure 1.3 for summary of these areas in an embryonic
day 12.5 (E12.5) mouse.
In normal development of the mouse, cortical neurogenesis occurs from embryonic
day 12 (El2) to El 8 (Gillies and Price 1993; Levers et al. 2001). At these ages, the
lateral ventricle is lined by a population of proliferating cells in a region called the
ventricular zone, which gives rise to most neurones and glial cells of the mammalian
cortex. These cortical progenitor cells are not a homogenous population and there is
mounting evidence that different progenitor cells generate different differentiated cell
types (Grove et al. 1993; Luskin et al. 1993; Reid et al. 1995; Tan et al. 1998; Heins













Figure 1.3 Schematic coronal section through the telencephalic vesicles at El 2.5
showing dorsal and ventral subdomains.Cortical Hem (CH).Medial Pallium (MP).
Dorsal Pallium(DP). Lateral Pallium (LP).Ventral Pallium (VP). Dorsal Lateral (dLGE)
and ventral lateral ganglionic eminence (vLGE). Medial ganglionic eminences
(MGE).The Figure is adapted from a figure in Schuurmans and Guillemot (2002).
Nuclei of ventricular progenitor cells undergo dynamic intracellular migration during
the cell cycle. Nuclei move away from the apical surface during Gl, occupy the outer
half of the ventricular zone during S phase and return apically in G2 so that mitosis
occurs at the ventricular surface (Sidman et al. 1959; Fujita 1964). Neurones exit the
cell cycle in contact with radial glial fibres to migrate into more superficial positions.
When neurones reach the top of the cortical plate they detach and associate into
layers with cohorts of a similar birth date. This results in the cortex being formed in
an 'inside-out' laminar fashion. After neural production has finished, astrocytes and
oligondendrocytes are produced in large numbers from precursors in the
subventricular zone (Gleeson and Walsh 2000; Morrison 2000).
The second group of neurons that cooperate in the formation of the mammalian
cortex are the tangentially migrating neurons. These GABAergic neurons originate in
the ventricular zone of the LGE and MGE; the majority originate in the MGE
(recently reviewed by (Marin and Rubenstein 2001; Nadarajah and Parnavelas
2002)). These neurones then move parallel to the surface of the brain along axons of
other neurons through the intermediate zone of the developing cortex to their final
destination in the cortex.
Cortical reqionalisation
As has been discussed above the developing telencephalon is often described as a
series of subdivisions. These subdivisions were originally based on differences in
morphology, connectivity and neurochemical profile. The mechanism behind this
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regionalisation has been contested. It is currently believed that the specification and
differentiation of neocortical areas during development are controlled by an interplay
between genetic regulation intrinsic to the neocortex and extrinsic influences arising
from outside the neocortex. The intrinsic influences are believed to be set up in the
progenitor cell layer of the cortex by regionalised expression of genes (Rakic 1988;
Dehay et al. 1993; Rakic 1995). The extrinsic influences are thought to be cues from
axons growing into the cortex later on in development, for example thalamocortical
axons (TCAs) coming from the thalamus (O'Leary 1989; Schlaggar and O'Leary
1991). These innervating axons, when they arrive, could modify and refine the early
regionalisation set up by the intrinsic factors.
Evidence of the importance of extrinsic factors comes from experiments such as
heterotopic transplantation experiments in rats(Stanfield and O'Leary 1985). Here,
when portions of the occipital cortex from foetal rats were transplanted to more
rostral cortical regions of newborn rats, it was found that the ectopic immature
cortical tissue developed efferent projections and histology that were characteristic of
the local cortical tissue(Stanfield and O'Leary 1985). This demonstrates that
anatomical and/or functional changes in axonal inputs to the neocortex can play a
role in modifying existing, and generating new, neocortical subdivision. However, in
the Gbx2 mutant mouse there are no thalamic axons innervating the cortex, but the
neocortical region-specific gene expression develops normally, thus demonstrating
that early neocortical regionalization does not require extrinsic information from the
thalamus (Miyashita-Lin et al. 1999). More recently, there have been many
descriptions of graded or restricted patterns of gene expression across the ventricular
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zone or the cortical plate before TCAs enter the neocortex (Donoghue and Rakic
1999; Miyashita-Lin et al. 1999; Nakagawa et al. 1999).
These intrinsic mechanisms that pattern the cortex are just beginning to be
elucidated. It is currently thought likely that there are several patterning centres that
control regionalisation of the telencephalon (recently reviewed (Rubenstein and
Beachy 1998; Rubenstein et al. 1998; Ragsdale and Grove 2001; Zakietal. 2003)).
The basic regionalisation in the developing forebrain is discussed here.
Anterior neural ridge and anterior-posterior specification
The earliest definitive step in cortical regionalisation is mediated by an organizer at
the rostral most end of the developing embryo known as the anterior neural ridge
(ANR). This forms after neural induction and is found at the junction between the
anterior neural plate and the anterior non-neural ectoderm. Removal of the ANR
from explants resulted in a failure to express the winged helix transcription factor
Foxgl (also known as Brain Factor 1 or BF1)(Tao and Lai 1992; Shimamura and
Rubenstein 1997). Foxgl is normally expressed in the developing neural tube in the
progenitor population at the rostral end (Tao and Lai 1992). In addition, Foxgl
homozygous null mutants die at birth and have a dramatic reduction in the size of the
cerebral hemispheres (Xuan et al. 1995).
Interestingly the ANR also expresses the gene fibroblast growth factor 8 (FGF8)
(Crossley and Martin 1995; Shimamura and Rubenstein 1997). FGF8 is a secreted
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signalling polypeptide and ectopic expression of FGF8 protein is capable of inducing
Foxgl expression, suggesting that FGF8 may regulate the development of
anterolateral neural plate derivatives. However, in the Foxgl mutant mice some
cortical tissue remains so there must be more unknown factors involved in
establishing the cortex (Xuan et al. 1995; Shimamura and Rubenstein 1997; Dou et
al. 1999; Stormed#/. 2003).
As well as inducing the anterior neural plate to become telencephalon, these
signalling processes can influence later anterior-posterior organisation in the
telencephalon. An anterior increase in FGF8 signalling results in a posterior shift in
cortical areal boundaries, a decrease in FGF8 signalling results in an anterior shift in
these boundaries, and the introduction of a posterior source of FGF8 results in partial
areal duplications (Fukuchi-Shimogori and Grove 2001).
Dorsal Ventral specification
Dorsal-ventral (DV) patterning mainly occurs later than anterior-posterior patterning.
The earliest event is the induction of the floor plate at the ventral midline of the
neural tube. At telencephalic levels this is influenced by the prechordal plate. The
prechordal plate is an axial mesendoderm derivative of the node (its role was recently
reviewed (Kiecker and Niehrs 2001)). The importance of the floor plate and the
notochord in dorsoventral patterning of cell differentiation along the dorsoventral
axis was shown in the chick neural tube by grafting an additional notochord or floor
plate into ectopic positions, or by deleting both cell groups. These resulted in
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changes in the fate and position of neural cell types, defined by expression of specific
antigens, suggesting that the differentiation of neural cells is controlled, in part, by
their position with respect to the notochord and floor plate (Yamada et al. 1991).
More specifically it has been shown that the vertebrate hedgehog-related gene Sonic
hedgehog (Shh) is expressed in the notochord and the floor plate (Echelard et al.
1993). Ectopic expression of Shh in the mouse developing central nervous system led
to the activation of floor plate-expressed genes suggesting that Shh may play a role in
the normal inductive interactions that pattern the ventral central nervous
system(Yamada et al. 1991; Echelard et al. 1993). In addition, once the floor plate is
induced it then expresses Shh as well(Yamada et al. 1991). Shh mutants lack basal
telencephalic structures and have defects in the establishment and maintenance of
midline structures such as the notochord and floor plate (Chiang et al. 1996). The
role of the secreted Shh glycoprotein signalling molecule as an important molecule in
DV patterning in the developing forebrain has been recently reviewed (Monuki and
Walsh 2001 ; Schuurmans and Guillemot 2002; Muzio and Mallamaci 2003).
Interestingly, loss of Foxgl leads to specific loss of Shh expression in the ventral
telencephalon(Huh et al. 1999). This is consistent with dorsal-ventral specification
probably following the anterior-posterior specification. However, the role of the Shh
is not straightforward. Nkx-2.1 homeobox gene (a transcription factor) expression is
restricted to the forebrain (Price et al. 1992; Shimamura et al. 1995; Qiu et al. 1998).
Loss of Nkx-2.1 leads to a dorsalization of the pallidal parts of the basal ganglia
(Sussel et al. 1999). Furthermore, Shh has been shown to induce Nkx2.1 expression
(Barth and Wilson 1995; Ericson et al. 1995; Pera and Kessel 1997; Shimamura and
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Rubenstein 1997; Qiu et al. 1998). Interestingly, analysis of Nkx-2.1 mutants showed
that the histogenesis of the major cortical subdivisions appear normal, although the
telencephalic expression of Shh is almost eliminated (Sussel et al. 1999). Thus this
suggests that Shh expression within the forebrain is not essential for cortical
regionalisation.
In the developing mouse-forebrain members of the cubitus interruptus (ci) Gli zinc-
finger-containing gene transcription factor family have been implicated as
transducers of the Shh signal (Matise et al. 1998). Loss of Gli 1 and 2 function have
no discernable telencephalon phenotype(Park et al. 2000). However, in Gli3 mutants
ventral telencephalic markers expand dorsally into the cortex (Grove et al. 1998;
Theil et al. 1999; Park et al. 2000; Rallu et al. 2002). This is opposite to the
phenotype observed in Shh mutants and suggests that a balance between the two may
be important in the establishment of DV patterning in the telencephalon.
Dorsal midline roof plate
Dorsal structures, such as the roof plate and the adjacent nonneural ectoderm, also
function to confer DV identities to early neuroectodermal cells (Lee and Jessell
1999). The roof plate expresses members of the bone morphogenetic protein (BMP)
family of secreted molecules (recently reviewed (Monuki and Walsh 2001; Ragsdale
and Grove 2001)). Recent in vitro evidence indicates that BMPs from the roof plate
regulate dorsal telencephalic expression of the homeodomain transcription factor
L/?x2(Monuki et al. 2001). If the roof plate is ablated genetically in mouse embryos,
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Lhx2 expression extends dorsally and expression levels are greatly reduced in cortex,
which is diminished in size(Monuki et al. 2001). The importance of BMP signalling
for local patterning of the dorsal midline has also been shown in vivo using a
CRE/loxP approach to disruption the BMP receptor type la in the telencephalon
(Hebert et al. 2002). In addition, ectopic application of BMPs into the neural tube has
been shown to dorsalize the chick telencephalon (Golden et al. 1999).
Interestingly, ectopic expression of BMPs in tissue explants has been shown to
repress Foxgl expression(Furuta et al. 1997). Furthermore, in Foxgl mutants BMPs
are ectopically expressed in the telencephalon (Dou et al. 1999). This suggests there
is interplay between BMP and Foxgl in the regionalisation of the telencephalon.
Cortical hem
Another important dorsal signalling centre is the cortical hem. This lies along the
medial edge of the cortex between the hippocampus and choroid plexus (Figure 1.3).
The cortical hem has been shown to expresses several Bmp and Wnt genes (recently
reviewed (Ragsdale and Grove 2001)). Wnt genes like BMP genes code for secreted
molecules that have been implicated in cell signalling in other areas of embryonic
development. For example, Wnt3a is normally expressed at the cortical hem and
mutations in this gene result in near complete deletion of the hippocampus
(archicortex) (Lee et al. 2000).
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The exact mechanism by which molecules from signalling centres surrounding and
within the developing telencephalon initiate the anterior-posterior and dorsal-ventral
patterning effects and exert their subsequent actions on cell morphogenesis is still
unknown. Many transcription factors are expressed in telencephalic sub regions
(some have been described above) and experiments on mutant mice have contributed
to an understanding of the functional importance of these factors (recently reviewed
(Monuki and Walsh 2001; Ragsdale and Grove 2001; Rallu et al. 2002; Schuurmans
and Guillemot 2002)). Therefore, it seems likely that the regional activation of
transcription factors in the telencephalon is an important intermediate step. One such
transcription factor is the homeobox containing transcription factor, Pax6. Pax6 has
not only been shown to have a role in forebrain regionalisation but also in
development of many structures of the developing embryo including the eye and
pancreas. It is the study of this transcription factor and its downstream targets that
forms the topic for this thesis.
The transcription factor PAX6
Pax6 is a member of a family of transcription factors characterised by the presence of
an N-terminal 128 amino acid DNA binding domain, the paired box. This domain is
divided into two helical sub-domains called PAI and RED that can each bind DNA
independently (Jun and Desplan 1996). Nine murine and human paired box genes
have been identified to date (Callaerts et al. 1997). Separated from the paired box by
a 78 amino acid glycine-rich linker sequence is a second 60 amino acid DNA binding
domain, the homeobox. These two domains can interact independently and
cooperatively with DNA. At the C-terminal of Pax6 is a 153 amino acid proline-
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serine-threonine (PST) rich domain that is thought to be the transcriptional regulatory
domain (Figure 1.4).
Pax6 is expressed in the retina, lens and cornea of the developing vertebrate eye
(Walther and Gruss 1991; Grindley et al. 1995). It is also expressed at a range of
developmental stages in regions of the forebrain, hindbrain, cerebellum, the ventral
neural tube and the pancreatic islet cells (Walther and Gruss 1991; Stoykova and
Gruss 1994; Grindley et al. 1995; St-Onge et al. 1997; Warren and Price 1997;
Kioussi et al. 1999). The expression pattern of Pax6 in the embryonic central
nervous system is summarised in Figures 1.5 and 1.6.
Humans heterozygous for mutations in PAX6 suffer from aniridia (iris hypoplasia),
which is associated with cataracts, lens dislocation, foveal dysplasia, optic nerve
hypoplasia and nystagmus (Jordan et al. 1992; Glaser et al. 1994). The vast majority
(92%) of known PAX6 mutations in humans are nonsense mutations (Hanson et al.
1999). A rare case of an infant with a compound heterozygous mutation in PAX6
suffered severe craniofacial and central nervous system defects, had no eyes, no
adrenal glands, and died neonatally, a phenotype similar to the homozygous null
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Figure 1.5. A summary of the main sites of expression of Pax6 (shaded)
during murine central nervous system development. (A) Shows expression of
Pax6 at E8-8.5 in regions of the anterior neural plate that will become
telencephalon (t), eyes (e) and diencephalon (d). The domain of Pax6
expression has a sharp posterior boundary at the border between
diencephalon and mesencephalon (m). The neural plate folds in the
directions shown by the curved arrows to form the forebrain vesicles. (B)
Shows a coronal section cut through the left telencephalic vesicle at E11.5-
E12.5; the section is at the level indicated by an arrow in (A), with dorsal at
the top. Within the telencephalon, expression of Pax6 is found in the
ventricular zone of the dorsal telencephalon, in the neuroepithelium of the
intermediate territory (separating the dorsal and ventral telencephalon), and
in a stripe of cells linking this territory with Pax6-expressing cells in the basal
part of the ventral telencephalon (in the region of the amygdala). The dorsal
telencephalon contains the presumptive neocortex and the ventral
telencephalon contains the ganglionic eminences, or striatum. (C) + (D)
Show parasagittal sections through the forebrain at E12.5-E14.5, at
approximately the level shown by an arrow in (A); anterior is at the top,
ventral is to the left, dorsal is to the right and abbreviations are as in (A). It is
as if the diagram in (A) were to be folded and then viewed from its left-hand
side. As the embryo develops, diencephalic expression becomes more
restricted. These summary diagrams are taken from a recent review on Pax6







































Figure 1.6. (E): A section at a similar level and plane to that in B, but at E15.5
and showing not just telencephalon but also diencephalon. Thalamocortical
axons grow from the dorsal thalamus, penetrate the ventral thalamus, avoid
the hypothalamus, travel dorsal to the amygdaloid region and enter the
cortex. Although Pax6 is expressed throughout the neuroepithelium of the
thalamus at ages up to E12.5, subsequently it becomes restricted to the
ventral thalamus. F,G,H: Sections cut at E12.5 in the planes indicated in C,
showing expression of Pax6 in (F) the olfactory epithelium and eye, G: the
hindbrain or rhombencephalon (sm, somatic motor neurons), and (H) the
spinal cord. These summary diagrams are taken from a recent review on






















Pax6 mutation in the mouse results in the Small eye (Sey) phenotype. At least eight
alleles of Pax6 have been identified in the mouse so far (Glaser et al. 1990; Hill et al.
1991; St-Onge et al. 1997; Lyon et al. 2000). A premature stop codon (marked on
Figure 1.4) in the linker domain generates the Pax6SeyEd allele (Hill et al. 1991).
Heterozygous mice have a reduced eye size, iris hypoplasia, corneal opacification,
and cataracts. Homozygotes die immediately after birth with no eyes, no nasal
structures and severe brain abnormalities, including malformed cerebral cortex
(Hogan et al. 1986; Hill et al. 1991; Schmahl et al. 1993; Caric et al. 1997). The
diencephalon is reduced in size, is not differentiated to a normal extent (Stoykova et
al. 1996; Warren and Price 1997), and fails to innervate the cortex (Pratt et al. 2000).
Vertebrates primarily express two alternatively spliced isoforms of Pax6 that differ
by the presence or absence of exon 5a that encodes an additional 14 amino acid
residues within the paired domain (Figure 1.4). This insertion changes the DNA-
binding specificity of the paired domain and has been proposed as a means of
modifying the downstream target genes of the transcription factor(Epstein et al.
1994; Kozmik et al. 1997). The isoform containing the extra exon is denoted here as
Pax6+5a. The ratio of canonical Pax6 mRNA to Pax6+5a mRNA seems to vary in
different tissues; this has been observed in bovine (Jaworski et al. 1997) and in mice
(Richardson et al. 1995). Unlike Pax6-null mice that exhibit anopthalmia with
central nervous system defects and lethality, 5a isoform-null mice had iris hypoplasia
and defects in the cornea, lens, and retina (Singh et al. 2002). Interestingly two
human cases with eye defects have been described that have a missense mutation in
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the 5a isoform (Nanjo et al. 2004). This requirement of the 5a isoform is believed to
be evidence that the evolution of this isoform contributed to advanced features of the
vertebrate eye (Singh et al. 2002). However, recent evidence has emerged that the
Notch signal promotion of growth of the eyes in the invertebrate Drosophila is
through the Pax6-like gene eyegone (Eyg), which has a truncated paired domain
(Dominguez et al. 2004). Like the vertebrate Pax6+5a isoform, eyegone recognises
DNA exclusively through the C-terminal sub region of the paired domain
(Dominguez et al. 2004). The two other Drosophila Pax6 genes are eyeless (ey) and
twin ofeyeless (toy).
A role for Pax6 in forebrain development
In Pax6~' mice both the cortical ventricular zone and the subventricular zone are
enlarged (Schmahl et al. 1993; Stoykova et al. 1996; Caric et al. 1997). In addition,
the cortical plate is thinner and within the intermediate zone (i.e. between the
subventricular zone and cortical plate) there are large collections of cells
characteristic of those in the subventricular zone. Cumulative labelling with
bromodeoxyuridine (BrdU) has revealed that proliferative rates in the early Pax6"
embryonic cortex increase (Estivill-Torrus et al. 2002). In addition, proliferating
cells in S phase are found scattered throughout the ventricular zone, suggesting either
a failure in interkinetic nuclear migration or asynchronous cycling of precursor cells
in the mutant cortex (Gotz et al. 1998; Estivill-Torrus et al. 2002). Birth dating
studies with BrdU in vivo show that many later-born neurones fail to migrate to the
cortical plate and accumulate in the subventricular zone (Caric et al. 1997).
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Immunohistochemical analysis of neurone-specific class III (3-tubulin isotype (TuJl),
an early marker for postmitotic neurones (Lee et al. 1990), has shown that cells in
Pax6'~ mutant cortices that fail to migrate do begin neuronal differentiation (Caric et
al. 1997). There is a similar defect in Small eye rats (rSey): the E20 cortices have an
abnormal clustering of cells in the ventricular and intermediate zones of the cortex
(Fukuda et al. 2000).
Not all cells in the ventricular zone express Pax6; rather, expression appears to be
localised to a subset of radial glial cells (Gotz et al. 1998). In Pax6'/~ embryos, the
morphology of radial glial cells is altered. At El 5.5, wild-type radial glia have
straight processes running towards the pial surface whereas mutant radial glial
processes appear wavy and have frequent small extrusions and branches (Gotz et al.
1998). Co-culture experiments mixing E13.5 Pax6" cortical cells and wild-type cells
failed to rescue the phenotype of mutant radial glial cells suggesting that the defect
may be cell-autonomous (Gotz et al. 1998). Work over the past few years has shown
that radial glial cells are able to generate not only glial cells but also neurons
(Campbell and Gotz 2002). In cultures of Pax6'' radial glial cells, less neural clones
and more non-neural clones were produced than in cultures of wild-type radial glial
cells (Heins et al. 2002). Furthermore, in vivo quantification showed a 50% reduction
of radial glial-derived neurones in the Pax6" cortex at E14 and El 6 (Heins et al.
2002). Infecting cells from E14 Pax6" cortex with a retroviral vector containing full
length Pax6 cDNA increased the number of differentiated neurones and appeared to
reduce proliferation (Heins et al. 2002). These findings suggest that Pax6 may play a
cell-autonomous role driving radial glial cells to produce cells of a neuronal fate.
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Some defects in the developing central nervous system of Pax6~ ~ embryos are not
due to a direct cell-autonomous requirement for Pax6 in the affected process.
Transplantation ofPax6" cortical precursors into a wild-type cortical environment
can rescue their migrational defect, suggesting that it may be secondary to defects of
other cells such as radial glia which normally guide migration (Caric et al. 1997).
Abnormally high levels of cell death among late-embryonic Pax6" dorsal thalamic
cells are most likely secondary to the inability of these cells to obtain trophic support
from the cerebral cortex, to which they do not connect (Lotto et al. 2001).
A role for Pax6 in cortical reqionalisation
The basic principle of cortical regionalisation was introduced above. Moving along
the developing telencephalic wall in a dorsal to ventral direction the telencephalon is
divided into two distinct parts; the pallium and the subpallium. The area of the
pallium that meets the subpallium is the ventral pallium. The part of the subpallium
that meets the pallium is called the dorsal lateral ganglionic eminence (dLGE) (see
Figure 1.3). In the absence of Pax6, cell migration from the subpallium into the
cortex is strongly enhanced, whereas migration from the pallium into the subpallium
is affected much less(Chapouton et al. 1999). This change in cell migration must be
due to changes in the expression of downstream targets from Pax6. Furthermore, this
demonstrates Pax6 has a role to play in cortical regionalisation. In wild type mice
Dlxl and Vaxl are usually expressed in the subpallium and not in the
pallium(Valerius et al. 1995). In Pax6 mutant mice Dlxl and Vaxl expression is
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found in the pallium (Stoykova et al. 1996; Hallonet et al. 1998; Yun et al. 2001). In
addition, in the wild type the expression domains of the basic helix-loop-helix
transcription factors, Mashl(Ascll) and Neurogenin 1 (Ngnl; also known as
Neurod3), Ngn2 (also known as Atoh4\ Atonal homolog 4) are expressed in a defined
dorsoventral pattern, with Mashl expressed at high levels in the developing
ganglionic eminence and Ngnl/2 restricted to the developing cortex (Gradwohl et al.,
1996; Ma et al., 1997). In Pax6 mutants the expression of ngnl, ngn2, and Mashl are
completely changed; ngnl and ngn2 expression is reduced dorsally and Mashl is no
longer confined to the subpallial area and is expressed in the neuroepithelium of the
ventral and lateral pallium (Stoykova et al. 2000; Toresson et al. 2000).
This progressive dorsal spread of gene expression from the subpallium structures of
the dLGE into the pallium is consistent with Pax6 being involved in the correct
dorsoventral regional specification of the developing telencephalon(Toresson et al.
2000; Yun et al. 2001; Muzio and Mallamaci 2003). In turn this specific expression
of Pax6 affects region-specific phenotypes, such as the migratory behaviour of
neurons(Casarosa et al. 1999; Fode et al. 2000).
Gsh2 is a homeobox containing transcription factor and is expressed in subpallial
progenitor cells (Valerius et al. 1995). In Pax6 mutants Gsh2 expression is found to
have expanded from the subpallium into the pallium (Valerius et al. 1995).
Interestingly, in Gsh2 mutants there is a reduction in the size of the LGE and a loss
of Dlx2 expression in the LGE but not a loss in the MGE (Szucsik et al. 1997; Yun et
al. 2001). Also Ngn2 expression is expanded ventrally into the dLGE (Yun et al.
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2001). In the absence of Ngn2, Mashl is ectopically expressed in the dorsal
telencephalon while most other ventral transcription factors do not expand
dorsally(Fode et al. 2000). This demonstrates that many genes are also necessary for
the maintenance of gene expression in telencephalic progenitors.
Pax6 is expressed in a gradient in the developing cortex. It is low-caudal-to-high-
rostral and low-medial-to-high-lateral (Walther and Gruss 1991; Bishop et al. 2000;
Bishop et al. 2002). Conversely, Emx2 a vertebrate homologue of the Drosophila
head gap transcription factor ems, is expressed in a gradient that is high-caudal-to-
low-rostral and high-medial-to-low-lateral(Gulisano et al. 1996). These opposing
expression patterns suggest there may be an interplay to confer regionalisation to the
developing neurones of the cortex. In the Emx2 mutants rostral areas are expanded
and caudal areas are contracted, which is the opposite effect seen in Pax6 mutants
(Bishop et al. 2000). Analysis of Emx2 mutant mice demonstrate that, like Pax6
mutants, there are specific changes in gene expression patterns and area-specific
connections between the cortex and thalamus(Bishop et al. 2000; Bishop et al. 2002).
In addition, analysis of double Pax6 and Emx2 mutants shows a similar affect on
these regionalised genes(Muzio and Mallamaci 2003). In the double mutant the
cortex is largely absent but there were residual signs of a cortex. Pallium specific
gene Ngnl and Ngn2 were absent, but there was expression of the subpallium genes
Vaxl, Dlxl, Gsh2 and Mashl (Muzio and Mallamaci 2003). This indicates a dorsal
to ventral transformation in the telencephalic specificity (Muzio and Mallamaci
2003).
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A role for Pax6 in diencephalon patterning
From El0.5 onwards Pax6 expression is seen extending from the telencephalon into
the diencephalon up to a sharp caudal boundary thought to be where the future
morphological boundary between the prosencephalon and mesencephalon
forms(Walther and Gruss 1991). Pax6 mutants lack this morphological boundary and
some gene expression in the caudal prosencephalon (such as Lhxl and Gshl) is lost
and Dbx expression which is typical of the mesencephalon is expanded rostrally into
the prosencephalon(Mastick et al. 1997). This could indicate that the caudal
prosencephalon is possibly partially transformed into mesencephalic fate and so
demonstrates that Pax6 may play a role in establishing this boundary.
In Pax6 homozygous mutants the anterior posterior pattern of gene expression in the
diencephalon is relatively normal (Stoykova et al. 1996; Warren and Price 1997).
Vmaz2, HbnF, are normally expressed in the dorsal thalamus (Lebrand et al. 1998;
Pratt et al. 2000). In wild types Lhxl (also known as Liml) and Nkx2.2 are expressed
in the diencephalon but not in the dorsal thalamus. In the Pax6 homozygous mutant
they are now expressed in the dorsal thalamus (Pratt et al. 2000). This indicates that
Pax6 may have a role in conferring a dorsal identity in the developing thalamus.
A role for Pax6 in eye development
An important role of Pax6 in eye development was indicated by its early expression
in all structures of the developing eye from E8.5 (Walther and Gruss 1991).
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Moreover, there is compelling evidence that Pax6 is necessary for eye formation in
vertebrates.
In mice the Pax6 homozygous Small eye (Sey) mutant completely lacks eyes (Hill et
al. 1991). Similarly, in humans, compound PAX6 heterozygotes have no eyes (Glaser
et al. 1994). This important role for Pax6 in eye development has been recently
reviewed (Ashery-Padan and Gruss 2001; Pichaud and Desplan 2002). Expressing
too much Pax6 protein also generates a similar phenotype to that of heterozygous
mutants (Schedl et al. 1996).
The refractive properties of the lens are dependent on the accumulation of high
concentrations of water-soluble proteins known collectively as crystallins
(Bloemendal and de Jong 1991). Pax6 has been shown to contribute to the
transcriptional activation of several crystallin genes: in the lens placode chicken 81-
crystallin (Cvekl et al. 1995) and mouse aB-crystallin (Gopal-Srivastava et al. 1996);
and in the lens, guinea pig ^-crystallin (Richardson et al. 1995) and mouse aA-
crystallin (Cvekl et al. 1995).
Using the cre/loxP approach to inactivate Pax6 in the eye surface ectoderm, it was
shown that Pax6 activity was essential for correct lens placode formation (Ashery-
Padan et al. 2000). Initially expression of Pax6 was detected in the surface ectoderm
at E9 but was no longer detectable by E9.5. Initial lens induction occurred in the
mutant but further development of the lens was arrested.
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Work in the last ten years has suggested that Pax6 function in eye development
seems to have been at least partially conserved between invertebrates and
vertebrates. This was first suggested when it was identified that eyeless (ey) of
Drosophila, Small eye of the mouse, and human aniridia are encoded by homologous
genes (Quiring et al. 1994). Later it was shown that expression of mouse Pax6 or
Drosophila ey in Drosophila imaginal discs resulted in the formation of ectopic eyes
(Haider et al. 1995). Ectopic expression of Pax6 mXenopus animal caps was also
shown to be sufficient for lens induction (Altmann et al. 1997). Further,
misexpression of Pax6 in Xenopus laevis can induce a small but fully differentiated
ectopic eye (Chow et al. 1999). More recently, expression of the human PAX6+5a
isoform induced strong eye overgrowth when expressed in Drosophila, whereas
expression of canonical PAX6 acted primarily on the specification and differentiation
of eye cells in vivo (Dominguez et al. 2004).
Pax6 has also be shown to be required later in uncommitted retinal cells, retinal
progenitor cells (RPCs), to retain their pluripotencey, thereby mediating the full
retinogenic potential of RPCs to generate the different cell types that compose the
retina (Marquardt et al. 2001). Examples of the retina cells generated from RPCs are
retinal ganglion cells, cones, and rods.
A role for Pax6 in hindbrain/spinal cord patterning
Pax6 expression is first detected in the presumptive hindbrain at E8.5 (Walther and
Gruss 1991). However, Pax6 expression in the metencephalon is not seen until El5,
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when it is seen in the external granular layer and in cells distributed in the dorsal
cerebellum (Walther and Gruss 1991).
In the spinal cord onset of Pax6 expression is coincident with neural tube closure at
E8.5 (Walther and Gruss 1991). Expression extends along the entire anteroposterior
axis up to the rhombencephalic isthmus and is mainly restricted to mitotically active
cells in the ventral ventricular zone (Walther and Gruss 1991). At this stage neural
differentiation in the spinal cord has not yet occurred and so Pax6 expression could
affect neural differentiation here (Walther and Gruss 1991). Interestingly in the
spinal cord there is a characteristic DV pattern, with specific classes of neurons
differentiating according to their DV position. Not only are different cell types
produced according to their DV position but also they emerge at different times. As
well as having a role in regionalisation of the forebrain Shh was first shown to be
very important for determining the DV pattern of the spinal cord and hindbrain. For
example Shh induces hindbrain progenitors to produce motor neurones (Ericson et al.
1995). More recent work has identified that Pax6 is a key intermediary in the Shh
dependent control of neuronal subtype identity in the ventral spinal cord and
hindbrain (Ericson et al. 1997). Elimination of Pax6 resulted in a dorsal to ventral
transformation in the identity of ventrally located progenitor cells and a consequent
change in motor neuron fate (Burrill et al. 1997; Ericson et al. 1997). This has also
been seen in the hindbrains of Pax6 homozygous mutant rats where the somatic
motor (SM) neurones were found to be missing (Osumi et al. 1997).
35
In the myelencephalon of the hind brain Pax6 expression is very similar to
expression in the spinal cord (Walther and Gruss 1991). Essentially, Pax6 is
expressed most abundantly in the ventricular zone (Walther and Gruss 1991). As
with the spinal cord it has been suggested that Pax6 may be involved in regulating
the specification of the ventral neurones by establishing the correct progenitor
domains (Takahashi and Osumi 2002).
Regulation of Pax6 transcription
The PAX6 gene is spread over 22kb of chromosome 11 in humans. Figure 1.7 shows
a schematic of the gene locus. The next 5' gene to PAX6 is reticulocalbin 1 precursor
(RCN1), which is 340kb upstream. The next 3' gene to PAX6 is elongation protein 4
homolog (ELP4) previously called Pax6 neighbour gene (PAX6NEB). This gene runs
antisense to PAX6 and the final exon (exon 12) is 6kb 3' to the last exon PAX6. The
canonical translation start point for PAX6 is in exon 4 (Glaser et al. 1992).
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Figure 1.7. The genomic organisation of the PAX6 locus. Red boxes are the
PAX6 exons. The yellow box is exon 5a. Blue boxes are the 3' exons of the
antisense neighbour gene ELP4. The extent of the PAX6 locus included in
the two YACs (Y589 and Y593) is indicated. P/EE is the pancreas/ectoderm
enhancer. PO and P1 are promoters 1 and 2. a is the alpha element. NRE is
the neuroretina enhancer. CE1, CE2, and CE3 are the intron 7 regulatory
elements. E100+ (Box 123) and HS234 are long range highly evolutionary
conserved elements. SIMO is the most distant human patient breakpoint. The
extent of these regions is indicated by the horizontal black bars. TO, T1, Ta,





























Transcription start site T1 and promoter P1
In 1992 a PAX6 cDNA sequence that contained 14 exons (exon 1 to 5, 5a, and 6 to
13) was identified (Glaser et al. 1992). A few years later in 1997, using a
combination of primer extension and RNase protection, a transcripton initiation site
was identified 108bp upstream of this cDNA sequence (Xu and Saunders 1997). In
this region several candidate promoter sites were identified and their activity tested
using promoter and enhancerless (3-galactosidase vectors. One 92bp region was
found to be required for basal level PAX6 promoter activity. This promoter site is
indicated on Figure 1.7 as PI and the transcription start site indicated by T1 and the
arrowhead.
Transcription start site TO, exon 0, and promoter 0
In 1999 several Pax6 cDNAs were identified (Xu et al. 1999). Some contained either
exon 1 or exon 0 at their 5' end. Studies using in situ hybridisation identified that the
two set of transcripts are differentially expressed during brain and eye development
(Xu et al. 1999). Further studies using transgenic mice generated using the promoters
and P-galactosidase demonstrated the elements direct gene expression in distinct
regions (Kammandel et al. 1999; Xu et al. 1999). The additional transcriptional start
site is marked as TO and by the arrowhead on Figure 1.7. Earlier studies in quail
identified two promoters in quail Pax6 (designated P0 and PI) that generated two
transcripts with different 5'UTRs (Dozier et al. 1993; Plaza et al. 1995).
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NRE and Pa
Comparison of nucleotide sequence identity between human, quail and mouse
identified a highly conserved 216bp element in Pax6 intron 4 (Plaza et al. 1995).
Further in vitro cell culture work identified that this functions as an enhancer in quail
neuroretina cells (Plaza et al. 1995). This element is identified on Figure 1.7 as NRE.
(3-galactosidase transgenic mice generated with the 216bp element in either
orientation and either promoter PO or PI showed identical expression patterns in the
eye distinct from those conferred by the PO or PI alone (Kammandel et al. 1999; Xu
et al. 1999). Mice generated with just the 216bp element failed to produce any (3-
galactosidase suggesting that the element had no promoter activity itself
(Kammandel et al. 1999).
Similar transgenic mice experiments with a human PAX6 promoter and the human
216bp conserved sequence (designated by this group as ele4H) showed that it
functioned as a spinal cord-specific enhancer (Xu and Saunders 1998). The P-
galactosidase was expressed at the thoracic and lumbar levels of the spinal cord when
it was linked to a functional PAX6 promoter; again the element had no promoter
activity on its own (Xu and Saunders 1998).
Using a combination of primer extension, RT-PCR, and genomic sequencing a
transcription start site was identified in intron 4 (Kammandel et al. 1999). This is
marked on Figure 1.7 with Ta and an arrowhead. The exact function of the 216bp
element is still controversial. Kammandel et al, (1999) describe the element as exon
a. Xu et al. (1999) described it as an enhancer. The same element has also been
39
described as neuroretina enhancer (NRE) (Van Heyningen and Williamson 2002).
However, Kleinjan et al. (2004) referred to it as a promoter and Anderson et al.
(2002) as an exon, exon/enhancer and putative promoter.
P/EE
Construction of transgenic mice with a 341 bp piece of Pax6 located approximately
3.5 kb upstream of the most proximal promoter (PO) of the Pax6 gene faithfully
reproduced the expression of Pax6 in the pancreas, surface ectoderm, lens, cornea,
conjunctiva, and lachrymal gland (Williams et al. 1998). This regulatory element is
designated pancreas/ectoderm enhancer (marked as P/EE on Figure 1.7). Similar
work confirmed that only 340bp of the fragment was necessary to reproduce the
expression (Kammandel et al. 1999). Further generation of mice with truncated
versions of this fragment found that a 107 bp fragment can reproduce the cornea and
lens expression (Kammandel et al. 1999). However, some ectopic expression was
also observed. This suggested that the 341 bp fragment might contain a regulatory
repression sequence.
Sequence alignment between the human and mouse Pax6 genes identified the region
is 93% identical; this is further evidence of conservation of Pax6 transcriptional
regulatory elements (Williams et al. 1998).
CE1, CE2, and CE3
Control elements lOkb downstream from P0 and PI have been identified. Genomic
sequence comparisons between human, mouse, pufferfish, and zebrafish have
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identified three conserved cw-regulatory elements in intron 7: CE1; CE2; and CE3
(Kleinjan et al. 2004). These elements are shown on Figure 1.7. Transgenic mice
made with these elements and P-galactosidase have demonstrated that they regulate
gene expression within distinct tissues (Kleinjan et al. 2004). EMSA on nuclear
extracts from the Pax6 expressing cell line ARPE showed that Pax6 can bind to a site
in CE2 (Kleinjan et al. 2004). As well as demonstrating the longer range of Pax6
control elements it is evidence that Pax6 can directly regulate its own expression.
Alternative translation start sites
Pax6 expression has been more recently complicated by the finding of more possible
translational start sites. Examination of the Pax6 open reading frame revealed four
additional possible ATG translation start sites in exons 7 and 8 downstream from the
ATG in exon 4. Truncation of quail Pax6 to remove the first ATG in exon 4 and then
in vitro transcription experiments produced 32 and 33KDa proteins that are
consistent with proteins made from some of these internal ATG sites (Carriere et al.
1995). More recently, a potential antisense transcript has been identified (Anderson
et al. 2002). The transcript is believed to begin at the a element but to run antisense
to the previously identified transcript. A protein product has not been identified.
Other control elements
Other, less well described elements have also been identified in the Pax6 locus.
A potential silencer element was identified in the region surrounding PI,
approximately 1,5kb to 2.5kb upstream of PAX6. No single element was identified
and it was suggested that a combination of elements controlled the expression of
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PAX6. Later analysis of human PAX6 sequence with transient transfection assays in
glioblastoma cells and leukemia cells confirmed the presence of a human PAX6
transcriptional silencer (Xu and Saunders 1997). This silencer seemed to have
different activities in different cell types (Xu and Saunders 1997). In addition, a 5kb
fragment between promoters PO and PI seemed to control expression in the
telencephalon, hindbrain, and spinal cord (Kammandel et al. 1999).
Experiments using electrophoretic mobility shift assays (EMSA) and co-
immunoprecipitation of nuclear extracts have identified protein-DNA interactions
between other upstream transcription factors and PAX6 (Zheng et al. 2001). These
led to the identification of a 57bp c/T-regulatory element in exon 1 of the human
PAX6 gene, designated exon 1 enhancer (EIE) (Zheng et al. 2001). Protein-DNA
interactions have also been investigated in quail. DNA foot printing experiments
identified a binding site for the quail Pax6 (Pax-QNR) protein within the promoter
region (Plaza et al. 1993). Thus Pax-QNR can potentially /rara-activate its own
promoter (Plaza et al. 1993).
Long range control elements
Genomic sequence comparisons have also identified long-range control elements in
humans, mice and Fugu (Griffin et al. 2002). The sequence comparison between
humans, mice and Fugu identified a 3' cis-regulatory region. Box 123, as an enhancer
lOOkb from the 3' end of Pax6 (Griffin et al. 2002). This was confirmed by
expression studies in mice (Griffin et al. 2002). The location of Box 123 in human
PAX6 is shown in Figure 1.7 as El00+.
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Interestingly there are also a few cases of PAX6 mutations in humans where the
mutation in PAX6 has been found several hundred kilobases away from the PAX6
transcriptional start site. Firstly, in 1995 two aniridia patients were identified in
which the PAX6 gene is not disrupted but in both cases a chromosomal breakpoint
was found at least 85 kb distal of the 3' end of PAX6 (Fantes et al. 1995). In 1996
another aniridia case was identified where the breakpoint lay between the PAX6
locus and a region approximately 100 kb distal to PAX6 (Crolla et al. 1996). Again
no detectable deletion was found within PAX6, suggesting again that the aniridia may
have resulted from the distal chromatin domain containing either enhancers or
regulators (Crolla et al. 1996). Later, two more human aniridia patients were found
to have deletions 1 lkb away from the 3' end of PAX6 (Lauderdale et al. 2000). 3'
RACE data strongly suggested it was PAX6 transcription rather than mRNA stability
that was causing the disease (Lauderdale et al. 2000).
Transgenic mice made using a 310kb YAC (YAC Y589) that contains human PAX6
and flanking regions in which the 3' end of the YAC ends approximately lOOkb 3' to
PAX6 , failed to rescue Pax6 Small eye phenotype in mice (Figure 1.7) (Kleinjan et
al. 2001). Further evolutionary sequence comparison and DNasel hypersensitivity
analysis identified a region more than 150 kb distal to the major PAX6 promoter PI
containing regulatory elements (Kleinjan et al. 2001). This is indicated in Figure 1.7
as HS234. Previously a 420kb YAC Y593 containing human PAX6 and flanking
regions was shown to rescue mouse homozygous Small eye lethality (a schematic of
the extent of the YAC is shown in Figure 1.7) (Schedl et al. 1996). YAC Y593
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extends well beyond the most distant human patient breakpoint, SIMO, identified so
far (Figure 1.7).
In summary, regulation of Pax6 transcription is extremely complex and not fully
understood. Regulatory elements are spread over a very considerable distance.
Importantly YAC Y593 has been functionally proven to include all of the necessary
elements for the correct expression of PAX6 (Schedl et al. 1996).
Regulation of transcription by Pax6
As described above Pax6 has been shown to affect cell proliferation, migration,
differentiation, adhesion, and signalling(Caric et al. 1997; Gotz et al. 1998;
Campbell and Gotz 2002; Estivill-Torrus et al. 2002; Heins et al. 2002). These
effects are brought about through the changes in expression in downstream genes,
either direct targets of Pax6 or indirectly. Some target genes have a distinct function
in cellular behaviour; others, such as transcription factors, have a broader effect on
cellular behaviour. Many potential target genes have been identified by virtue of
changes in their expression level in animals lacking functional Pax6. In addition,
studies using micro arrays of eye mRNA from various Pax6 over-expressing and null
mutant cells have shown changes in the expression of around 400 genes(Chauhan et
al. 2002; Chauhan et al. 2002). There are some examples of direct binding of Pax6 to
down stream targets. Accordingly, the following discussion on some of the known
targets of Pax6 is grouped by two mechanisms by which Pax6 has been shown to
function. The first way is by the Pax6 protein binding to regulatory elements in the
DNA of a downstream gene and either activating or repressing transcription. The
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transactivating function associated with the C-terminal region of Pax6 has been
demonstrated by the fusion of the proline-, serine-,and threonine-rich C-terminal
domain of sea urchin and mouse Pax6 to the DNA-binding domain of the yeast
GAL4 transcription factor and subsequent activation of GAL4-responsive(Czerny
and Busslinger 1995). Similar results were obtained with GAL4-human Pax6 fusion
proteins (Glaser et al. 1994). Transcriptional repression by Pax6 has been most
closely described in the crystallin genes(Chauhan et al. 2002).
The second method by which Pax6 has been shown to regulate the transcription of
other genes is by the Pax6 protein binding to another protein, a binding partner, and
then modulating transcription of a downstream target. To further complicate the
mechanism by which Pax6 regulates transcription some evidence has emerged of
Pax6 protein binding to both regulatory DNA elements in a gene and other proteins
involved in the transcription of the downstream gene. Both of these methods of
function are discussed in turn here.
Pax6 Binding targets
As has been discussed above, Pax6 contains two distinct DNA binding motifs, the
paired domain and the homeodomain. These DNA binding domains can bind the
target DNA either independently or cooperatively. Figure 1.8 is a diagram showing
the consensus binding sites. The original sites were suggested based on comparing
Pax6 sequence homology between different species and comparing the Pax6
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A) The paired domain(without exon 5a)
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FIGURE 1.8. Pax6 DNA binding consensus sites. A) Paired domain
without exon5a (Epstein et al., 1994.The grey box is the core motif. B)
Paired domain including the extra 14 amino acids coded by exon5a
(Epstein et al., 1994).C) Homeodomain DNA binding sequence (Wilson
et al., 1995).
sequence with other genes containing DNA binding domain. More recently, the
DNA-binding sites have been demonstrated to function in vitro (Epstein et al. 1994;
Wilson et al. 1996). In addition, the paired domain binding has been confirmed by X-
ray crystallography (Xu et al. 1999).
A) Crystallins
The Pax6 regulation of crystallin genes has been mentioned already above in the
section about eye development. Crystallins, which make up 80-90% of the
soluble protein of the lens, are the most numerous set of genes known to be
targets of Pax6(Simpson and Price 2002). Many have dual functions, both as
components of the refractive properties of the lens and also as either metabolic
enzymes or heat shock proteins(Piatigorsky 1998). Evidence of a direct
interaction between Pax6 protein and crystallin genes has been demonstrated in
the promoter of aA-crystallin by electrophoretic mobility shift assays (EMSA)
studies(Cvekl et al. 1995). Subsequent co-transfection experiments demonstrated
that Pax6 highly activates the promoter of aA-crystallin (Cvekl et al. 1995)
(3-crystallin gene is an example of a target that appears to be repressed by Pax6.
Co-transfection of Pax6 expression constructs into chick retinal epithelial cells
led to >90% reduction in reporter gene expression driven from the P-crystallin
promoter(Duncan et al. 1998). In this experimental system, deletion of the C-
terminal transactivation domain of Pax6 in the expression construct did not ablate
repression, suggesting a critical role for the paired and/or homeodomains. Pax6
also appears to repress yF- and yE-crystallin promoters when studied in transient
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transfections(Kralova et al. 2002). Interestingly, in vivo studies have
demonstrated that Pax6 interacts with the chicken 51-crystallin enhancer at two
sites, one acting as a positive element while the other represses expression (Muta
et al. 2002).
Regulation of the crystallin genes by Pax6 also provides an illustration of a
second complexity of Pax6 biochemical control. The eye predominantly
expresses the isoform of Pax6 lacking exon 5a (Jaworski et al. 1997). This isoform
binds preferentially to a promoter element of the ^-crystallin gene at a site that is
highly similar to the consensus paired domain binding sequence (Epstein et al.
1994; Richardson et al. 1995; Jaworski et al. 1997). This preference for binding
the Pax6 isoform lacking exon 5a allows high levels of ^-crystallin to be
expressed specifically in the eye rather than in other regions where the Pax6
exon5a splice forms are more equally represented.
B) Regulation of cell adhesion molecules by Pax6
The expression patterns of some adhesion molecules are altered in Pax6 mutants.
Expression of the extracellular matrix molecule tenascin-C (TN-C) at the cortico-
striatal boundary is abolished and the expression of some cadherins (calcium
dependent adhesion molecules) is altered in the cortex (Stoykova et al. 1997;
Bishop et al. 2000). The expression domain of the homophilic adhesion molecule
R-cadherin and that of Pax6 have some overlap (Ganzler and Redies 1995;
Matsunami and Takeichi 1995) and, in the absence of functional Pax6,
expression of R-cadherin mRNA is reduced considerably in areas that normally
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show co-expression (Stoykova et al. 1997). Expression of PI20 catenin (pl20ctn),
a member of the armadillo family of proteins implicated in cell-cell adhesion and
signal transduction, and Paxillin, a focal adhesion adapter protein implicated in
integrin mediated signalling pathways, are highly elevated. Expression of N
cadherin and a catenin are both slightly elevated, a5 integrin and [11 -integrin
accumulate in lens although E cadherin and a6 integrin expression appears
normal (Duncan et al. 2000).
There is evidence to suggest that Pax6 protein may directly interact with the
regulatory elements of genes encoding adhesion molecules. The gene for neural
cell adhesion molecule (N-CAM) has a Pax6 paired-domain binding region
within its promoter(Holst et al. 1997). In addition, Pax6 activates the expression
of Ll-luciferase reporter constructs in neuroblastoma cells(Meech et al. 1999).
Although this and other studies suggests an interaction between Pax6 and the cell
adhesion molecule LI, which regulates axonal guidance and fasciculation during
development (Chalepakis et al. 1994; Meech et al. 1999; Honig et al. 2002), the
interaction is likely to be complex. For example, the expression domains of Pax6
and LI only partially overlap and it has been shown that there is no change in LI
expression in the intermediate, ventricular and subventricular zones of E19 Pax6'
'
mice(Caric et al. 1997).
In summary, a large body of evidence indicates that Pax6 regulates the
expression of cell surface molecules mediating cell-cell adhesion and signalling.
Many of the developmental processes in cortical and eye development require
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correct cell adhesion and signalling. For example, when wild-type and
homozygous Pax6Sc'y cells are mixed in either in vitro aggregation assays or in
chimaeric animals, they segregate from each other. This has been observed in
tissues including the eye and forebrain and indicates that Pax6 exerts a strong
influence on the molecular composition of the cell membrane(Quinn et al. 1996;
Stoykova et al. 1997; Warren et al. 1999). Defects in cell adhesion and signalling
may explain some of the abnormalities, including the restriction of cells within
discrete territories, defective cell migration and axon growth, seen in the cortex
of animals lacking Pax6.
c) Keratins
Cellular morphology and adhesion are also affected by Pax6 mediated effects on
the expression of a number of structural eye genes. Keratins contribute to
intermediate filaments and are expressed by many different types of epithelial
cells throughout development. In most epithelial cells a basic keratin is
coexpressed and paired with an acidic keratin. The expression of keratins is
characteristic of the epithelial tissue. For example, expression of keratin complex
1, acidic gene 12 (Krtl-12) is restricted to the corneal epithelium(Liu et al.
1999). In cotransfection experiments using human corneal epithelial cells Pax6
has been shown to up regulate the Krtl-12 promoter(Liu et al. 1999).
d) Transcription factors
As described earlier many transcription factors have altered expression patterns
in Pax6 mutants. Regulating the expression of other transcription factors allows
for complex changes in individual cell behaviour and characteristics. There is
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evidence that Pax6 can directly affect expression of several transcription factor
genes. The basic helix-loop-helix family members Mashl, Math5 and Ngn2 are
known to play important roles in cell lineage determination and differentiation
during embryonic development(Guillemot 1999). As mentioned above, in Pax6
mutants the expression of these transcription factors is altered. Pax6 has been
shown to bind directly to sequences in the enhancers and promoters of Mashl,
Math5 and Ngn2 (Marquardt et al. 2001; Scardigli et al. 2001).
e) Finally, the Pax6 gene itself contains putative Pax6 binding sites within some
of its regulatory elements. This may mean Pax6 is able to regulate its own
expression (Plaza et al. 1993). Indeed, Plaza et al (1993) showed that quail Pax6
can bind to and transactivate its own promoter in a cell culture assay.
Protein-Binding targets
The chick 8-crystallin gene contains an enhancer site designated DC5 (Kamachi and
Kondoh 1993). This has been shown to have lens specific activity that is dependent
on the binding of SOX2 protein in the presence of a previously unknown
protein(Kamachi et al. 1995). This protein has been recently demonstrated to be
Pax6 (Kamachi et al. 2001). Not only are both transcription factors required to be
bound for the activation of chick 8-crystallin gene but Pax6 protein and SOX2
protein were shown in vivo and in vitro to be able to bind each other (Kamachi et al.
2001). Furthermore the DNA binding site in DC5 is distinct to the Pax6 consensus
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binding site and in the absence of SOX2 Pax6 binds to it 25-fold less efficiently to
the Pax6 consensus binding sequence (Kamachi et al. 2001).
gelB is a member of the matrix metalloprotease (MMP) family of zinc proteases and
is important in eye development (Sivak et al. 2004). gelB has been demonstrated by
EMSA to contain two Pax6 binding sites(Sivak et al. 2004). Pax6 via its paired
domain has been shown to bind to one (Sivak et al. 2004). The other site has been
shown by gel shift assays and immunoprecipitation to bind the protein complex of
Pax6 bound to the transcription factor AP-2a(Sivak et al. 2004). The binding of Pax6
to AP-2a was demonstrated by deletion series to be via the Pax6 C-terminal
activation domain(Sivak et al. 2004).
Immunoprecipitation experiments have demonstrated that Pax6 binds to
retinoblastoma protein via the Pax6 homeodomain. (Cvekl et al. 1999).
Retinoblastoma protein/Pax6 complexes were found in lens nuclear extracts and it
has been suggested that Pax6 and retinoblastoma protein may have a role in
controlling epithelial cell division, fiber cell elongation, and crystallin gene
expression during lens development. (Cvekl et al. 1999).
The glucagon gene is expressed in the pancreatic endocrine a-cells of the pancreatic
islets. Caudal-related factor 2 (cdx2) and Pax6 can bind the G1 element of the
glucagon promoter and transactivate expression (Hussain and Habener 1999).
Interestingly, isolated nuclear extracts have been found to contain several protein
complexes, one of which contained Pax6 protein in a heterodimer with the cdx2
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protein(Ritz-Laser et al. 1999). It has also been demonstrated that Pax6 protein can
bind to cdx-2/3 protein in the absence of DNA (Ritz-Laser et al. 1999). Furthermore,
cdx2 and Pax6 have also been shown to bind with p300 in a transcription complex
(Hussain and Habener 1999).
The transcription ofglucagon is further complicated by the emerging evidence that
Maf, a member of a family of transcription factors containing a basic region leucine
zipper DNA-binding domain, may be involved. It has also been found that Pax6
binding to the glucagon transcription element G1 is enhanced by the presence of Maf
(Planque et al. 2001). A binding site has been identified in the G1 promoter and
demonstrated to be bound to and activated by Maf family members(Planque et al.
2001). However, binding of Maf protein to G1 is not required for G1 activation
(Planque et al. 2001). It is possible that Maf has a role in interacting with the Pax6
protein. Furthermore Maf transcription has itself been shown to be regulated by Pax6
during vertebrate eye development in in vitro studies (Sakai et al. 2001). Analysis
with EMSA and DNase 1 footprinting has shown that there are at least three Pax6-
binding sites located in the 5'-flanking and 5'-non-coding regions of the Maf
gene(Sakai et al. 2001). Mafhas also been shown to play an important role in the
cellular differentiation of several other tissues (Blank and Andrews 1997). In
addition, it is possible that the interactions of Maf and Pax6 vary depending on which
tissue they are expressed in.
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Identifying characteristics of cells capable of expressing
Pax6
Clearly Pax6 affects many cellular processes via interactions of downstream targets
through a number of different mechanisms. One way of understanding these
processes is to investigate the role of Pax6 using tissue culture experiments.
Currently if cells are collected for cell culture experiments, cells are dissected from
tissues, invariably resulting in heterogeneous cell populations. A transgenic mouse
with green fluorescent protein (GFP) as a reporter for the gene Soxl has recently
been made and fluorescence activated cell sorting (FACS) used to separate Soxl
positive cells from Soxl negative (Aubert et al. 2003). A similar approach could be
used to isolate highly purified populations of Pax6 expressing cells.
By designing a transgenic mouse that expresses a marker (such as GFP) in all cells
that express Pax6, bins of cells expressing Pax6 can be identified by FACS using the
GFP signal. Alternatively, resistance to antibiotics, for example neomycin resistance,
could be used to isolate a purified cell population. Creating discrete homogenous
Pax6 expressing cell populations will allow investigation of cell proliferation,
differentiation, cell signalling, and factors that affect Pax6 expression and function
both up-stream and down-stream without the extraneous non Pax6 expressing cells
interfering with the analysis. Crossing such a 'Pax6 reporter' mouse with mice with a
different status of Pax6 (e.g. Pax6 + +, Pax6 +Pax6'conditional Pax6, etc) will
enable bins of cells with different levels of Pax6 protein to be analysed.
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Influence of Pax6 levels on target gene expression
A mass of experimental evidence has been presented above, showing that Pax6 alters
the expression of many downstream targets. One approach to rapidly identifying
candidate downstream targets is the use of micro arrays to examine gene expression
changes in isolated mRNA from wild type and Pax6 mutants. One study using a
micro array has been conducted on different tissues from wild type and Pax6 mutants
and identified 400 possible targets in the developing eye(Chauhan et al. 2002;
Chauhan et al. 2002).
In order for the changes in expression to be meaningful the tissue that the mRNA
comes from must be exactly the same tissue in both the wild type and the mutant.
However, in homozygous null mice this creates an obvious problem for the analysis
of the roles of Pax6 in tissues such as the corneal epithelium and retina that never
form in the mutants. This means analysis of later roles during the differentiation of
the lens and olfactory epithelium is not possible.
One way to purify large numbers of Pax6 expressing cells is to use cells collected
from the Pax6 reporter mouse and sort them by FACS. The two populations of cells
will be purified populations of Pax6 expressing cells and non-Pax6 expressing cells.
For instance if the reporter mouse is bred onto a Pax6 mutant background to derive
the genotype Pax6+/~:Pax6 Reporter and this is in turn bred with Pax6+/" and the
embryos collected then a full range of Pax6 status can be investigated (see Table 1.1
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isolated from the FACS). Bins la, 2a, and 3b all have the same upstream signals
activating Pax6 but they each have a different Pax6 status and hence a different Pax6
protein status. This means bin la cells are wild-type Pax6 expressing cells. Bin 2a
contains cells capable of Pax6 expression but the cells are Pax6 heterozygotes and
hence may have a difference in amount of Pax6 protein produce compared to the
wild-type. Bin 3a contains cells capable of Pax6 expression but the cells are Pax6
homozygotes and hence no Pax6 protein is produced. Collecting mRNA from these
bins of cells and comparing gene expression with micro arrays will reveal what
difference the amount of Pax6 protein is making to the cells and hence will help
understand the role of Pax6. The original tissue that was used as the source of cells
could be as crude as whole brain or whole eye, or come from a dissection such as the
telencephalon. The benefits of this system are:
1. The cells are homozygous populations since the FACS sorts each cell one by
one.
2. This experimental system separates the up stream signals that are regulating
Pax6 expression from the downstream targets of Pax6.
These are powerful gains over other techniques in identifying candidate targets of
Pax6 and will greatly aid in contributing to the emerging understanding of the role of
Pax6 in transcription regulation. Once these candidate genes have been identified
then other techniques should be used to understand the mechanism further. For
example EMSA could be used to demonstrate whether Pax6 is directly regulating the
candidate gene transcription or not.
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More complex analysis of the role of Pax6 in gene regulation is possible by breeding
the Pax6 reporter with other mutants, for instance, either a Gsh2 or Emx2 mutant, and
then using the Pax6 reporter to identify cells capable of expressing Pax6 in the
telencephalon. This will be of immense interest in understanding the interacting roles
of these three genes in regionalising the telencephalon; particularly when the reporter
is bred onto a double knock-out of Gsh2 and Pax6 or Emx2 and Pax6. Dissection of
the telencephalon from the double knock outs on a Pax6 reporter background and
purifying the Pax6 capable cells by FACS will allow identification of changes in
gene targets. A previous study using double knock-outs of Gsh2 and Pcix6 or Emx2
and Pax6 was complicated by the absence of a cerebral cortex (Muzio and Mallamaci
2003). Extreme anatomical changes as a result of mutations make it difficult to be
accurate with dissection and so complicates the isolation of cells. This makes
analysis of mRNA changes to identify changes in gene expression difficult.
However, if the Pax6 reporter is used then the actual Pax6 capable cells in the
mutants can be identified rapidly and accurately by FACS rather than having to
estimate where the cortex and the striatum would have formed, as was necessary in
Muzio et al., 2001 study, and then isolate this "cortex'Mike and "striatunT'-like tissue
by assumed anatomical features which will result in heterogeneous cell populations.
In the Muzio et al., 2001 study the tissue could have been prepared for Pax6 mRNA
in situ using a label that is stable for single cell dissociation and FACS analysis and
then the Pax6 positive cells identified and mRNA isolated for identifying down
stream targets. However, once generated the Pax6 reporter can be bred onto any
viable mutant background and Pax6 capable cells rapidly identified.
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Examining autorequlation of Pax6
One of the downstream targets of Pax6 is potentially Pax6 itself. As described above,
the transcription regulatory elements for Pax6 are extremely complex and there is
emerging evidence that expression of Pax6 may be, in part, regulated by Pax6 itself.
Direct binding of Pax6 protein to Pax6 control elements was first demonstrated with
quail Pax6 protein(Plaza et al. 1993). Autoregulation of Pax6 has been mostly
investigated in the developing eye. It has been shown that Pax6 regulates its own
expression in the presumptive lens ectoderm (Grindley et al. 1995). Pax6 is initially
detected in a broad area of the head surface ectoderm before the lens placode has
appeared. Later expression is more concentrated in the lens placode and lens vesicle.
It has been shown in vivo that Pax6 in the prospective lens ectoderm is itself required
in the ectoderm for sustained Pax6 gene transcription. Detailed analysis of chimeric
mouse embryos consisting of Pax6'A and wild type cells indicates that Pax6 auto
regulates during lens development in a cell autonomous fashion(Quinn et al. 1996;
Collinson et al. 2000). It has been demonstrated using reporter assays that the Pax6
enhancer is activated by Pax6 (Aota et al. 2003). This interaction may be
complicated by a role of Sox2/3 co-binding to the Pax6 enhancer (Aota et al. 2003).
In transgenic mice that express a reporter gene, such as GFP, under the control of the
Pax6 regulatory elements the level of GFP intensity and hence Pax6 expression in
individual cells could be established using FACS. In addition, by breeding the
reporter mouse to other animals with a different status of Pax6 this would allow rapid
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quantification of Pax6 expression levels across different Pax6 protein status. More
specifically, you could tell:
a) If the absolute number of cells expressing Pax6 changes with Pax6 status.
b) If the same number of cells are expressing Pax6 but at a different expression
level.
Autoregulation of Pax6 has only been described in the developing eye to date.
However, it is possible that autoregulation occurs in other tissues, including
forebrain. but has not yet been documented.
Making a 'Pax6 reporter' transgenic mouse
Transgenic reporter strains
Many reporter transgenic mice have been developed for many genes using a variety
of strategies, each with its own advantages and limitations. For a recent review of
reporter transgenic mice see (Kisseberth et al. 1999; Naylor 1999). Several reporter
genes are available. A very commonly used reporter gene used is lacZ. This is a
bacterial gene that encodes the protein (3-galactosidase. The expression pattern is
visualised by fixing and then staining tissue from the transgenic animal. The most
commonly used chemical substrate for visualising (3-galactosidase activity is X-gal.
Other reporter genes commonly used that require chemical substrates are
chloramphenicol acetyltransferase (CAT), horseradish peroxidase (HRP), Luciferase,
and human placental alkaline phosphatase (hPLAP). An alternative to using reporter
genes that require a chemical substrate for visualisation is GFP. Since the tissue and
cells require no prior fixing or the addition of a substrate, the expression pattern in
living cells can be identified. Also since no intermediary substrate is needed, and
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hence no signal amplification used, the level of gene expression can be examined by
measuring the GFP fluorescence.
Whichever reporter gene is used, transgenic mice are particularly useful because they
provide both temporal and spatial information about a particular gene product, even
at a single cell level (discussed more below). Other typical uses of reporter
transgenic include analysing the activity of cis-acting genetic elements such as
enhancer and promoters as described above for Pax6. This is not the only way to
examine the activity of these elements but it is a commonly used technique. They
have also been used to characterise receptors and their ligands; for example, the use
of the Ca2+ -sensitive photoprotein aequorin as a reporter (Stables et al. 1997).
Changes in intracellular Ca2+ as a result of ligand binding are visualised as flash
response (Stables et al. 1997). They are also a convenient way to identify cells that
have come from a particular animal in chimeras.
There are basically two types of reporter transgenic mouse. The first is generated
using homologous recombination in ES cells to introduce reporters such as (3-
galactosidase or GFP into the gene of interest; commonly known as "knock-in"
transgenic animals. The reporter gene is placed into the open reading frame of the
gene of interest. This has been done previously with Pax6: a "knock-in" mouse
Pax6lmlpgr was made with P-galactosidase placed into the translational start site in
exon 4. This placed P-galactosidase under the control of the endogenous promoter
and enhancers (St-Onge et al. 1997). It was found that the P-galactosidase activity in
heterozygous embryos was identical to the expected Pax6 expression. However, this
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has a clear disadvantage that because the Small eye mutation is caused by Pax6
haploinsufficiency, and the p-galactosidase reporter sequence disrupts one of the
copies of Pax6, the animal is now Pax6 heterozygous and therefore a Small eye
mutant. In such mice it is not possible to study the expression pattern in wild-types.
A way round the problem of creating a heterozygous mutant with this type of
transgenic is to use an internal ribosome entry site (IRES). An IRES is believed to
allow the translation of two cis genes from a single transcript by a cap-independent
recruitment of the 40S ribosomal subunit to the mRNA (recently reviewed (Vagner
et al. 2001)). The strategy is to place the IRES into the 3' untranslated region (3'
UTR) of the gene of interest. Downstream to the IRES a reporter gene is placed and
the reporter gene should be expressed in the same cells that are expressing the gene
of interest. Since the IRES reporter is not placed into the open reading frame of the
gene of interest this strategy is less likely to create a heterozygous mutant. This
approach has been successfully used to make a reporter transgenic for the gene Oct-4
(Mountford et al. 1994). In this transgenic the IRES and the reporter gene P-
galactosidase were introduced into the 3' UTR of Oct-4. The disadvantage of using
this technique with a gene with many control elements dispersed over a large area,
such as with Pax6, is that it may be difficult to find a position where the insertion of
the IRES reporter will have no effect on the expression of Pax6. A second
disadvantage is that some reports have indicated that there can be problems with
reduced expression of the 3' cistron (recently reviewed (Kozak 2003)). Thus the
IRES driven expression of the reporter gene may be at a level either too low to be
detectable or useful.
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The second type of transgenic animal is the addition transgenic. These are commonly
made by pronuclear microinjection of a DNA construct into fertilised mouse eggs.
The construct contains promoter and enhancer elements of the gene of interest, and a
suitable reporter gene such as P-galactosidase or GFP. Thus, in theory the reporter
gene will be expressed at the same time and in the same place as the endogenous
protein. However, genes often have more than one set of promoters and enhancers.
Many of these are tissue or temporally specific and so control a subset of the overall
expression pattern. This approach has been successfully used with Pax6 by making
reporter transgenic lines with some of the cis elements from Pax6 and |3-
galactosidase (Kammandel et al. 1999; Xu et al. 1999; Kleinjan et al. 2004). As
described above it is now known that Pax6 has several long range control elements,
some as much as 200kb away from the Pax6 locus.
Many possible vectors are available: plasmid; bacteriophage; cosrnid; PAC (Pl-
derived artificial chromosome); BAC (Bacterial artificial chromosome); YAC. Each
one has a size limitation which limits the length of genomic sequence that can be
included with the reporter gene. Plasmids, bacteriophage and cosmids can hold 40-
50kb of DNA (Peterson et al. 1997). PACs and BACs have been reported to contain
as much as 300kb (Huxley 1998). YACs can contain up to about 2MB of DNA
(Peterson et al. 1997).
There is already a YAC (YAC Y593) containing the human PAX6 gene that has been
demonstrated to contain enough of the surrounding genomic sequence to rescue Pax6
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mutant mice (Schedl et al. 1996). Therefore, I decided to modify the YAC Y593 by
the introduction of a reporter gene, and then generate an addition transgenic mouse
with the modified YAC, generating a 'Pax6 reporter' mouse. The detailed design of
the 'Pax6 reporter' YAC transgenic is discussed in detail in Chapter 2 and 3. Briefly,
a GFP and neomycin resistance cassette was placed under the control of PAX6
regulatory elements. Importantly the PAX6 gene in the YAC is disrupted so that it is
no longer able to produce PAX6 protein from the main canonical translational start
site in exon 4.
When this modified YAC integrated into the mouse genome it integrated at a distant
position away from the endogenous Pax6 gene; an addition transgenic. This meant it
would not affect endogenous Pax6 expression, unlike alternative strategies that use
either a reporter gene inserted into the endogenous gene (commonly known as a
"knock-in") or an IRES reporter inserted into the 3'UTR. This should mean that
every cell capable of expressing Pax6 will also express GFP and be neomycin
resistant. More specifically in Pax6'' mice even though no functional Pax6 protein is
thought to be expressed, the cells that have upstream signals activating the mutated
endogenous Pax6 gene will also activate the reporter gene so the cell will be labelled
with GFP regardless of the fact no functional Pax6 protein is actually being
produced. Therefore, this novel tool should allow the identification and isolation of
Pax6 expressing cells, independent of any mutation at the endogenous Pax6 locus,
thereby helping to understand the normal function of Pax6. This means the "Pax6
reporter' mouse could be mated with mice with any Pax6 status to identify those
cells that are capable of expressing Pax6. Further, by incorporating a neo selectable
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marker under the control of Pax6, the reporter mouse will allow isolation and
purification of Pax6 expressing cells in vitro.
Making YAC transgenics
There are several different ways to transfer the YAC into the mouse embryo and
these techniques can be divided into two groups. The first group requires the
isolation of the YAC DNA from the rest of the yeast endogenous chromosomes and
then the transfer of the DNA into the cell, usually by lipofection or microinjection.
The second way is to do yeast spheroplast-cell fusion. This obviates the need to
isolated YAC DNA and has been done several times (Davies et al. 1993; Jakobovits
et al. 1993; Green et al. 1994; Mendez et al. 1995; Mendez et al. 1997). However,
the YAC is not separated from the yeast endogenous chromosomes and some of the
endogenous chromosomes are also inserted into the mouse genome along with the
YAC. The exact implications of the yeast genome DNA on mammalian cells is still
unclear (Peterson et al. 1997).
I decided that since the implications of including pieces of the yeast genome in
transgenic are not understood the best method was to generate the transgenic mouse
using isolated modified-YAC DNA, discussed in Chapter 3, and microinject it into
one cell embryos, discussed in Chapter 4. This was a very technical and time
consuming procedure and is discussed in detail in the relevant chapters. The
procedure was successful and nine transgenic lines were generated and the analysis is
discussed in Chapter 5.
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Specific aims of the project
The primary aims of this study were to investigate the downstream targets of Pax6.
Previous studies have demonstrated changes in expression of Pax6 downstream
targets in Pax6 mutant mice. The first step at looking at these targets is the
generation of a Pax6 reporter transgenic mouse that expresses reporter genes in cells
that are capable of expressing Pax6. Once this mouse is generated it is clear that it
can be used for a wide range of analysis. For the purpose of this thesis I specifically
wished to examine the following areas:
1. Demonstrate that using a 420kb YAC containing the human PAX6 contains
enough of the regulatory Pax6 elements to drive GFP expression to
recapitulate the Pax6 expression pattern in developing mouse embryos.
2. Examine changes in target gene expression using micro arrays in discrete
FACS sorted populations of Pax6 expressing cells depending on changes to
Pax6 status
3. Demonstrate autoregulation in discrete isolated cells that are expressing Pax6
using FACS to identify and sort the cells capable of Pax6 expression and to
quantify the number and amount of fluorescence.
Unfortunately due to an underestimation of the complexity of generating the Pax6
reporter mouse only the first aim was achievable in the time available.
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Summary of remaining chapters
The description of the production and subsequent analysis of the reporter mouse is
broken down into four parts. Chapter 2 describes the modification of the original
Y593 YAC with a bacterial construct, pDTl. Chapter 3 describes how this new
modified YAC was isolated and the DNA purified ready for microinjection. Chapter
4 describes the microinjection of the modified YAC into mouse one cell embryos.
Chapter 5 describes analysis of the expression pattern of the nine generated lines of
transgenic mice.
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Chapter 2. Generation of Pax6 reporter construct.
Introduction
My aim was to generate a transgenic mouse that will express GFP and neomycin
resistance under the control of PAX6 regulatory elements - a LPax6 reporter' mouse.
As discussed in Chapter 1 this novel tool will allow the identification and isolation of
Pax6 expressing cells, independent of any mutation at the endogenous Pax6 locus,
thereby helping to understand the normal function of Pax6. The only practical way to
produce this transgenic line was to modify the yeast artificial chromosome (YAC)
that contains the human PAX6 gene, YAC Y593. This YAC also includes
approximately 200kb of flanking sequence and has been previously demonstrated to
rescue loss of endogenous Pax6 in Pax6SL} se} mice (Schedl et al. 1996).
The description of the production of the reporter mouse is broken down into four
parts. This Chapter describes the modification of the original Y593 YAC. Chapter 3
describes how this new modified YAC was isolated. Chapter 4 describes the
microinjection of the modified YAC into mouse one cell embryos. Chapter 5
analyses the expression pattern of the generated lines of transgenic mice.
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PART I. Generation of YAC targeting construct pDT1
The starting point for the Pax6 reporter mouse was the YAC Y593 isolated by
Schedl et al in 1996. An expression cassette containing a GFP reporter and a
neomycin resistance cassette was inserted immediately in frame into the translation
start site AUG (in exon 4) by homologous recombination using a yeast URA3
selectable marker. It was critical for the construct to be in frame with the start site or
the GFP would not be expressed. It was also highly desirable that the first codon of
the GFP immediately follow the AUG otherwise extra amino acid(s) could be
introduced. The introduction of an extra amino acid at the beginning of the tau
protein could lead to protein misfolding and the tau failing to work properly.
The YAC targeting construct pDTl contains the following features (see figure 2.1).
a) Approximately lkb PAX6 homology arms. tauGFP was to be precisely inserted at
the normal ATG of PAX6 located in exon4. This meant that a bacterial construct
needed to be positioned in exactly the correct part of PAX6 in Y593. In order to do
this I flanked both ends of the bacterial construct with about lkb of human PAX6
from either side of the PAX6 ATG (PAX6 5'arm and PAX6 3'arm in Figure 2.1). The
homology arms were made using PCR and the arms cloned into the final targeting
construct. The exact mechanism how pDTl was inserted into Y593 is described in
Chapter 2 Part II. One of the requirements was that one of the homology arms must





Figure 2.1. Map of the final YAC targeting construct
pDT1. The map also includes the location of the
restriction site Eco47lll that is used to linearise the
plasmid in order for it integrate into the YAC Y593.
should be approximately in the centre of the arm and must not appear elsewhere in
the targeting construct; in this case I identified Eco47III as a suitable site.
b) Coding sequence for tauGFP fusion protein. GFP can easily be visualised in living
cells under appropriate illumination. This would visually identify the cells expressing
Pax6. tau is a microtubule binding protein. tauGFP is a fusion protein between tau
and GFP. The coding sequence for TauGFP is a gift from Tom Pratt, Edinburgh
University. As shown by Pratt et al (2000a, 2000b) the tau domain of the fusion
protein causes localisation of the GFP signal to the cytoskeleton. This produces a
sharper, more distinct expression pattern rather then the more diffuse pattern that we
would get with soluble GFP. tauGFP is also particularly useful at identifying axonal
projections(Pratt et al. 2000).
c) Internal Ribosome Entry Site (IRES) that is followed by an optimised Kozak
translation consensus start site (IRESKozak). I wanted the tauGFP and neomycin
resistance to be expressed only where there is Pax6, therefore I used the PAX6
promoters and control elements. IRESKozaks are believed to allow the translation of
two cis genes from a single transcript by a cap-independent recruitment of the 40S
ribosomal subunit to the mRNA, recently reviewed by Vagner (2001). In this
instance the IRESKozak was positioned between the 5' tauGFP gene and the 3'
neomycin resistance gene, discussed below. Some reports have suggested that there
can be problems with reduced expression of the 3' cistron, recently reviewed by
Kozak (2003). So I decided that since the tauGFP reporting is more critical to the
project, the tauGFP would be positioned 5' to the IRESkozak.
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d) neomycin resistance (neoR) gene. This allows the use of G418 antibiotic resistance
to select cells that are expressing Pax6. This would be particularly useful for tissue
culture experiments where antibiotic resistance could be used to select for cells that
are expressing Pax6.
e) Polyadenylation (pA) site is to enable polyadenylation of the tauGFP-IRES-neo
mRNA, producing fully functional tauGFP-IRES-neoR mRNA in eukaryotic cells.
f) C2MAZ. C2MAZ is a MAZ site that is found in between the complement gene C2
and Factor B. It is thought these sites slow down RNA polymerase II, pausing
transcription and preventing misexpression of complement genes[Ashfield, 1991
#29; Ashfield, 1994 #30; Yonaha, 2000 #31], I used it in this instance as a strong
stop site in an attempt to promote transcription termination in intron4, thereby
significantly reducing the likelihood of the entire locus being transcribed. The aim
was to exclude the possibility of exon3 splicing to downstream exons and removing
the construct from the transcript. If this were to happen then an isoform of human
PAX6 gene could be expressed from one of the putative ATG sites downstream from
exon4. This could lead to the production of a PAX6 protein. It has already been
demonstrated by Schedl et al (1996) that full human PAX6 can rescue the small eye
phenotype. Therefore, if splicing from exon 3 to downstream exons occurred it
would prevent the analysis of Pax6 mutant mice since their phenotype would be
affected by the isoform of the human PAX6 gene and the cells would not be labelled
with GFP or neomycin resistance. The complete splicing out of transgenes has been
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reported previously with the |3-Amyloid Precursor Protein Gene (PAPP) transgenic
mouse (Muller et al. 1994). The authors undertook to completely abolish the PAPP
gene by inserting into exon 2 a cassette containing the neomycin resistance gene in
the antisense orientation and a lkb putative transcription termination sequence UMS
(upstream mouse sequence). Unfortunately it seems that exon 2 was spliced out
during mRNA splicing so that a read through transcript joining exonl to exon3, and
then exon 3 to the rest of the downstream exons was produced. The presence of the
mRNA transcript was demonstrated by northern blot analysis and RT-PCR and the
presence of the protein was confirmed by western blot analysis(Muller et al. 1994;
Muller et al. 1996). Previously it had been shown in tissue culture experiments that
the UMS acts as a potent transcription terminator in certain cell types(Heard et al.
1987). This therefore indicated that there was risk of the Pax6 reporter cassette
being spliced out and it ruled out using the UMS as a transcription terminator.
g) URA3 is a yeast gene coding for the pyrimidine biosynthetic enzyme OMP
decarboxylase (orotidine-5'-phospahate carboxy-lyase). The strategy used here to
produce the reporter construct was to modify the human PAX6 YAC 593 with a
bacterial construct. URA3 would be used initially to select for yeast colonies
transformed with pDTl. It would then be used to counter select transformed yeast
cells during a second round of recombination. This was possible because 5-
fluoroorotic acid prevents the growth of URA3+ yeast cell Boeke (1987). The exact
mechanism of how this selection occurs and why it was used is discussed later.
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Fortunately all of the sequences for the components of the construct were known.
This meant a comprehensive plan could be put into place designing a thorough
cloning strategy to produce the construct that could be "tested" in silico. Once this
was achieved I was able to undertake the task of actually cloning the various pieces
together. All of the techniques used are standard molecular biology protocols and are
described in the Appendix.
Cloning steps to make pDT1
STEP1 (See figure 2.2)
The source of the C2MAZ element was pPHCAG-C2-egfp which was a kind gift
from Ian Chambers, ISCR, University of Edinburgh; a complete map of the clone is
in the Appendix. The 132bp C2MAZ fragment was then isolated using PCR.
Forward primer: actg TCTAGA GGATCC cttgggggaggggga
Reverse primer: acGAGCTC ACTAGT cagctcactcccctgttga
The 5' ends of the primers had restriction sites included in the primer sequence,
indicated by the uppercase characters in the primer sequence. This would result in
the 5' end of the PCR product having an Xbal site 2bp in. The primer also included a
BamFII site that would be used in a later cloning event. The 3' PCR product included
a SacI and a Spel site that would result in a SacI and a Spel site close to the 3'end.
The Spel site would be used later in STEP 7. The most immediate 5' end of the
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Figure 2.2 Flow diagram of cloning steps 1,2 and 3. STEP 1. The 132bp
fragment containing the C2MAZ element was amplified from pPHCAG-C2-
egfp by PCR. STEP 2. A 252bp BamFII and Xbal fragment containing the pA
site was cloned from pBS-pKnpA into the BamHI and Xbal sites of vector
pBS IIKS to make pBSpA. STEP 3. The BamFII Xbal pA fragment from
pBSpA was then inserted into vector pZeroC2MAZ that had been cut with




























primer (in the case of the Forward primer "actg" is random sequence added to
improve the efficiency of the restriction sites.
The purified PCR product was digested with Xbal and SacI and cloned into vector
pZero2 (Invitrogen, Carlsbad, CA, USA) that had been cut with Xbal and SacI. This
cloning product was called pZeroC2MAZ.
STEP2 (see Figure 2.2)
The pA site is originally from pBS-PKnpA a plasmid generated previously in the
laboratory for another research project. A complete map of the clone is in the
Appendix.
A 252bp BamHI and Xbal fragment containing the pA site was cloned into the
BamHI and Xbal sites of vector pBS IIKS- (Stratagene, La Jolla, CA, USA) to make
pBSpA. The only reason for moving the pA from its original plasmid pBS-PKnpA
which has a pBS backbone into pBS IIKS- was in order to facilitate sequencing of
the pA site in both directions. Previously the sequence of the pA site was known but
I thought it prudent to sequence all of the components before beginning the cloning
protocol.
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STEP3 (see Figure 2.2)
The BamHI Xbal pA fragment from pBSpA was then inserted into vector
pZeroC2MAZ that had been cut with Xbal/BamHI. This cloning product was called
pZeropAC2MAZ.
STEP4 (see Figure 2.3)
The neoR cassette came from pMMneoflox8 (a kind gift from Werner Miiller,
Institute for Genetics, Cologne, Germany). A complete map of the clone is in the
Appendix.
An 802bp fragment encompassing neoR was amplified using the PCR primers:
Forward primer: cacctcgagatgggatcggccattg
Reverse primer: atcACTAGTtcagaagaactcgtcaagaagg
The reverse primer includes a Spel site in the sequence, indicated by the uppercase
characters in the primer sequence. This will result in a Spel site being near the 3' end
of the PCR product.
The purified product was cloned into pTOPO-TA (Invitrogen) following the
manufacturer's instruction to form pTopoNeo. Briefly, the PCR product was
generated with Taq polymerase, which often puts an extra adenosine base overhang
onto the 3' end of each PCR product strand. In the centre of the Topo vector multiple
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cloning site is a thymine overhang on the 5' end of each strand. This means the PCR
fragment can be cloned into this site in the centre of the multiple cloning site.
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Figure 2.3 Flow diagram of cloning steps 4 and 5. STEP 4. An 802bp
fragment encompassing neoR cassette was amplified from pMMneoflox8 by
PCR._The reverse primer included a Spel site in the sequence. This resulted
in a Spel site being near the 3' end of the PCR product. STEP 5. An
Apal/Spel 850bp fragment was cut from pTopoNeo containing the neoR
sequence and a small piece of the Topo vector and cloned into Apal/Xbal cut













Inserting the neoR(STEP5) into pZeropAC2MA2




STEP5 (see Figure 2.3)
An Apal/Spel 850bp fragment cut from pTopoNeo containing the neoR sequence and
a small piece of the Topo vector was cut out and cloned into Apal/Xbal cut
pZeropAC2MAZ. Spel and Xbal can ligate together because they have compatible
cohesive overhangs; this results in both the Spel and Xbal site being destroyed. The
cloning product formed was called pZeroNeoPaC2MAZ.
STEP6 (see Figure 2.4)
The IRESkozak is from pIRES-EGFP (Clonetech, Palo Alto, CA). A complete map
of the clone is in the Appendix.
The IRESkozak was amplified by PCR using the primers.
Forward primer: actgTCTAGA ACTAGT gggatccgcccctctc
Reverse primer: agat CTCGAG catggttgtggccatattatca
Both primers include restriction sites in their sequences so sites are engineered onto
each end of the PCR product. The 5' end of the PCR product has a Xbal site and Spel
site. The 3' end has a Xhol site.
The 626bp PCR product containing the IRESkozak sequence was cut with
Xbal/Xhol. The pZeroNeoPaC2MAZ was cut with Xbal/Xhol and the two ligated
together to form pZeroIRESkNeoPaC2MAZ.
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Figure 2.4 Flow diagram of cloning steps 6 and 7. STEP 6. The IRESkozak
was amplified from pIRES- by PCR. Both primers include restriction sites in
their sequences so sites are engineered onto each end of the PCR product.
The 5' end of the PCR product has a Xbal site and Spel site. The 3' end has
a Xhol site. This 626bp PCR product containing the IRESkozak sequence
was then cut with Xbal/Xhol. The pZeroNeoPaC2MAZ (from STEP5) was cut
with Xbal/Xhol and the two ligated together to form
pZerolRESkNeoPaC2MAZ. STEP 7. A 1.8kb Spel fragment contain the
IRESkozak Neo pA C2MAZ was cut from pZerolRESkozakNeoPaC2MAZ
(generated in STEP 6) and cloned into the Spel site of pBSURA3. This










G neoR P^MAZ\Spel IRESkozak/ URA3|URA3 I Inserting the 1 #/ pZerolRESkNeoPaC2MAZ (STEP7) % Mf into pBSURA3 results in the plasmid fpNSI RESkNeoPaC2MAZura3
pBSURA3 pBSIRESkNeoPaC2MAZura3
STEP7 (see Figure 2.4)
pBS URA3 is a kind gift from D.A. Kleinjan, HGU, Edinburgh, UK. A map of the
clone is in the Appendix.
A 1.8kb Spel fragment contain the IRESkozak Neo pA C2MAZ was cut from
pZeroIRESkozakNeoPaC2MAZ and cloned into the Spel site of pBSURA3. One
Spel site had been previously engineered onto the 5' end of the IRESkozak by PCR
(part of STEP 6) the second Spel site had been engineered onto the 3' end of C2MAZ
by PCR (part of STEP 1). This formed the cloning product
pBSIRESkozakNeoPaC2MAZura3.
STEP8 (see Figure 2.5)
The two PAX6 homology arms were made from cFAT5, the cosmid of human PAX6,
a gift from D.A. Kleinjan. A map of the clone is in the Appendix.
The 1.2kb homology arm immediately 5' to the ATG site, including the ATG, was
created by using the primers.
Forward primer: aaagcagtgaggcgagg
Reverse primer: catgctggctctggctgg
The purified PCR product DNA was cloned into the pTOPO cloning system
following the manufacturer's instruction. The cloning product was called
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Figure 2.5 Flow diagram of cloning steps 8,9,10, and 11. STEP 8. The 1.2kb
homology arm immediately 5' to the ATG site, including the ATG, was
amplified by PCR. The purified PCR product DNA was cloned into the
pTOPO cloning system, the product was called pT0P05'arm. STEP 9. The
1,2kb homology arm 3' from the ATG site, beginning immediately after the
ATG was created using PCR. Both the 5' and 3' primers included EcoRI
sites, which resulted in the PAX6 3' homology arm PCR product being
flanked with EcoRI sites. The purified PCR product DNA was cloned using
the TOPO cloning system, creating the cloning product pT0P03'arm. STEP
10. The 1.2kb Sacl/Xhol fragment containing the 5'homology arm was cut
from pT0P05'arm and cloned into Sacl/Xhol cut pBS II KS-. The resulting
plasmid was called pBS5'arm. STEP 11. The PAX6 5'homology arm in
pBS5'arm was partially digesting with EcoRI. This resulted in a solution
containing two digestion products of 4.2kb. Treating both restriction digest
products with Pfu and then re-ligating then resulted in a solution containing
two pBS plasmids with the 5'arm insert, one plasmid with the EcoRI site
ablated at the Sacl 5' end and the other plasmid with the EcoRI ablated at
the Xhol 3'end. The plasmid with the EcoRI site ablated at the Sacl site was
the version needed and was identified by restriction mapping. Once identified
























pT0P05'arm. The PCR product includes the ATG for PAX6, but this would be
removed during subsequent cloning and be replaced with the ATG from tauGFP.
STEP9 (see Figure 2.5)
The 1,2kb homology arm 3' from the ATG site, beginning immediately after the
ATG was created using the following primers.
Forward primer: GAATTC agaacagtaagtgcctctggtctttc
Reverse primer: GAATTC cagcgacaaacgctcagg
Both the 5' and 3' primers included EcoRI sites, which resulted in the PAX6 3'
homology arm PCR product being flanked with EcoRI sites.
The purified PCR product DNA was cloned using the TOPO cloning system
following the manufacturer's instruction, creating the cloning product pTOP03'arm.
STEP10 (see Figure 2.5)
The 1.2kb Sacl/Xhol fragment containing the 5'homology arm was cut from pTOPO-
5arm and cloned into Sacl/Xhol cut pBS II KS-. The resulting plasmid was called
pBS5'arm.
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STEP11 (see Figure 2.5)
The PAX6 5'homology arm in pBS5'arm was flanked at each end by EcoRI sites.
Both of these needed to be removed in order for subsequent cloning reactions to
work. The EcoRI site at the 3' most end of the homology arm was removed later, but
the one at the 5' end needed to be ablated.
This was achieved by partially digesting pBS5'arm with EcoRI. If a complete EcoRI
digestion was done then a 1,3kb and a 2.9kb product were produced. Conditions
were set up to optimise the chances that only one EcoRI site would be cut, leaving
the other one uncut. This resulted in a solution containing two digestion products of
4.2kb. EcoRI digests leave a 3'overhang, which can be removed using Pfu DNA
polymerase (Stratagene). Treating both restriction digest products with Pfu and then
re-ligating then resulted in a solution containing two pBS plasmids with the 5'arm
insert, one plasmid with the EcoRI site ablated at the SacI 5' end and the other
plasmid with the EcoRI ablated at the Xhol 3'end. The plasmid with the EcoRI site
ablated at the SacI site was the version needed and was identified by restriction
mapping. Once identified this clone was renamed pBSabEcori5'arm.
STEP12 (see Figure 2.6)
The tauGFP used was from pTP6 a kind gift from T. Pratt, Edinburgh University. A
complete map of the clone is in the Appendix.
A 2kb PCR product of tauGFP fusion gene was generated using the primers
Forward primer: catggctgag ccc cgcc
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Reverse primer: tg CTCGAG GAGCTC ttatttgtatagttcatccatgccatgt
This was a long PCR product and needed to have no polymerase transcription errors
so high fidelity proofreading Pfu polymerase (Stratagene) was used to reduce the risk
of errors. This also resulted in a PCR product that was blunt ended, which was
important for the next cloning step.
The reverse primer had both Xhol and a SacI sites included to engineer these at the 3'
end of the PCR product.
The plasmid pBSabEcori5arm was cut with SphI and the 3' overhangs polished with
T4 DNA polymerase to leave blunt ends; with the optimised dNTP concentration T4
DNA polymerase has 3' to 5' exonuclease activity. Part of the 3' overhang included
the ATG from PAX6 but this was to be replaced with the ATG from tauGFP, thus
putting the tauGFP fusion protein in frame with PAX6.
Next the vector was cut with Xhol to create a Xhol sticky overhang at one end.
The tauGFP PCR product was cut with Xhol. Thus the 3' end had a Xhol cohesive
end and the 5'end was still blunt. Figating this with the Sphl/Xhol cut
pBSabEcori5'arm generated the plasmid pBS5'armtauGFP
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Figure 2.6 Flow diagram of cloning steps 12 and 13. STEP 12. A 2kb PCR
product of tauGFP fusion gene was generated from pTP6. The reverse
primer had both Xhol and a Sacl sites included to engineer these at the 3'
end of the PCR product.The plasmid pBSabEcori5arm (generated in STEP
11) was cut with Sphl and the 3' overhangs polished with T4 DNA
polymerase to leave blunt ends. Next the vector was cut with Xhol to create a
Xhol sticky overhang at one end. The tauGFP PCR product was cut with
Xhol. Thus the 3' end had a Xhol cohesive end and the 5'end was still blunt.
Ligating this with the Sphl/Xhol cut pBSabEcori5'arm generated the plasmid
pBS5'armtauGFP. STEP 13. A 3.3Kb Sacl fragment containing the
5'homology arm and tauGFP was cut from pBS5'armtauGFP and cloned into
the Sacl site of pBSIRESkNeoPaC2MAZura3 (generated in STEP 7) to
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STEP13 (see Figure 2.6)
A 3.3Kb SacI fragment containing the 5'homology arm and tauGFP was cut from
pBS5'armtauGFP and cloned into the SacI site of pBSIRESkNeoPaC2MAZura3 to
generate the cloning vector pBS5'armin.
STEP14 (see Figure 2.7)
An EcoRI fragment from pT0P03'arm containing the 3'homology arm was cloned
into the EcoRI site of pBS5'armin. This completed the cloning strategy. The final
10.4kb clone was called pDTl, see Figure 2.1 and 2.8 for a complete map of the
clone.
Once produced the plasmid pDTl was extensively checked with diagnostic
restriction digests and sequencing. Figure 2.8 summarises the restriction digests. The
entire pDTl was then sequenced in both directions and the primers used appear in
the Appendix A.
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Figure 2.7 Flow diagram of the final cloning step 14. STEP 14. An EcoRI
fragment from pT0P03'arm containing the 3'homology arm was cloned into
the EcoRI site of pBS5'armin (generated in STEP 13). This completed the

















Figure 2.8. Summary of restriction digests of four midi preps of clones from
final cloning step. A) EcoRI digests of four midi preps, all contain the insert.
B) Apal restriction digest of two of the midi preps, both are correct. C) Apal
digest of two midi preps, both are incorrect. D) Xbal digest of four of the midi
preps. 1 and 2 are correct. E) Sacl digest of midis 1 and 2, both are correct.
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PART IIA. Integration of YAC Y593 into yeast window strain W3
Before modifying the parental YAC Y593 with the Pax6 reporter construct, it was
introduced into a window yeast strain. This was necessary because the YAC Y593
when run on a pulse field gel (PFG) co-migrates with similar sized endogenous yeast
chromosomes, therefore making it difficult to distinguish the YAC from the
endogenous chromosomes. It was necessary to distinguish the YAC from the
endogenous chromosomes because in order to isolate the modified YAC DNA for
microinjection, it was first necessary to separate the YAC chromosome from the
other yeast chromosomes. The most straight forward way to do this was using
alternating contour-clamped homogeneous electric field (CHEF) pulse field gel
electrophoresis (PFGE) (Chu et al. 1986). This technique separates the chromosomes
by size. So the solution was to use yeast "window strains" (Hamer et al. 1995) in
which appropriate yeast endogenous chromosomes were cut by using recombination-
mediated chromosome fragmentation (Vollrath et al. 1988). The technique involves
splitting a chromosome at a specific site by transformation with short linear
molecules containing a target sequence from the chromosome that is being split at
one end and telomeric sequences at the other. Recombination between the end of the
linear molecules and homologous chromosomal sequences gives rise to chromosome
fragments. A set ofSaccharomyces cerevisiae host strains have been systematically
constructed. Each strain contains defined alterations in its karyotype, which provide a
large-size interval devoid of endogenous chromosomes, i.e., a "window". Window
strain W3 which was produced by (Dr L. Hammer, Department of Biological
Sciences, West Lafayette, IN, US) was mated with Y593 using the kar-cross method
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(Hugerat et al. 1994; Spencer et al. 1994). Briefly, this is a technique that takes
advantage of the properties of karl mutants altered in a gene required for normal
karyogamy (nuclear fusion) during mating. The progeny of the cross were grown in -
AT yeast growth medium. -AT is a double "drop out" selective medium for this
particular YAC. Typical S. cerevisiae growth medium YPD contains glucose, yeast
nitrogen base, and all essential nutrients needed for S. cerevisiae to grow. The exact
requirements of nutrients depend on the genotype of the S. cerevisiae clone being
grown. Different genotypes have different auxotrophic genes from the biosynthetic
pathway. YAC Y593, in addition to the Human PAX6 gene locus, also contains the
biosynthetic genes ADE2 and Trp for yeast cells to produce adenine (A) and
tryptophan (T). By removing adenine hemisulfate salt and tryptophan from the list of
ingredients in the growth medium it is possible to select for only yeast colonies that
express these genes. Therefore, all of the colonies that grow should contain YAC
Y593. Figure 2.9 shows two gels of the parental window strain W3 and the progeny
of the cross between W3 and Y593. The additional YAC is clearly visible in both
gels.
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Figure 2.9. Images of the two yeast strains. (A) Lane 1 is
the original parental strain. Lane 2 is the parental strain w3
crossed with Y593. (B) Lane 1 is the Yeast Chromosome
PFG Marker (New England BioLabs) . Lane 2 is the
original parental strain. Lane 3 is the parental strain w3
crossed with Y593. Lane 4 is the Lambda Ladder PFG
Marker (New England BioLabs). The location of the YAC is
indicated in both gels with an asterisk.
Part I IB. Integration of reporter cassette into Y593 by homologous
recombination.
Once the Y593 had been moved into the window strain it was transformed with the
bacterial construct pDTl using modified lithium acetate yeast transformation (details
of the protocol are included in the Appendix). The final step of the protocol was to
plate onto -AT yeast growth medium, which selected for yeast colonies that contain
Y593. Therefore, all of the colonies that grew should have contained Y593 but only a
proportion of the yeast cells in the transformation event would have integrated the
reporter construct pDTl. However, the window strain has a defective URA3 gene
and so is unable to respond to pyrimidine starvation. Up until this point uracil has
been included among the essential nutrients in order for the yeast to grow (Botstein
et al. 1979). The bacterial plasmid contained the yeast gene URA3, which meant that
any cell harbouring Y593 into which pDTl had recombined would now have been
able to survive pyrimidine starvation. Therefore, uracil was now left out of the -AT
growth medium as well and only yeast colonies that contained the YAC Y593 and
that had been successfully transformed were able to grow. A schematic of the
integration of pDTl into Y593 is shown in Figure 2.10.
Several colonies were picked and screened for the presence of the complete pDTl
using PCR for parts of pDTl distant from the URA3 gene, in this case neoR. The
human PAX6 homology arms that flanked either end of pDTl were included to
ensure that the reporter cassette pDTl was positioned exactly in the correct part of








Figure 2.10. Schematic diagram of the first round of integration of pDTI into
Y593.The exons of PAX6 are indicated by the boxes with the exon number in it.
exon 4 was immediately followed by tauGFP. The correct location of pDTl was
confirmed by Southern blot analysis; see Figure 2.11. There was still a second round
of recombination, discussed below, to be done to remove the repeated PAX6
sequence. Therefore, sequencing of the junction from PAX6 into tauGFP to check
that everything was in frame with no additional amino acids was conducted later
after all recombination events had been finished.
YAC colonies harbouring the correct first round recombination event were plated on
5-fluoroorotic acid (5-FOA) plates. The presence of the URA3 gene meant that the
yeast cells were unable to grow in the presence of 5-FOA (Soderholm 2001; Boeke
JD 1987). Therefore, the colonies were grown for several days on 5-FOA. The 5-
FOA selection would then resulted in two outcomes; either the entire pDTl would be
lost by internal homologous recombination resulting in the recreation of the original
YAC Y593 or the repeated PAX6 exons would be removed, giving the correct
modification of Y593 with pDTl, see Figure 2.10. In order for the 5-FOA selection
to work the growth medium had to be supplemented with uracil again otherwise all
of the yeast colonies would have been unable to grow. This process of using URA3
to select for and then subsequently counter select is more commonly know as "pop-
in/put-out" selection and is widely used in yeast molecular genetics(Boeke et al.
1987; Soderholm et al. 2001). See Figure 2.12 for a diagram showing the two
outcomes of 5-FOA selection.
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Figure 2.11. A) Southern blot screen of first round clones. Clones 1-10, 1-11,
1-13, are all incorrect. Clone 1-12 is correct. B) Schematic diagram of the
first round of integration of pDT1 into Y593. The red boxes are exons of
PAX6. The yellow is exon 5a. The purple box is the URA3 yeast gene. The
green box is the reporter cassette (GFP-IRESkozak-NeoR-pA-C2MAZ). The
restriction sites used to digest the yeast clone DNA are shown. The location

































Figure 2.12. Schematic diagram of the second round of integration of pDT1
into Y593.The exons of PAX6 are indicated by the boxes with the exon number
in it. Both of the two potential outcomes are shown.
Finally, the colonies were screened by PCR for the presence of neoR and checked for
rearrangement with southern blots. 18 clones were picked and screened for correct
first round rearrangement. I was happy with clone 12, giving a success rate of 1:18 or
5.6%. This clone was used in the second round 5-FOA selection. Nine clones were
picked from the 5-FOA plate, designated 1121 to 1129. Southern blots were done to
identify correct clones, see Figure 2.14 and 2.15. Clone 1123 was identified as
correct, giving a success rate in the second round of about 11 %. PCR was then
conducted to confirm the individual parts of the reporter cassette were present in the
clone, see Figure 2.13. The areas around where the reporter cassette integrated was
also examined by PCR, see Figure 2.16. Restriction digests were done on some of the
PCR products to examine them more closely, Figure 2.17. The junction from PAX6
into tauGFP was also checked by sequencing across the junction in both directions,
the primers used are in the Appendix A. Figure 2.18 shows a PFG sizing the
successful clone 1123. The original YAC Y593 is 420kb. Targeting with pDTl
would have added 3.6 kb, therefore the total expected size of the targeted YAC 1123
was 424kb. This was consistent with the size of the band on the PFG panel A. Panel
B is a southern blot of the PFG probed with a 375bp StuI fragment from PAX6 exon
3. The YAC 1123 is easily distinguished from the other endogenous chromosomes.
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Figure 2.13. PCR reactions to confirm parts of pDTl have integrated into
the YAC.Y593 is the original targeted YAC.cFAT5 is a cosmid of the PAX6
cDNA. (A) Primers TauGFPfor and TauGFPrev that flank tauGFP, this has an
expected size of 1.9 kb. (B) Primers IRESkzFor and IRESkzRev that flank the
IRESkozak.,expexted size 615 bp.(C) neoFOR and neoREV flank NeoR-
expected size 806bp. (D) Primers C2MAZFor and C2MAZRev, expected size
125 bp. (E) Schematic of PAX6 showing the locations of the primers.The
red boxes are PAX6 exons. The green box is the inserted reporter cassette
(tauGFP-IRESkozak-NeoR-pA-C2MAZ). Primer sequences are in Appendix
A.
Figure 2.14. Southern blot of Apal/EcoRI restriction digested Y1-12-3 and
Y593. The red boxes are PAX6 exons. The yellow box is exon 5a. The green
box is the reporter cassette (tauGFP-IRESkozak-NeoR-pA-C2MAZ). The
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Figure 2.15. Southern blot of diagnostic restriction digests to confirm the
clone 1-12-3 is correct. The locations of the restriction sites are indicated on
the diagram of the genomic organization of 1-12-3. The red boxes are PAX6
exons. The yellow is exon 5a. The green is the reporter cassette (tauGFP-
IRESkozak-NeoR-pA-C2MAZ). The location of the southern probe is
indicated by the asterisk.
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Figure 2.16. PCR reactions to confirm the areas around where the reporter
cassette integrated are present. Y593 is the original targeted YAC. cFAT5 is
a cosmid of the PAX6 cDNA. A) Primer pair Targ3.1 and Targ 4.1, that have
an expected size of 1.4 kb. B) Primers Targ1.1 and Targ 2.1, expected size
1.3kb. C) Primers Targ1.1 and DTE, expected size is 4.4kb. D) Primers
PAX6_5F and PAX65R, expected size 1.2kb. E) Primers PAX6_3F and
PAX6_3F, expected size 1.2kb. F) Schematic of PAX6 showing the locations
of the primers. The red boxes are PAX6 exons. The yellow box is exon 5a.
The green box is the inserted reporter cassette (tauGFP-IRESkozak-NeoR-


































Figure 2.17. Restriction digests of PCR products. A) Apal digest of PCR
product from TauGFPfor and TauGFPrev. B) Stul digest of the PCR product
PAX6_5F and PAX6_5R. C) EcoRI digest of PCR product Targ3.1 and
Targ4.1. D) Schematic of area around where the reporter cassette inserted
into YAC Y593. The red boxes are PAX6 exons. The green box is the
reporter cassette (tauGFP-IRESkozak-NeoR-pA-C2MAZ). The locations of
primers and restriction sites are shown. The sequences of the primers are




Figure 2.18. Sizing of 1-12-3. A) Lane 1 is the Yeast Chromosome PFG
Marker (New England BioLabs) . Lane 2 is YAC colony 1-12-3. Lane 3 is the
Lambda Ladder PFG Marker (New England BioLabs). The location of the
424kb YAC is indicated with an *. B) Southern blot of the same PFG, probed
with a 375bp Stul fragment from PAX6 exon3.
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In addition to making Y1123 a second YAC was constructed. This work was done as
part of a collaboration with Dr Dirk A Kleinjan and Prof. Veronica van Heyningen at
the MRC Human Genetics Unit (Edinburgh). The same YAC targeting construct
pDTl was used. However, YAC Y593 was modified before the targeting with pDTl.
Dr Dirk A Kleinjan used a bacterial targeting construct to place LoxP sites around a
regulatory element in intron 7 of PAX6 in YAC Y593. This modified YAC was then
targeted with pDTl in the same manner as described for generating YAC Y1123.
Eight clones were picked and screened for correct first round rearrangement. I was
happy with clone seven, giving a success rate of 1:8 or 12.5%. This clone was used
in the second round 5-FOA selection. 12 clones were picked from the 5-FOA plate,
designated 371 to 3712. In the same manner for identifying clone 1123 PCR,
restriction digests, and southern blots were used to identify clone 374 as correct. This
gave a success rate in the second round of about 8%. The junction from PAX6 into
tauGFP was also checked by sequencing across the junction in both directions, the
primers used are in the Appendix A. The addition of the LoxP sites added 64bp to
intron 7 of YAC Y593. It is believed that this will make no difference to the Pax6
expression pattern. The LoxP sites have no bearing on this project and are going to
be used by Dr Dirk A Kleinjan and Prof. Veronica van Heyningen in their ongoing
research. Therefore, the difference in the two YACs is ignored for the remainder of
the work in this thesis.
As a precaution a frozen stock was made from the two correct second round
recombination clones Y1123 and Y374 before proceeding to isolating and purifying
the modified YAC prior to microinjections.
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Chapter 3. Isolation and purification of YAC.
Background
The description of the production of the reporter mouse has been broken down into
four parts. The previous Chapter described the modification of the original Y593
YAC with a bacterial targeting construct pDTl. Once these new modified YACs
(Y1123 and Y375) were constructed they were isolated from the yeast endogenous
chromosomes and the YAC DNA microinjected into one cell mouse embryos.
There is no generally accepted protocol to isolate and purify YAC DNA. Every
laboratory empirically determines an optimum protocol for their circumstances. This
Chapter describes the optimisation of an appropriate protocol. Chapter 4 then goes on
to describe the microinjection of the isolated YAC DNA into mouse one cell
embryos, and Chapter 5 analyses the expression pattern of the generated lines of
transgenic mice.
High molecular weight DNA, such as isolated YAC DNA, is at risk from degradation
because its long length means that it is susceptible to shearing forces. Therefore the
following precautions were taken throughout.
1. Cut-off or wide bore pipette tips were used at all times when handling the
DNA. Although shearing of the DNA by the microinjection needle will take
place, this was unavoidable.
2. The YAC is separated from the yeast endogenous chromosomes by gel
electrophoresis. Any gel containing YAC DNA that was stained with
ethidium bromide (EtBr) and exposed to high intensity UV (ultraviolet) light
for visualising was not used in the preparation of the final DNA for injection.
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This was because the high molecular weight DNA was very vulnerable to
degradation when it was visualised this way. This degradation was verified
empirically by visualising the YAC DNA with EtBr staining and UV light.
When this DNA was analysed there was strong evidence of degradation. In
addition, any carry over of EtBr could be a potential mutagen to the embryos
when the DNA solution was used for microinjection. This meant that at any
point when the location of YAC DNA needed to be identified the gel was
divided longitudinally into three sections in the direction the gel had been run
(see Figure 3.1). The middle section (approximately 90% of the gel width)
was left unstained, and the two flanking slices (each approximately 5% of the
gel width) were stained and used for visualising the location of the DNA. The
location of the DNA in the thin slices was marked by cutting the slices with a
blade. The whole gel could then be reassembled and the location of the DNA
in the rest of the gel could be determined from these marks. The slices that
had been stained with EtBr would no longer be used for the preparation of the
final DNA.
3. It is standard procedure when cutting out high molecular weight DNA from a
preparative agarose gel not to use metal blades, since the metal ions may bind
to the DNA and contribute to degradation (Smith et al. 1988). Instead it was
recommended using a glass cover slip to cut the agarose. Prior to use the
glass cover slip was cleaned with ethanol and rinsed with deionised water.
4. Lowering the concentration of the DNA in solution was a straightforward







STEP1. After running gel cut two thin slices from
each flank with a glass cover slip and remove
slices for staining.
STEP2. Stain the two slices with EtBr
and visualise with UV light.
I I I II
F1
STEP4. Reassemble gel pieces on a
clean EtBr-free surface. Location of three
chromosomes can now be determined
by location of marks. Excise the three
slices containing the YAC, and two
markers.
STEP3. Whilst visualising with EtBr
mark the location of the three
chromosomes with a nick made with a
glass cover slip
Figure 3.1. Staining the gels without contaminating the whole gel with
EtBR or exposing the DNA to UV light.
such as ethanol and salt precipitation, or evaporating the solution away were
not suitable. These techniques require incubation and or centrifugation.
Neither of these is desirable in isolating high molecular weight DNA because
these would expose the DNA to shearing forces.
Initial protocol
There are several different schemes used by different researchers to isolate YAC
DNA. The original protocol that was used for the isolation of the YAC DNA was
suggested by Dr Andreas Schedl (Institute ofHuman Genetics, University of
Newcastle upon Tyne), and was used in the production of the transgenic mouse
PAX77 using YAC Y593 (Schedl et al. 1996). The scheme is outlined below. A
complete description of the scheme is described in the Appendix, Protocol 1:
Preparation of High Density Plugs Protocol A, followed by Protocol 2: Preparation
of YAC DNA for Pronuclear Injection Protocol. The basic scheme is broken down
into five sections, see figure 3.2 for a flow diagram.
1. High concentration plugs
From frozen storage stocks the yeast colony was grown for 144hours at 30°C with
shaking. The final saturated culture should contain between 1x10^ and 4x10^
cells. The colonies were spun down and the weight of the pellet determined. An
equal volume of 1% low melting point agarose solution containing Zymolyase (ICN)
and 14mM (3- mercaptoethanol was added and mixed and the resulting solution
poured into a plug mould that had been chilled on ice. Zymolyase , which is
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1. High concentration Plugs
2. Separation of YAC DNA from Yeast endogenous
chromosomes
3. Concentration of the isolated YAC DNA
using a 4% gel
4. Melting the gel
5. Dialyse the DNA into injection buffer
Amplification of YAC in
selective medium
I




Stain marker lanes on either side
{ I
Isolate YAC containing gel slice




electrophoresis in 4% LMP
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Stain marker lanes on either side
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Isolate YAC containing gel slice
I
Equilibrate YAC containing slice in
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Check concentration and integrity of
isolate YAC DNA with PFGE
Figure 3.2. Schematic diagram of original YAC isolation protocol.
available commercially in a purified form, is prepared from Arthrobacter luteus. The
primary yeast lytic activity of Zymolyase is (3-1, 3-glucan laminaripentaohydrolase.
This hydrolyzes glucose polymers at the (3-1,3-glucan linkages in yeast cell walls
releasing laminaripentaose as the principal product and so breaks down the thick cell
wall of yeast cells (Kitamura et al. 1971). Once the plugs had set they were washed
in a solution containing more Zymolyase for several hours at 37°C and then
overnight in an SDS wash solution containing (3-mercaptoethanol and proteinase K.
Finally, the plugs were washed in TE and then stored in 0.5M EDTA at 4°C until
needed.
2. Separation of YAC DNA from yeast endogenous chromosomes.
A 0.5% TAE agarose gel was cast with a continuous slot for a well to load the plugs
into. This gel has to be made with TAE because the boric acid in TBE has been
observed to inhibit subsequent agarase reactions (New England BioLabs, P-Agarase,
product information). The plugs were loaded into the slot and the gel run. The
individual setting for the PFGE depend on the size of the YAC. By trial and error the
optimal settings were found to separate the YAC from the endogenous
chromosomes.
Once separated the gel was divided longitudinally, perpendicular to the well, as
described above. Roughly 3cm edge strips were used for the EtBr staining and the
centre portion of the gel kept. Once the 3cm edge strips were stained the DNA was
visualised under UV light. The gel strips were nicked with a blade to mark the
position of the YAC, and the upper and lower chromosomes flanking the YAC. The
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gel was then reassembled on a glass sheet and thin slices cut that contained the YAC,
and the lower and upper chromosomes. The lower and upper chromosomes were
subsequently used as markers to calculate the migration of the YAC DNA (Figure
3.1).
3. Concentration of the isolated YAC DNA using a 4% gel.
The isolated gel slices containing the YAC and the upper and lower chromosomes
were turned through 90° and a 4% TAE low melting point agarose gel cast around
them. This concentrating gel was run overnight at 4°C with the buffer re-circulated.
The gel was then cut into three longitudinal sections and the upper and lower
chromosomes stained with EtBr. Visualisation with UV light showed the location of
the compacted bands of the upper and lower chromosomes. With ordinary
electrophoresis gels as opposed to PFGE, DNA longer than 45kb migrates at a rate
independent of the size of the DNA. This means the upper and lower chromosomes
will have migrated the same distance as the YAC. Therefore, the location of the
concentrated YAC DNA can be identified and removed.
4. Melting the gel.
The YAC gel slice was then melted at 68°C for 5 minutes and then incubated at 40°C
for 2 hours with 1U agarase per lOOmg of gel slice. The YAC DNA solution was
then placed at 4°C. This verified that all of the agarose had been digested, any
undigested agarose would solidify. If digestion was not complete then the protocol
suggested repeating the melting process.
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5. Dialyse the DNA into injection buffer.
The YAC DNA was dialysed using floating boat dialysis against injection buffer.
The solution was dialysed overnight and then the DNA was carefully taken up and
40-50 pi was loaded onto a 1% agarose PFG to confirm the DNA was intact. A YAC
plug was loaded next to it to act as a molecular weight marker.
Even after repeating the above scheme several times to eliminate technical
inexperience there was very little DNA isolated. The DNA was never visualised on a
gel even if the entire 150pl solution of isolated DNA was loaded on to a PFG. Figure
3.3 is a typical outcome of the isolation procedure. In the two attempts shown
(Figure 3.3) there is clearly no isolated DNA of the correct size. There is lower
molecular weight DNA in both of the attempts shown that was interpreted as DNA
degradation. Generally speaking you would expect to see greater than 50ng of DNA
stained with ethidium bromide (Sharp et al. 1973): so 150pl of solution at a
concentration greater than 0.3ng/pl would be visible. This indicates that if there was
any high molecular weight DNA in the final product it would have to be at a
concentration lower than 0.3ng/pl otherwise it would be visible. The concentration of
DNA needed for microinjection is 0.3 to 5 ng/pl. So even if there was intact high
molecular weight DNA in the final solution at a concentration too low for detection
by ethidium bromide it was also at a concentration too low for microinjection. In
addition, from the PFG it was clear that the vast majority of the isolated DNA was
degraded low molecular weight DNA, so the vast majority of any transgenic mice
made would only have short transgenes made from these fragments. Given the time












Figure 3.3. Results of Isolating Intact YAC DNA.
offspring that are produced it seemed it was not an option to use the DNA in this
state to produce mice carrying the entire 424kb YAC.
Trouble shooting the isolation of the high molecular weight DNA
At this stage, it was unclear if the bulk of the DNA was either simply being lost due
to procedural error during the protocol or if the DNA was all being lost due to
degradation or a combination of the two.
Identifying at which specific step the intact DNA was being lost
The scheme to isolate the YAC DNA is a long protocol with a number of steps. In
theory the DNA could be lost or degraded at any one of the steps. To address this
problem the original protocol was followed but samples of DNA were removed at all
points and analysed on a diagnostic PFG to see what condition the DNA was in at
each point. It was expected that this would identify either the stage where the DNA
was being lost or if there was further evidence of major DNA degradation.
From the first PFG (step 2 in Figure 3.2) it was clear that YAC DNA was intact at
this point, that is YAC DNA was initially being separated from the endogenous yeast
chromosomes. So samples were removed after the 4% concentrator gel (step 3), after
heating to 68°C (step 4), after 2 hours at 40°C (step 4), and after dialysis (step 5).
Looking at the gels the DNA was intact after steps 1,2 and 3. The DNA was still
mostly intact immediately after melting at 68°C, although there were some signs of
smearing (midway through step 4). However, at the end of the 40°C incubation (end
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of step 4) the DNA was no longer visible on a PFG. Therefore, it seemed that the
problem was due to one or more of the following.
a) DNA escaping from the micro-centrifuge tube that it was in during the
melting and heating.
b) The 40°C incubation process was somehow degrading the entire DNA;
possibly some factor in the DNA solution was causing this (e.g. nucleases).
c) Something prior to the 40°C incubation was priming the DNA so that during
the 40°C step the process of complete degradation was being finished.
It seemed very unlikely that the DNA was escaping from the micro-centrifuge tube.
So the protocol was repeated removing samples as described before. However, at
step 4 several options were taken. Some of the DNA was melted at 68°C and kept.
Some was melted in the same manner and incubated at 40°C. Some was only
incubated at 40°C and some was neither melted nor incubated at 40°C. It was found
that DNA was not lost if it was untreated or only incubated at 40°C. DNA that was
melted at 68°C and then kept had signs of smearing that were taken to be degradation
and the DNA melted at 68°C and incubated at 40°C was completely lost. Therefore,
it was concluded that the heating of the DNA to 68°C was definitely contributing to
the loss of DNA, possibly by mechanical degradation, and the 40°C step was
finishing the process off, possibly through the action of enzymes.
Removing the melting stage was not an option in this scheme, and neither was
reducing the temperature, since 68°C is the minimum temperature required to melt
the low melting point agarose. But eliminating repeating the heating stage when part
of the agarose was not melted was done and became standard.
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This scheme had been shown to work by several people in different laboratories.
This suggested that there was something wrong with the way the protocol was being
followed, or a subtle and undocumented but essential part of the protocol was
missing, or this particular YAC is very sensitive to degradation.
Identifying the unknown factor that resulted in DNA being degraded
during the melting of the agarose.
There are several potential factors that could lead to the loss of the DNA and each
once is discussed in turn below.
a) Nucleases in the solutions, for example in the TAE. Initially the solutions had
been made using general laboratory stocks of reagents and deionised water produced
in the laboratory. Therefore, all solutions were remade taking great care that the
reagents supplied were certified DNAse and RNAse free and that any lab ware, e.g.
to measure out the reagents, was also DNAase and RNAase free. It was also ensured
that any water used was the highest quality polished deionised water. In addition,
using the autoclave to sterilise solutions was avoided since the metal ions from the
autoclave itself could be contaminating the solutions. Very small amounts of metal
ions from using steel blades to cut the agarose containing high molecular weight
DNA have been suggested previously to cause degradation. It therefore, seemed
possible that very small amounts of metal ions from the autoclave itself could
contaminate the solutions. After making these minor changes there was still no DNA
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isolated. However, these high standards for reagents seemed prudent and so were
maintained subsequently.
b) The growth of the yeast was examined closely by looking at and counting the
growing colonies at regular time points for signs of anything unusual. There were no
obvious problems with the growth. In addition, the plug forming protocol used
proteinase K and EDTA in the solutions. Both of these should have prevented the
action of any nucleases from the yeast culture that were carried over into later steps.
An additional reason for analysing the growth is that previously it has been found
that the use of yeast concentrations greater than 6x10 9 per ml in agarose plugs leads
to a significant loss of resolution of the YAC DNA on PFGs (Bauchwitz and
Costantini 1998). It was feasible that the smearing which was evident on the PFGs
was due to this; however, routinely counting the growth of the yeast colonies with a
haemocytometer proved the final yeast concentration was always <6x10 9 per ml.
c) Examination of the protocol for forming the plugs. The PFG gels that were used to
separate the YAC from the endogenous yeast chromosomes had some background
smearing that originally had been understood to be normal but, after discussions with
other groups, was thought more likely to indicate degradation. Therefore, alternative
protocols for the way the plugs were made were investigated. There are a few groups
that work with high molecular weight DNA. Initially it seemed best to make minor
modifications to the protocol before embarking on changing the entire protocol. It
was still unknown if technical inexperience was a factor and continually changing
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the protocol and making new errors due to inexperience rather than learning how to
carry out one of the protocols correctly seemed a possibility.
Originally the plugs were made by preparing a 50:50 mix of pelleted yeast culture
and 1% low melting point agarose in SE buffer. This buffer was 1M sorbitol, 20mM
EDTA, pH8.0, Zymolyase , and 14 mM P-mercaptoethanol. The function of
Zymolyase has already been discussed (it is a typical reagent used to break down
yeast cell walls). The addition of P-mercaptoethanol is believed to predispose the
yeast cells to action of the lytic enzyme Zymolyase (Campbel and Duffus).This
works by breaking disulphide bonds in yeast cell proteins, therefore giving
Zymolyase easier access to its target the cell wall protein P-glucan. EDTA stops
phosphomannose (part of the wall polymer) from inhibiting the digestive activity of
Zymolyase (Rayner and Munro 1998). The sorbitol stabilises the yeast cells
osmotically. Once the plugs were set they were washed overnight in 1% SDS, 0.1M
Tris pH 8.0, 200mM EDTA pET 8.0, 0.5M NaCl, 0.5 M P-mercaptoethanol, lmg/ml
proteinase K.
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A subtly different plug preparation protocol was suggested by Dr Simon Fisher
(Oxford University). The protocol leaves out the proteinase K, exchanges the
detergent 1% SDS for 1% lithium dodecyl sulphate, and adjusts some of the
concentrations of EDTA and Tris in some of the solutions; complete protocol is in
the Appendix, Protocol 3: Preparation of High Density Plugs Protocol B. The
protocol was tried a few times. It reduced the amount of background smear, which
probably indicates less degradation was taking place. Figure 3.4 is a comparison of
the original plug making protocol (Protocol 1: Preparation of High Density Plugs
Protocol A) and this protocol (Protocol 3: Preparation of High Density Plugs
Protocol B). Isolating the YAC DNA from the plugs using the remainder of the
existing protocol (described in the Appendix, Protocol 2: Preparation of YAC DNA
for Pronuclear Injection Protocol) resulted in no intact DNA being purified.
In tandem a different agarose plug protocol suggested by Dr Clare Huxley (Imperial
College School of Medicine) was tried and that also resulted in better resolution of
bands. But again, isolating the YAC DNA from the plugs using the remainder of the
existing DNA isolation protocol (see Appendix, Protocol 2: Preparation of YAC
DNA for Pronuclear Injection Protocol) resulted in no intact DNA being purified. Dr
Huxley's protocol also leaves out the proteinase K and uses the detergent 1% lithium
dodecyl sulphate. The complete plug preparation protocol is in the Appendix,
Protocol 4: Preparation of High Density Plugs Protocol C.
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Figure 3.4. Comparison of different plug making
techniques, (a) Plugs made using plug protocol A.
(b) Plugs made using plug protocol B.
d) Possibility of DNA degrading factor present in PFG equipment. Previously the
equipment was rarely cleaned and was often left for long periods of time full of old
running buffer exposed to sunlight. The equipment was washed with reagents
suggested by the manufacturer but there was no obvious improvement in DNA
preparation. The equipment was primarily being used for analytical work and so any
DNA degradation was less important. This protocol required equipment for
preparative work. Therefore another group was identified that maintained their
equipment at a higher standard. From this point onwards it seemed prudent to use
this equipment.
With all these changes intact DNA was still not being purified. The systematic
examination of the protocol had identified that the DNA was being lost during the
agarose melting stage. Even though the modifications discussed above had failed to
identify the factor that was causing this, these adjustments had resulted in the bands
on the PFG being distinctly clearer and sharper. It seemed better to have this than
more diffuse bands with a high amount of background smear.
DNA concentration
It was also a possibility that even with the heating and melting optimised, and the
prior preparation optimised the concentration of the DNA to begin with was too low.
That is, the melting and heating steps even when optimised may always lose a certain
unavoidable percentage and so if the initial DNA concentration was too low the
protocol would fail.
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The protocol specifies the number of yeast cells to be used in making the plugs. Each
haploid yeast cell contains one copy of the YAC. Therefore the DNA concentration
in the separated YAC DNA band in the first PFG (Figure 3.2 step 2) was predictable.
This prediction assumed that the number of yeast cells being lysed and releasing their
DNA was consistent. According to the manufacturer of the Zymolyase the extent of
yeast cell lysis will vary with yeast growth and cultural conditions and so the yeast
growing conditions can have a detrimental effect on the amount of DNA produced.
However, the growing conditions of the yeast colonies had previously been
examined, see above, and so it was considered probable that the Zymolyase was
working correctly.
The next step in the scheme was to excise the DNA. The slice was cut as small as
possible with the least amount of surrounding gel to ensure the DNA concentration
was as high as possible. After this the DNA was concentrated into a smaller band
(concentrator gel, step 3) and again the gel slice cut as close as possible to this so as
to maintain a high DNA concentration. At neither of these points was the actual
isolated DNA visualised. As explained above, the position of the DNA had to be
estimated by dividing up the gel and using EtBr stained markers. Therefore, there
was the possibility that the concentration was not as high as anticipated. Post staining
the gels with EtBr after the slices had been removed gave some indication as to how
effectively the DNA band had been excised. If it was felt too much DNA had been
missed the protocol could be aborted.
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Running an aliquot of the DNA sample collected prior to the 68°C melting step
demonstrated there was some DNA present; however, the exact concentration of the
DNA was unknown. Unfortunately the expected DNA concentration at this stage was
not discussed in the protocols. The concentration of DNA in the agarose gel prior to
the 68°C melting step can be established by examining the intensity of the DNA
band if a known standard molecular marker of a similar size is available. High
molecular weight markers are commercially available, but the concentration of each
band in the marker is unknown, and so the concentration of DNA can not be
calculated from them.
Since the concentration of DNA prior to the melting step is unknown but the final
product is no or very little intact injection quality DNA and there are several
different alternative methods to isolate YAC DNA, it seemed a good idea to examine
the alternatives. Most of the schemes use the same growing and similar plug
manufacture processes to the ones described above. The major difference in the
approaches is the way the DNA is concentrated. In the original protocol a 4%
concentrator gel is used. One alternative protocol suggested by Dr Lluis Montoliu
(Campus de la Universidad Autonoma de Madrid, Spain) is to place the DNA
solution in a spin column and briefly centrifuge. A brief outline of the changes is
discussed below, also see figure 3.5. The complete protocol appears in the Appendix,
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Figure 3.5. Schematic of the different protocols.
1. High concentration plugs
This was conducted in a similar manner to Dr Clare Huxley's plug preparation
protocol.
2. Separation of YAC DNA from yeast endogenous chromosomes.
This was conducted in the same manner as before but a 1% low melting point
agarose TBE gel was used because the final equilibration of the excised band is into
agarase buffer (lOmM Bis-Tris-HCl pH 6.5, 0.1 mM EDTA, lOOmM NaCl, 30 pM
Spermine, 70 pM Spermidine). The equilibration was done at least overnight. Part of
this equilibration will dilute any boric acid and so prevents the boric acid from
inhibiting subsequent agarase reactions.
3. Melting the agarose gel.
Conducted the same as before
4. Concentrate the isolated DNA using a filter column.
The YAC DNA was pipetted onto a Millipore Ultrafree-MC 30,000 NMWL Filter
Unit (Millipore Cat # UFC3 TTK 00). The filter unit is filled with the DNA solution
and centrifuged at 3000 g in a microcentrifuge for 5 min. The liquid that had passed
through the filter was discarded. The 5 min centrifugation was repeated until 200 to
300 pi of the liquid had passed through the filter. This gave a 2 to 4 x concentration.
Generally the centrifugation had to be repeated 5-10 times. Once concentrated, the
remaining DNA solution was removed by pipetting up and down once or twice
slowly to dislodge the DNA from the surface of the filter.
5. Dialyse the DNA into injection buffer.
This was conducted in the same manner as before.
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The new protocol was attempted a few times without success. The protocol was then
repeated removing samples at every step and analysing them on a PFG. Again the
DNA was found to be lost at the step where the agarose was melted at 68°C and
incubated at 40°C.
Alternatives to heating at 68°C and incubating at 40°C for two hours
Examination of the literature on high molecular weight DNA revealed that most
protocols are based on either this new protocol (spin columns) or are based on the
original protocol (concentrator gel). Both types of protocol required the agarose to be
melted at 68°C at some point to isolate the DNA from the agarose. It is possible to
use electroelution to isolate the DNA from the agarose (Strong et al. 1997). The rest
of the protocol was similar to either of the two already tried. Electroelution devices
are available commercially and ElutaTube™ (Fermentas, Lithuania) was purchased
and tried but with no success.
Ingredients in solutions added to protect the high molecular weight DNA from
degradation.
A number of different schemes have been tried to protect high molecular weight
DNA from breakage. A review of the different schemes reveals a large degree of
conflicting empirical evidence.
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Additives used to compact the DNA to reduce shearing forces
The salts commonly used for protecting high molecular weight DNA in this way can
be broken down into three classes: Polyamines such as spermidine and spermine;
Na+; or combinations using both polyamines and Na+. These approaches are believed
to reduce the radius of gyration of large linear DNAs by compacting them in these
various salts (Bauchwitz and Costantini 1998). It has also been suggested that they
might protect the DNA by forming inter as well as intra-molecular bridges (Schedl et
al.).
Comparing protocols that include and exclude polyamines, it was found that the
presence of polyamines, specifically 5mM spermine, was essential for the isolation
of intact 280kb YAC DNA (Couto et al. 1989). Analysis of another protocol that
excluded polyamines found that the average size of recovered YAC DNA was
approximately 150kb, whereas including polyamines (750 pM spermidine and 300
pM spermine) in the protocol the average size increased to greater than
400kb(McCormick et al. 1989).
Using commercial yeast chromosomes as a source of high molecular weight DNA,
another group identified that high molecular weight DNA prepared in agarose was
degraded when heated to 68°C in the presence of 30mM NaCl but with no
polyamines (Larin et al. 1991).They found that to eliminate this effect it was
necessary to include 750pM spermidine and 300pM spermine to prevent degradation
of large (in this case greater than 620kb) DNA fragments (Larin et al. 1991)
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Later it was confirmed that the presence of polyamines (750 pM spermidine and 300
pM spermine) enabled the recovery of intact 250kb YAC DNA (Gnirke et al. 1993).
In addition, Gnirke et al. (1993) found that without NaCl or polyamines the yeast
chromosomes degraded during agarase treatment (Gnirke et al. 1993). However, in
their hands the DNA prepared sedimented too much to be used for microinjection
(Gnirke et al. 1993). They found that polyamines precipitated the DNA at NaCl
concentrations of 60 mM or less (Gnirke et al. 1993). Interestingly, they found NaCl
concentrations as low as 30 mM in the absence of polyamines protect the DNA from
being sheared (Gnirke et al. 1993). Furthermore, at NaCl concentrations of 100 mM
or more they found that polyamines appeared to have no effect (Gnirke et al. 1993).
Therefore they used NaCl at lOOmM with no polyamines to isolate YAC DNA.
However, another group found, that the reliance on Na+, either alone or in
combination with polyamines, will not provide protection of YACs comparable to
that from polyamines alone (Bauchwitz and Costantini 1998). In addition, they found
that the presence of sodium will antagonize the protective effects of the polyamines
on YAC DNA (Bauchwitz and Costantini 1998).
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Other possible additives
It has been discussed above that metal ions from metal blades can lead to degradation
of high molecular weight DNA. Previously it had been shown that Fe2+ complexed
with EDTA bound strongly to DNA and caused cleavage of single and double
stranded DNA when heated to 68°C in the presence of reducing agents(Schultz and
Dervan 1983). It had also been observed that high levels of Mg2+ protected DNA in
agarose from degradation when heated to 68°C (Larin et al. 1991). This may be due
to the high ionic strength of Mg2+, preventing DNA from denaturing, or because
2"b • 1 *
Mg" forms a complex with EDTA and competes with any metal ions (found in
commercial agarose) for the chelation site (Larin et al. 1991). Therefore Larin et al.
(1991) supplemented their solutions with lOmM MgCh.
It is impossible to satisfy all of the above conditions since some are contradictory.
Also it is important to remember the aim of this project, is to generate a 'Pax6
Reporter' mouse, and not to explain the inter-molecular dynamics of high molecular
weight DNA. It seemed that the remedy was to find a complete scheme that worked
in my hands with this particular YAC; Up until this point two protocols based on
using lOOmM NaCl and polyamines to protect the DNA had been unsuccessfully
used. One used a 4% gel to concentrate the DNA and one used brief centrifugation.
Parts of these protocols had been modified, specifically the way the agarose plugs
were made, but with no success. Therefore it seemed logical to try a protocol that did
not use the same salts to protect the DNA. Dr Clare Huxley suggested a protocol for
isolating high molecular weight DNA (included in full in the Appendix, Protocol 6)
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that omitted polyamines, maintained a high NaCl concentration, and used
commercially available embryo quality water throughout rather than deionised water
made in the laboratory. The protocol used the spin column method of concentrating
the DNA, and prior to the agarose melting step the agarose gel slice was equilibrated
into a solution that was not supplemented with polyamines. This protocol was tried
and after a few attempts worked satisfactorily, see Figure 3.6. The recovered intact
DNA was resuspended in lOmM Tris, 0.2mM EDTA, lOOmM NaCl made in embryo
grade water. The DNA appeared stable at 4°C for several months.
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agarose plug Purified YAC
Figure 3.6. Photograph of a PFG of the purified
YAC DNA alongside a yeast plug.
Chapter 4. Microinjection of YAC DNA into one cell embryos.
Introduction
The description of the production of the LPax6 reporter' mouse has been broken
down into four parts. Chapter 2 described the modification of the original Y593 YAC
with a bacterial targeting construct pDTl. Chapter 3 described the optimisation of an
appropriate protocol to isolate and purify the YAC DNA from the yeast endogenous
chromosomes. This Chapter describes the microinjection of the isolated YAC DNA
into mouse one cell embryos, and the next Chapter analyses the expression pattern of
the generated lines of transgenic mice.
Materials and methods
Microinjection is a highly specialised skill and it was decided to enlist the expertise
of a specialist microinjection facility. After identifying and contacting a few places it
was arranged that the work would be carried out by two groups. Group One was a
specialist microinjection group at the University of Manchester and they would inject
YAC Y1123. Group Two was Dr Dirk A Kleinjan and Prof. Veronica van Heyningen
at the MRC Human Genetics Unit (Edinburgh) and they injected YAC Y374.
Group One: University of Manchester, UK
This work was conducted by technicians at the University of Manchester, UK. We
supplied the DNA at three different concentrations and they injected approximately
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the injections. It was decided to try different concentrations of DNA because in the
YAC literature and from talking to groups that have successfully generated YAC
transgenics by microinjection, they generally isolate about 1 to 5 ng/pl and
subsequently inject at concentrations of 0.3 to 5 ng/pl.
The oocytes used for microinjection were isolated from crosses of C57B1/6 and
CBA.
Group Two: MRC Human Genetics Unit, Edinburgh, UK.
Several aliquots of DNA were supplied at a concentration within the recommended
range for injection concentration (0.3 to 5 ng/pl). Table 4.2 summarises the details of
the injections.
The oocytes used for microinjection were obtained from crossing B6CBAFl/JIcoCrl
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Outline of injection and embryo transfer procedure
Generally speaking similar protocols were used by both groups. 25 jul of isolated
YAC DNA is enough to inject 200-250 one-cell embryos. The groups also used
exactly the same needles to inject the YACs as they use for plasmid DNA, although
they aimed for larger diameter holes at the end of the needles. Furthermore, they
loaded the needles by capillary action from the back of the needle, not by aspiration
of the DNA through the needle end because this leads to unnecessary degradation of
the DNA. The microinjection itself was typically performed using a balance pressure
setting high enough to ensure continuous outflow of DNA.
Another difficulty was that the efficiency rate with YAC transgenics is somewhat
lower than with plasmids and a reasonable estimate was that 5% of injected one-cell
embryos will ultimately be born. Thus the number of injections needed would be
higher than for plasmid injections.
Once injected the one cell embryos were either replaced immediately into a
pseudopregnant female mouse or cultured overnight until two-cell and then
transferred to pseudopregnant female mice. Mice typically have litter sizes of 10
pups and it was expected that many of the embryos would not make it to full term;
therefore, more than 10 one cell embryos were returned to each female. As well as
using fewer mice it also meant that the actual live litter size was larger and closer to
10. It has been reported anecdotally that female mice that give birth to litters with far
less than this can destroy the litter. It was therefore prudent to engineer it so that the
females would give birth to numbers closer to 10.
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Once the transgenic pups were born they were left until weaning (about three-weeks
old) when they were ear punched for identification. The tissue biopsies from the ear
punching were digested with proteinase K and DNA isolated using standard
molecular biology techniques. The DNA was then used in a PCR with primers
specific for mouse Pax6 and Human PAX6 (details of the primers in the Appendix).




In total nine transgenic founders were identified. Four were identified from the YAC
Y1123 (see Table 4.1) and five from YAC Y374 (see Table 4.2). Each identified
founder was bred with CD1 mice to establish nine lines. The nine lines were each
denoted by the original number assigned to the founder plus the name of the YAC.
Hence, the four Y1123 lines are DTyl 123.9, DTyl 123.22, DTyl 123.42, and
DTyl 123.54. The five Y374 lines are DTy374.001, DTy374.028, DTy374.223,
DTy374.226, and DTy374.227. Unfortunately, founder 1123.9 appeared to be sterile
and so did not pass on the transgene, 374.223 died before breeding, and it was
unclear if 374.227 was actually transgenic or not. It is possible that 374.227 was a
very low percentage mosaic and this may make it difficult to be conclusive. Breeding
of the line should establish if it is transgenic or not.
Summary
This Chapter has described the microinjection of the two YACs Y1123 and Y374 by
two different groups. A total of nine transgenic founders were identified and
transgenic lines were established by crossing these founders with CD1 mice. Further
analysis on these lines was done to confirm the extent of the YAC that has been
integrated, the copy number, and the GFP expression pattern. This is described in
Chapter 5.
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Chapter 5. Analysis of 'Pax6 reporter' mice.
Summary
Chapter 5 describes the characterisation of the nine lines of the 'Pax6 reporter' mice,
whose generation was described in Chapters 2, 3, and 4. This analysis shows that the
GFP expression is largely the same in some of the lines as the previously reported
Pax6 expression pattern. In other lines that were analysed the GFP expression was
incomplete and seen in only a subset of where Pax6 expression has been previously
reported.
Introduction
PCR was used to initially identify transgenic founders (described in Chapter 4). The
GFP expression has been analysed at a range of developmental stages by imaging
appropriate mouse embryos. In addition, the calculation of the copy number and
extent of the YAC incorporated in each of the nine lines is described.
Materials and Methods
Extent of YAC Y1123 and YAC Y374 incorporated in the transgenic founders
The extept of each YAC that incorporated into the transgenic founder was
investigated using PCR. From each founder DNA was isolated from ear notches that
had been made for the purpose of identification of the mice. PCR reactions were set
up with 500ng of the ear notch DNA and pairs of human PAX6 specific primers. The
primer sets span the length of the YAC and location is shown in Figure 5.1. The
primer sequences are given in Appendix A.
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Number of copies of the YAC that incorporated in the transgenic founders
The number of copies of the YAC that incorporated was established by using
quantified real time PCR (qPCR). A QIAGEN QuantiTect SYBR Green PCR Kit
(Qiagen) was used according to the manufacturer's instructions. Briefly, the kit
contains an optimized fluorescent dye SYBR Green 1. This dye binds all double-
stranded DNA molecules, emitting a fluorescent signal on binding. This signal can
be detected using a real time PCR machine (MJ Research, San Francisco, USA) and
the amount of original target material calculated.
The number of copies of the YAC incorporated in four (DTyl 123.22, DTyl 123.42,
DTyl 123.54, and DyY374.001) of the lines was calculated. From each line DNA
was isolated from ear notches that had been made for the purpose of identification of
the mice. DNA was collected from at least six mice from each line.
300ng of the isolated ear notch DNA was added to each of the qPCR reactions. The
qPCR reactions were set up according to the SYBR Green manufacture's
instructions. Each reaction contained the template DNA, primers, and the SYBR
Green mix supplied by the manufacturer. Three sets of qPCR were set up with
different sets of primers. Set one used the human PAX6 specific primers previously
used in identifying the transgenic founders. Set two used the mouse Pax6 specific
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Figure 5.1. Diagram of the locations of primers along YAC Y593. The primer
set location is indicated by a grey vertical line and the name of the primer set
is written above. Red boxes are the PAX6 exons. The green box is the GFP-
neoR reporter cassette. The yellow box is exon 5a. Blue boxes are the 3'
exons of the antisense neighbour gene ELP4. E100+ (Box 123) and HS234
are long range highly evolutionary conserved elements. SIMO is the most
distant human patient breakpoint. The approximate minimum extent of the

































































































1123.9 1123.22 1123.42 1123.54 374.001 374.028 374.223 374.226 374.227
primers used in identifying the transgenic founders. Set three used mouse specific
Pax3 primers. The sequences of all the primers are given in the Appendix A.
Sets two and three are controls and will produce a predicable amount of SYBR
Green fluorescence since the gene copy number of both is known to be two. By
comparing the fluorescence generated against the fluorescence generated when the
same amount of DNA is used in set one the number of PAX6 gene copies can be
calculated. This assumes that the DNA is homogenously mixed. The strategy was
recommended by the manufacturers of the real time machine, see Figure 5.17 for a
diagram explaining the calculation. Each qPCR was standardised against the same
set of serial dilutions of known quantities of DNA. In all reactions the samples
appeared on the standard curve within a confidence of >95%. Each reaction was
repeated three times.
Tissue processing for Vibratome sections
Embryos or tissues were fixed in ice cold 4% paraformaldehyde in phosphate
buffered saline (PBS) overnight and embedded in 4% low melting point agarose.
Embryos were obtained from natural matings of transgenic mice and CD1 mice and
the day of the vaginal plug was designated day E0.5.
Sections (200pM) were cut on a Vibratome in ice cold water. Some sections were
counterstained with 0.5pM of T0PR03 (Molecular Probes, NL). T0PR03 binds
nucleic acids. Sections were then mounted on glass slides.
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Figure 5.17. Graph for qPCR calculations. A step by step example of calulating the
number of copies of the YAC with founder x is:
1) For each founder sample 300ng of homogenous DNA was used. Containing N copies
of the genome. However, as this is a homogenous solution the number of copies of
genome is proportional to the mass of DNA used and the amount of DNA used is the
same for each set of primer. Hence N is the same for all the samples.
2) With founder x
FX1 is the fluorescence intensity with Pax6 primers = 91
(from N numbers of genome each with 2 copies of Pax6)
Fx2 is the fluorescence intensity with Pax3 primers = 76 (from 2 initial copies)
(from N numbers of genome each with 2 copies of Pax3)
Fx3 is the fluorescence intensity with PAX6 primers = 42
(from N numbers of genome each with ? copies of PAX6)
There is a linear relationship between SYBR green fluorescence and amount of DNA. So:
no. of initial copies of
fragment amplified by PAX6 X PCR amplification fluorescence intensity with
primers
_ PAX6 primers
no. of initial copies of ~ fluorescence intensity with
fragmnt amplified by Pax3 ^ PCR amplification Pax6 (or Pax3) primers
(or Pax6) primers
The fragment sizes are very similar so the PCR amplification is assumed to be the same
and so cancels out, and:
no. of initial copies of fragment amplified by Pax6 primers = N genomes x2 copies in each genome
no. of initial copies of fragment amplified by Pax3 primers = N genomes x 2 copies in each genome
no. of initial copies of fragment amplified by PAX6 primers = N genomes x ? copies in each genome
4) This leaves:
no. of genome copies ^ ^




Therefore ? = 2 x42 = 0.9 copies
91
and
no. of genome copies ^
based on Pax3 primers: ^ = j-q
1 _ 42
2 76
Therefore ? = 2 x 42 =1.1 copies
76




Cells and tissue were imaged using a Leica TCS NT confocal system and associated
software with DMIRBE (inverted) or DMRE (compound) microscope in a facility
run by Linda Wilson. Corresponding bright field images were collected in the
transmitted channel. GFP was detected in the FITC channel. With the counterstained
sections the T0PR03 was detected in the TRITC channel.
Results
Most of the nine transgenic founders bred and passed on the transgene successfully.
However, DTy374.223 died before it was mated and so the line was lost and
DTyl 123.9 was sterile. In both cases no analysis of the expression pattern was
possible although the extent of the YAC incorporated in the founder was investigated
in both lines as well as in the other seven remaining lines. With line DTy374.227 it
was inconclusive if it is transgenic or not. Some of the results with DTy374.227 were
positive, some were negative. A possible explanation is that it was a very low
percentage mosaic and that repeated breeding would establish the line.
Number and extent of incorporation of YAC Y1123 and YAC Y374 in the
transgenic founders
The results of the PCR to establish the extent of the incorporation of the YAC are
summarised in Figure 5.1. The diagram has horizontal dashed lines indicating the
minimum amount of transgene that is present. It is not necessarily the maximum
amount present since the truncation does not necessarily have to have occurred
146
immediately next to the last set of primers that worked. The extent of the YAC
incorporated in the nine lines of transgenic founders was found to be different in
each line. Some (DTyl 123.54, DTy374.001, DTy374.223) had incorporated the
majority (at least 300kb) of the 424kb YAC. The exact 5' end of the incorporated
transgene was hard to identify. The 5' end contains many repeats and may potentially
be a region of variability from the published human sequence and so the primers
used may not work. The other six founders had incorporated smaller lengths.
DTyl 123.22 and DTyl 123.42 were the most truncated and did not seem to have
even incorporated all of the PAX6 exons.
The number of copies of the YAC incorporated in some of the lines is summarised in
Table 5.1. In all cases examined the copy number was found to be low. The results
are shown from each set of standards (Pax6 or Pax3). There is a small mean
difference between the copy numbers calculated from each standard but it is less than
half a copy number. The standard errors are all less than one copy number. Since
only whole copy numbers are possible I am confident that for line DTyl 123.54 the
copy number is one. For lines DTyl 123.22, DTyl 123.42, and DTy374.001 the copy










DTy1123.22 1.3 ± 0.5 1.0 ± 0.5 6
DTy1123.42 1.4 ±0.5 1.2 ±0.5 8
DTy1123.54 0.8 ±0.2 0.9 ±0.4 7
DTy374.001 1.4 ±0.5 1.8 ±0.8 11
Table 5.1. Real-time quantitative PCR to determine transgene copy number,
n is the number of different animals analysed from each line.
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Initial analysis of GFP expression in the transgenic animals
Six lines (DTyl 123.22, DTyl 123.42, DTyl 123.54, DTy374.001, DTy374.028, and
DTy374.226) were identified as able to successfully pass on the transgene and
therefore could be used to establish transgenic colonies. All six lines are potentially
very interesting since the truncated versions include some but not the entire set of
regulatory elements of PAX6. However, analysing the GFP expression pattern in all
six lines is a huge undertaking. Therefore, only a selection was examined in detail.
Initially, DTyl 123.22, DTyl 123.42, DTyl 123.54, and DTy374.001 were
investigated. This was done by looking at GFP expression in the eyes of live adult
transgenic mice. Pax6 has been previously reported to be expressed in the eyes of
adult mice (Walther and Gruss 1991; Ton et al. 1992; Beimesche et al. 1999). This
analysis was performed by shining a blue LED torch (Inova™ X5™, Emissive
Energy, RI, USA) into the eyes of the live animals. The light is only in the visible
spectrum and so does not harm the animal. The torch emits blue light at the correct
wavelength to excite the GFP. The emitted light was visualized using an appropriate
filter (Tyas et al. 2003). The GFP was clearly evident in the eyes of some of the
transgenic animals. Any pigmentation of the eye made it difficult to be conclusive in
all of the animals. In addition, it is technically very difficult to take a photograph of
this to report the result. Therefore, the eyes from dead transgenic adults were imaged
using confocal microscopy. The eyes were counterstained using T0PR03. The
results are shown in Figure 5.2. All of the four transgenic lines had GFP expression
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Figure 5.2.Confocal images of whole mount adult eyes.
(A-F) are merged green fluorescent andT0PR03
images. (A) Wild type. (B) Y1123.22. (C) Y1123.42. (D)
Y1123.54. (E) Y374.001. (F) Y374.001/Pax6+/Sey. Bar is
400pm.
in the adult eye. DTyl 123.22 had very faint expression. The greatest level of GFP
expression was seen in DTyl 123.54 eyes.
Analysis of GFP expression in a developmental time series in lines
DTv1123.54 and DTv374.001
DTyl 123.54 and DTy374.001 both had incorporated the largest extent of the YAC.
Therefore, the GFP expression in these animals was investigated in greater detail.
Embryos were collected from both lines at several developmental stages. With line
DTyl 123.54 embryos were collected at ages E9.5, E10.5, and E14.5. With line
DTy374.001 embryos were collected at ages E8, E10.5, and E16. A summary of the
development stages examined and index to the corresponding figures is given in
Table 5.2. Some of the embryos were imaged whole mount, with the older ones
appropriate vibratome section were cut and imaged. GFP expression was seen at all
six time points analysed.
a) DTyl 123.54 developmental series
At age E9.5 it is possible to confocal image the whole embryo. Figure 5.3 is a
confocal image of a E9.5 DTyl 123.54 embryo along side a wild type litter mate. The
wild type litter mate has some green colour; however, when viewing the embryo with
the microscope the mouse looks more 'yellowish green', which is typical of auto-
fluorescence, rather than the 'bluer' green of GFP. It is difficult to capture a whole
mount image that can clearly distinguish the two as there is a lot of surrounding
tissue. However, the eye clearly has GFP signal in the transgenic (see Figure 5.3A).
In the wild type litter mate (see Figure 5.3B) there is no signal there.
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Table 5.2. Summary of Figures in this Chapter of GFP expression analysed










Figure 5.3.Confocal images of whole mount embryos,
imaged through only the GFP channel. (A) Y1123.54 at
E9.5. (B) Part of Y1123.54 (Tg) and wild-type (wt) litter
mate at E9.5. Eye (ey), spinal cord (sc).The arrow
indicates the diencephalon. Bars are 200 pm.
Later stage DTyl 123.54 embryos had to be sectioned before imaging. This
significantly reduced background auto-fluorescence. Some of these sections
were counter stained with T0PR03 which is a nucleic acid stain and marks
the nuclei of cells and appears blue in the sections presented here.
At E10.5 (Figure 5.4) GFP expression was seen in the neural tube and the
pons. Expression was also seen in the diencephalon. There was also GFP
expression in the cerebral cortex and it appears to be in a rostral (high) to
caudal (low) gradient. Figure 5.12 is a wild type litter mate for comparison.
GFP expression was also seen in the lens, neural retina, and optic nerve (see
Figure 5.5).
Coronal sections through heads of DTyl 123.54 at E14.5 clearly show that the
GFP expression (see Figure 5.6) is in the epithalamus, pineal, ventral
thalamus, parts of the ganglionic eminence, eminentia thalami, and cerebral
cortex. In addition, the retina and lens is expressing GFP (Figure 5.6). Figure
5.7 shows a magnified confocal image of an El 4.5 eye of a DTyl 123.54
embryo. Figure 5.6 shows that the optic nerve is clearly expressing GFP at
E14.5.
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Figure 5.4. Confocal image of a 200[jM central sagittal section through
a DTy1123.54 E10.5 embryo. (A) and (B) are both merged GFP and
T0PR03 images. (A) Embryo head and trunk, scale bar is 200|jM. (B)
Enlargement of boxed red area in (A), scale bar is 20|jM. (C) Diagram
showing a red line that indicates the plane of section of (A). Cerebral
cortex (cc), basal plate of pons (po), diencephalon (di), neural tube




Figure 5.12.Confocal image of 200pM coronal section
through the head of an E10.5 wild type littermate. Image is
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Figure 5.5.Confocal image of a 200|jM section through an
El 0.5 DTy1123.54 eye.The image is a merged GFP and
T0PR03. (B) Pax6 mRNA in situ of E10.5 eye (taken from
Fig.3 Bernierefa/., 2001). Retinal pigmented epithelium
(rpe), lens (Is), distal portion of retina - ciliary margin (cm),
neural retina (nr).(on) optic nerve.The scale bar is 200pm.




















Figure 5.7.Confocal image of 200 pm sections through eye of
Y1123.54 El 4.5 embryo. (B) is a magnified view of the boxed area
in (A). Both images are merged GFP and T0PR03. (C) Pax6 mRNA
in situ of El 3.5 eye (taken from Fig. 5 Callaerts et at., 1997). Neural
retina (nr), lens (le), optic nerve (on). Bar is 200 pm in (A) and 20
pm in (B).
Temporal (Posterior)
Lateral -4- ->• Medial
Cutting DTyl 123.54 E14.5 in the sagittal plane (Figure 5.8) allows the GFP
expression to be confirmed in the locations already identified; the basal plate
of the pons, the epithalamus, cerebellum, ventral thalamus, and optic tract.
b) DTy374.001 developmental series.
The earliest embryonic developmental stage looked at with any of the
transgenic lines was with DTy374.001 at E8.0, data not shown. The
dissection at the stage was difficult and only conducted on one litter. There
was potential GFP signal, however, it was difficult to identify the exact
location. Therefore, this needs to be repeated and with carefully cut thin
sections in order to fully demonstrate the expression.
El 0.5 whole mount DTy374.001 was imaged, see Figure 5.9. As with other
whole mount embryos there is a lot of tissue and so imaging is difficult
because of the auto-fluorescence. However, the eye is clearly labelled with
GFP. Parts of the brain are also possibly expressing GFP but it is difficult to
be certain because of the auto-fluorescence.
Cutting sections from E16 embryos allowed GFP expressing tissues to be
clearly identified. Figure 5.10 is a transverse section through the head of a
DTy374.001 embryo. The eye, optic nerve, optic tract, and telencephalon are
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Figure 5.9. Confocal image of whole mount embryo











Figure 5.10. Confocal image of a 200 pm transverse section of El 6
Y374.001 embryo. (A) Image is GFP channel only.(B) Diagrams
showing the plane of section. Eye (ey), telencephalon (tel),
olfactory epithelium (oe),optic tract (ot),and optic nerve (on). Bar
is 200 pm.
Analysis of GFP expression in E14.5 DTy1123.22 and DTy1123.42
From the PCR analysis it was believed that lines DTyl 123.22 and DTyl 123.42 only
incorporated a small part of the YAC Y1123. Interestingly, neither of these two lines
appeared to have incorporated all of the PAX6 exons. Therefore, one developmental
stage (El 4.5) was selected to analyse the GFP expression of these two lines.
Figure 5.11 shows the expression in two coronal sections of the head of an E14.5
DTyl 123.22 embryo. GFP expression was seen in the ventral thalamus and parts of
the ganglionic eminence, amygdala, prospective entopeduncular nucleus, and the
cerebral cortex. However, GFP expression was absent in the eye at E14.5. There was
no apparent ectopic GFP expression seen in any of the sections.
Figure 5.13 shows the GFP expression in a coronal section of the head of a
DTyl 123.42 embryo. Some GFP expression was seen in the retinal pigmented
epithelium in the E14.5 eye (see Figure 5.13B for an enlargement of the eye) and
possibly parts of the brain, such as the pineal gland and the dorsal thalamus.
However, the level of brain expression is only slightly above background auto-
fluorescence and appears to be ectopic, such as in the basal telencephalon, Figure
5.13. Compare this expression level to the potential GFP expression in the
extraocular muscles (Figure 5.13) and the actual GFP expression verses auto-
fluorescence is questionable. There is also a very low level of expression in the lens.
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Figure 5.13. Confocal image of 200 pm coronal section
through the head of an Y1123.42 El 4.5 embryo. Both images
are merged GFP and T0PR03. (B) is an enlargement of the
red box in (A).(C) Camera lucida diagram showing the plane
of section of (A). Retinal pigmented epithelium (rpe), dorsal
thalamus (dt), lens (Is), basal telencephalon (bt), extraocular
muscles (eom),and pineal (pi). Scale bar is 200 pM in both.
Discussion
Extent of the YAC integrated in the 'Pax6 Reporter' mice
Using PCR primers to establish the extent of the incorporation of the YAC revealed
that a varying amount was integrated in each line. PCR is not a conclusive method of
establishing the extent of the integration since it will only identify short pieces and I
have to assume that if corresponding flanking short sequences are present then the in-
between sequence (that is not included in the PCR) is also present. In addition, the 5'
most primer pair (5395F and 5395R) failed to produce a band with any of the
founders, and the next set of primers (5083F and 5083R) produced a band with some
of the founders (for example DTyl 123.54). I can not conclude that the YAC
necessarily truncates at this point. The primers are 90kb apart and so the truncation
could be anywhere between them.
The YAC is 424kb long and so sequencing is not an option. The PCR analysis shows
that lines DTyl 123.54, DTy374.001, and DTy374.226 have incorporated the
majority of the YAC. Furthermore, GFP expression was seen in lines DTyl 123.54
and DTy374.001 in locations appropriate for Pax6 expression, discussed below. The
GFP expression in line DTy374.226 was never examined. The fact that the GFP was
seen in areas consistent with previously reported Pax6 expression is evidence that the
regulatory elements are probably all present since the expression appears correct.
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GFP expression in DTy1123.54 and DTv374.001
Looking at the various DTyl 123.54 and DTy374.001 embryos (see Table 5.2 for
index of figures) it is clear that the GFP expression pattern seen is the same in both at
the developmental stages when both lines were examined.
a) E9.5
GFP expression at E9.5 was only examined in line DTyl 123.54 (Figure 5.3).
This Figure is a whole mount embryo and so the background auto-
fluorescence is high. However, in Figure 5.3B the spinal cord of a
DTyl 123.54 embryo is shown next to the wild-type. Comparing the spinal
cord of the transgenic against the wild type litter mate it is clear that the
spinal cord has specific GFP expression. Pax6 mRNA has been detected in
the spinal cord of E9.5 embryos before (Filosa et al. 1997; Bernier et al.
2001). Also see Figure 1.6 in Chapter 1.
The clearest GFP expression is in the eye. In the transgenics the eye appears
as a bright green ring, in the wild type it does not. Pax6 mRNA expression in
the eye at E.9.5 has been previously shown (Walther and Gruss 1991; Bernier
et al. 2001).
The forebrain, probably the diencephalon, indicated by the arrow in Figure
5.3 seems to have a defined GFP expression in the transgenic DTyl 123.54.
This is consistent with Pax6 mRNA expression that has been seen in E9.5
forebrains before (Bernier et al. 2001; Ohtoshi et al. 2002).
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b) E10.5
GFP expression at E10.5 was examined in both DTyl 123.54 and
DTy374.001.
Figure 5.5 shows that GFP was clearly expressed in the neural retina and lens
of the eye of E10.5 DTyl 123.54 embryos. At this age the lens pit, optic cup,
and presumptive retina have been shown to express Pax6 protein (Faber et al.
2001 ).Pax6 mRNA expression has also been previously detected at this age
in the retinal pigmented epithelium, iris, distal portion of the retina, and the
lens (see Figure 5.5 B for Figure from Bernier et al., 2001)(Bernier et al.
2001), the lens pit and surface ectoderm of the eye (Grindley et al. 1995), and
the lens and neural retina (van Raamsdonk and Tilghman 2000). Expression
in the eye was also easily seen in E10.5 DTy374.001 whole mount embryos,
see Figure 5.9. However, as with other whole mount embryos there is a lot of
tissue and so imaging is difficult without a lot of auto-fluorescence.
Whole mount E10.5 DTy374.001 embryos also appeared to have specific
GFP expression in the brain (see Figure 5.9). A sagittal section of a
DTyl 123.54 embryo at this age reveals the specific GFP expression in the
brain. It appears to be localised to the diencephalon, both the ventral and
dorsal thalamus (see Figure 5.4A and B). This is consistent with previously
reported Pax6 expression (Walther and Gruss 1991; Warren and Price 1997).
The enlargement in Figure 5.4 demonstrates the expression is cellular rather
than from axon tracts. The cerebral cortex is also expressing GFP, (Figure
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5.4). In addition the expression appears to be in a rostral (high) -caudal (low)
gradient. GFP expression was also clearly seen in the neural tube. All of these
observations fit with previously reported Pax6 expression at El0.5 (Walther
and Gruss 1991).
c) E14.5
This developmental stage was only examined in DTyl 123.54 but it was
examined in two different planes of section.
Coronal sections through heads of DTyl 123.54 El 4.5 clearly show that the
GFP expression is the same as previously reported Pax6 expression. More
precisely, in Figure 5.6 the epithalamus, pineal, ventral thalamus, eminentia
thalami. and cerebral cortex express GFP. All of these structures have
previously been shown to have Pax6 mRNA expression at El4.5 (Stoykova
et al. 1996; Warren et al. 1999). In addition, the retina is expressing GFP
(Figure 5.6). It has been previously shown at age E12.5 (Grindley et al. 1995)
and El3.5 (Callaerts et al. 1997; Bernier et al. 2001) that Pax6 is expressed in
the neural retina, lens and optic stalk of DTyl 123 at E14.5 (see Figure 5.7 A
and B, also see Figure 5.7C for a comparative Pax6 mRNA El3.5 expression
pattern from Callaerts et al., 1997). At El 7.5 Pax6 expression has been
detected in the ciliary body and iris(Bernier et al. 2001). Figure 5.6 and
Figure 5.7A and B show that the optic nerve and optic tract are clearly
expressing GFP at E14.5. In addition, Figure 5.7B is a magnified image of
the optic nerve and the GFP is clearly not co-localised with the nuclear
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T0PR03 counter stain, hence demonstrating that the GFP is expressed in the
cell body. More specifically, the cell body appears to be fibrous, this is
consistent with the GFP expression being in the optic nerve. The optic stalk
has been shown to slightly label for Pax6 mRNA before (Callaerts et al.
1997). It is thought that since the cell body and nucleus for these cells is in
the retina of the eye that there may be some Pax6 mRNA and protein in the
cell body (the optic stalk and optic nerve) that will label. In this thesis the
GFP used is tauGFP so it is expected that the microtubule containing
elements, such as axons, would contain the GFP. Hence, these structures are
labelled with GFP. This is also seen in coronal sections of DTyl 123.54 E14.5
embryos (see Figure 5.6). This does provide a useful way of identifying
possible target sites of Pax6 expressing cells.
The ganglionic eminence also appears to express GFP. Previously the
reporting of Pax6 expression in this area is a little mixed. It has been
previously reported that Pax6 expression is in the ventricular zone of the
cortex but specifically not in the medial and lateral ganglionic
eminence(Stoykova et al. 1996). See Figure 5.14 for a reproduction of the
figure from the publication, one of the Stoykova et al., 1996 figures is also
included in Figure 5.6 as panel D for easy comparison with the Y1123.54
expression in Figure 5.6 panels A and B. However, more recently it has been
reported that Pax6 mRNA is expressed in the dLGE and vLGE (see Figure
5.14 for reproduction of the published figure(Yun et al. 2001)). In addition,
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A) Pax6 in situ mRNA hybridization at e12.5
(Actual size figure from Fig1, Stoykova, A. et al., 1996)
Bright Field Pax6 mRNA
<D
w
B) Pax6 in situ mRNA
hybridization at e14.5
(Actual size figure from Fig3,
Stoykova, A. et al., 1996)
C) Pax6 in situ mRNA
hybridization at e12.5
(Actual size figure from Fig2,
Yun, K. et al., 2001)
Figure 5.14. Previous published figures of Pax6 expression in the sections of the
developing mouse embryo. Amygdale (AA), anterior entopeduncular area
(AEP), anterior hypothalamus (AH), chorioid plexus (ChPI), dorsal lateral
ganglionic eminence (dLGE), dorsal thalamus (DT), eminentia thalami (EMT),
epithalamus (ET), hippocampal primordium (Hi), hypothalamic cell cord (HCC),
hypothalamus (HT), infundibulum (IN), lateral ganglionic eminence (LGE),
lateral ventricle (LV), medial ganglionic eminence (MGE), neocortex (NCX),
optic stalk (OS), paraventricular nucleus (PA), piriform cortex (PC), posterior
entopeduncular area (PEP), anterior preoptic area (POA), posterior preoptic
area (POP), posterior commissure (PC), retrochiasmatic area (RCH), rathke's
pouch (RP), septum (SE), suprachiasmatic area (SCH),
supraoptic/paraventricular area (SPV), tuberal hypothalamus (TU), ventral
lateral ganglionic eminence (VLGE), ventricular zone (VZ), ventral thalamus
(VT), and third ventricle (3V).
this has been confirmed that Pax6 protein is seen in the LGE (see Figure 5.6
E (Toresson et al. 2000), the Toresson et ah, 2000 Figure is also included in
panel E of Figure 5.6 for easy comparison). The expression in the LGE is
identical to the expression in Line Y1123.54 shown in Figure 5.6 part (A),
left cerebral hemisphere. Also unpublished data, see Figure 5.15, indicates
there may be Pax6 positive cells in the ventricular zone of the ganglionic
eminence. In addition, close inspection of the ventricular area of the
ganglionic eminence of Figure 5.14 panel A of the work presented by
Stoyoka et ah, 1996 there is a definite difference in colour that could be
interpreted as low level Pax6 expression. This band of colour is not discussed
by the original authors. In conclusion, the present work and the more recent
publication have demonstrated that there clearly is some Pax6 expression in
parts of the ganglionic eminence.
As was discussed in Chapter 1 there is a body of literature investigating the
role of Pax6 in specifying the regionalisation of the telencephalon. Fully
reconciling the results presented in this thesis with the body of literature will
require further work. However, it is also worth remembering this is a reporter
mouse that has tauGFP expression controlled by PAX6 regulatory elements
and therefore, will not necessarily have an identical expression pattern as an
mRNA in situ or a Pax6 immunohistochemistry (this is discussed later in this
discussion). In addition, there are sensitivity differences in mRNA in situ and
Pax6 protein immuno studies and there is no reason why the reporter mouse
will not have a different sensitivity to both of these. All of these factors mean
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Figure 5.15. Pax6 Immuno histochemistry of a
coronal section of an e15.5 embryo.The arrow
head marks where that Pax6 expression extends
along the ventricular zone of the ganglionic
eminence. Figure courtesy ofTom Pratt,
unpublished data.
there may be some differences in details of the expression pattern depending
upon the method of analysis.
In addition the DNA sequence for the Y1123 is human PAX6 and not mouse
Pax6. There are some differences in the sequences and it is possible that the
difference in expression pattern is due to the difference in regulatory elements
between mouse and human PAX6. Also it is currently unknown what the
half-life for tauGFP is compared to Pax6 protein and this may complicate
analysis of the expression pattern. Interestingly, in the Y1123.22 line (See
Figure 5.11 panels A and B, this Figure also contains the Stoykova et al.,
1996 in panel D, and the Toresson et al., 2000 Figure for easy comparison)
that carries a truncated version of the YAC1123 the expression pattern in the
ganglionic eminence at this age is different to the one seen with the Y1123.54
line. It is unknown without further work which is correct. In line Y373.001
that has also incorporated the full length YAC, expression analysis of the
ganglionic eminence has not been done. The difference in expression pattern
seen in Y1123.22 and Y1123.54 could be a position effect or subtle alteration
in the regulation of Y1123.54 that is leading to the ganglionic eminence GFP
expression to be different.
The only way to answer this is further work. Initially I would label some of
the sections from the Pax6 Reporter for Pax6 mRNA and others for Pax6
protein. Then use confocal microscopy to look for coincidence of labelling
between the GFP and the immuno or GFP and the mRNA in situ. As well as
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addressing the issue of establishing the Pax6 expression pattern in the
ganglionic eminence these comparative analysis will potentially help to
understand the role of Pax6 in the telencephalon; particularly its role in
establishing the pallial-subpallial boundary.
Further work also needs to establish if the tauGFP in the ganglionic eminence
is nuclear or axonal projections. Pax6 is a nuclear protein, and therefore Pax6
immunos will show nuclei staining. tauGFP is designed to label cytoskeletal
projections, such as the ones found in axons, and is specifically excluded
from the nucleus. In cells that do not have axons it is expected the cytoplasm
will be labelled. Flowever, further work such as higher magnification
confocal microscopy with the nuclear co-stain T0PR03 will help.
Sagittal sections of DTyl 123.54 (Figure 5.8) reveal expression in the basal
plate of the pons. This area has been described previously to express Pax6
protein (Vitalis et al. 2000). In addition, expression in the epithalamus,
cerebellum, ventral thalamus, and optic tract is again seen.
d) El6
The latest developmental stage examined was at El6 in DTy374.001
embryos. Figure 5.10 is a transverse section through the head of a transgenic
embryo. The eye is clearly labelled along with the optic nerve, and optic tract.
This has been discussed above. Pax6 expression has been detected in the
ciliary body and iris at El7.5 (Bernier et al. 2001). The telencephalon is also
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labelled with GFP. Pax6 mRNA expression in the telencephalon has been
observed previously at E16 (Toresson and Campbell 2001). The olfactory
epithelium is also possibly expressing GFP. This is consistent with previously
reported Pax6 expression at El6 in the olfactory epithelium (Walther and
Gruss 1991).
In summary, the GFP expression mostly matches the Pax6 mRNA and protein
expression seen before at this range of ages in both DTyl 123.54 and DTy374.001.
The only expression that needs further investigation is in the ganglionic eminence,
and the further work that I would suggest has been discussed above.
In terms of developmental age of expression, GFP was clearly visible in the correct
places at age E9.5 and potentially at E8.0 (data not shown). This is consistent with
the point when Pax6 is first expressed in the mouse.
Partial GFP expression in E14.5 DTy1123.22 embryos
Figure 5.11 shows that some of the GFP is expressed in regions that are appropriate
for Pax6 expression. In Figure 5.11 panels D and E are examples of published Pax6
expression in the brain for comparison. The cortex, ventral thalamus, amygdala, and
ganglionic eminence GFP expression seems to be as expected for this age(Stoykova
et al. 1996; Toresson et al. 2000). The open arrow heads in Figure 5.11 B and the
Stoykova et al., 1996 figure in panel D (ii) are a positive stream of Pax6 positive
cells all along the external medullary lamina and are believed to contribute to part of
the ventral lateral geniculate body (VLG)(Stoykova et al. 1996). The open arrow
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head in Figure 5.11 B and D (ii) is the prospective entopeduncular nucleus (EP)
which has been previously shown to strongly express Pax<5(Stoykova et al. 1996).
The interesting aspect of the GFP expression is in the eye. Figure 5.6 shows that GFP
expression was very clearly evident in the eye of DTyl 123.54 E14.5 embryos.
Flowever, with DTyl 123.22 this was not the case. Several sections were examined
and the GFP expression level was always very similar to background auto-
fluorescence.
This is a truncated YAC so there are several possibilities why this could have
occurred. Firstly, the truncated YAC might not include a necessary eye regulatory
element. Figure 5.2 shows that in adult DTyl 123.22 GFP is also expressed at a very
low level. This is possibly due to the truncated YAC not containing the regulatory
element required for GFP expression. Secondly, the truncated YAC could be as small
as 65kb. This might be small enough that the position where it has integrated has an
effect on the expression, such as tissue specific silencing of the truncated YAC.
Detailed Southern blot analysis and fluorescent in situ hybridisation will have to be
done to elucidate the exact extent of the YAC integrated and the location of the
insertion site, this is described below. In addition, detailed analysis of developmental
stages of DTyl 123.22 would have to be examined in order to understand the GFP
expression. The truncation may have resulted in the loss of a regulatory element
required for El 4.5 and adult expression or it could be more general and mean that
GFP is never expressed in the embryonic eye.
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Partial GFP expression in E14.5 DTy1123.42 embryos
GFP expression in El4.5 DTyl 123.42 embryos was also very interesting. The GFP
expression was seen at a low level in the pigmented retinal epithelium, (Figure 5.13).
The presumptive pigment epithelium has been previously shown to expresses a low
level of Pax6 (Walther and Gruss 1991).
GFP was also possibly expressed in parts of the brain; however, it is difficult to
establish what is auto-fluorescence and what is GFP expression.
Interestingly, Figure 5.2C shows the GFP was expressed clearly in the eye of adult
DTyl 123.42 mice. The level of GFP expression in the eye is possibly lower in
DTyl 123.42 compared to DTyl 123.54 (compare the adult eyes in Figure 5.2C and
Figure 5.2D and the E14.5 embryonic eyes in Figure 5.13B and Figure 5.6).
Comparing Figure 5.13B against Figure 5.7B it seems that in E14.5 DTyl 123.42
embryos the optic tract and nerve do not express GFP. As discussed above the GFP
expression in the optic nerve and tract are probably due to expression in the cell
bodies of the axons in the retina. Since there appears to be very low expression in the
eye in general it seems reasonable that there is low or no GFP expression in the optic
nerve and tract.
From the PCR analysis it was known that the YAC integrated in DTyl 123.42 was
truncated. As discussed above for DTyl 123.22 there are many reasons why this
truncation could result in unexpected GFP expression. What is more interesting is
that from the PCR analysis both DTyl 123.22 and DTyl 123.42 seem to have
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integrated at least 65kb of the YAC but probably less than 150kb, but the expression
pattern is completely different in the two lines. DTyl 123.22 seems to express in the
correct areas of the brain in E14.5 embryos but has very low expression in the eye.
On the other hand DTyl 123.42 seems to have some expression specifically in the
retinal pigment epithelium and possibly some in the brain. This difference could be
due to the truncation being different and including different regulatory elements or
due to the position the YAC integrated, or a combination of both.
An important conclusion is that in lines DTyl 123.54 and DTy374.001, which have
both incorporated at least 300kb of the 424kb YAC the GFP expression is largely
consistent with previously seen Pax6 expression over the developmental time series
examined (E8.0 to E16). However, truncated YACs, that is the ones incorporated in
lines DTyl 123.22 and DTyl 123.42, do not recapitulate the complete Pax6
expression. Therefore, using a vector containing many hundred kilobases of the
PAX6 locus, for example a YAC, is the only way of correctly describing the
expression pattern of Pax6 in addition transgenic reporter mice. As discussed in
Chapter 1 the alternative method of generating a reporter mouse by homologous
recombination in ES cells to introduce the reporter gene (more commonly known as
"knock-in") could not be used in this case because it would disturb one of the
endogenous Pax6 loci, resulting in the small eye phenotype,
Further analysis of the truncated lines
From the PCR analysis both DTyl 123.22 and DTyl 123.42 seem to have integrated
at least 65kb of the YAC but probably less than 150kb. The exact truncations in both
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case need to be established. I would suggest using southern blot analysis with first a
Pax6 cDNA probe to confirm all of the PAX6 locus has incorporated. Genomic
DNA isolated from the founder will contain both the endogenous Pax6 DNA and the
YAC DNA. Comparing the sequences of the two reveals that there are differences in
the distribution of restriction enzyme sites in the intronic regions. Digestion of the
founder genomic DNA with these restriction enzymes prior to Southern blotting with
the Pax6 cDNA will reveal two distinct patterns. One for the endogenous Pax6 and
one for the human PAX6. Analysis of this will confirm if all of the Pax6 locus is
there. Once it is established the extent of the PAX6 locus that has been integrated
short probes spaced every 50kb from the 5' and 3' ends should be used to establish
the extent of the incorporated YAC. Once this is established finer tuning could be
used to find the exact amount of the YAC integrated..
In line Y1123.22, no GFP expression was observed in the eye. There are several eye
enhancers and regulatory elements with the Pax6 locus, e.g. NRE (Kammandel et al.
1999; Xu et al. 1999). If the Southern analysis confirms that most of the PAX6 locus
has incorporated then it must be assumed that these particular eye regulatory
elements are present. As was discussed in Chapter 1 there are several long range
elements that have been identified. These have mostly been identified in the human,
(Fantes et al. 1995; Crolla et al. 1996; Lauderdale et al. 2000). Aniridia is typically
diagnosed by an eye phenotype. Hence, all of these cases will have an eye
phenotype. However, the fact that there are humans with eye phenotypes who have
mutations, in some case several hundred kb 3' demonstrates there are eye regulatory
elements this far away. Box 123 that is lOOkb away from the 3' end of Pax6 has been
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shown to contain an 800bp regulatory element, Box3 that directs LacZ expression in
transgenic mice specifically in the neural retina(Griffin et al. 2002). Interestingly, it
did not have expression in the lens or cornea(Griffin et al. 2002). Box 123 also
contains regulatory elements that have been shown to direct LacZ in other subparts of
the Pax6 expression pattern (Griffin et al. 2002). It is possible that there is
redundancy with control elements, which is why the central nervous system
expression seemed intact. However, further more detail analysis of this expression
pattern may identify sub sets of cells (possibly at particular developmental time
points) that are missing. It would also be interesting to look at the olfactory system in
the truncated lines since Box 123 also contains an olfactory regulatory
element(Griffin et al. 2002).
Pax6 Reporter mouse might not report all Pax6 expression
It is important to realise that the 'Pax6 reporter' mouse might not report all Pax6
expressing cells. The GFP was placed into the protein translation start site in exon 4.
So it will work with mRNA transcripts produced from the promoters P0 and PI that
begin transcription in exon 4. However, there is some evidence emerging that Pax6
may have several different mRNA transcripts that contain different potential protein
translation start sites. The putative additional possible ATG translation start sites are
downstream from the ATG in exon 4(Carriere et al. 1995). As discussed in Chapter 1
some of the putative start sites have been demonstrated to make potential protein
using in vitro translation assays. However, this has still not been demonstrated in
vivo. In addition, there is also the recently identified potential antisense transcript
(Anderson et al. 2002).
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The putative sense translation start sites that are downstream from exon 4 would all
produce potential protein that initiates after the reporter construct. This means firstly,
the reporter would probably fail to report cells that are producing protein only using
one or a combination of these downstream translation start sites. Secondly, the
modified YAC has been designed to not produce Pax6 protein (the exact mechanism
by which this works is discussed in Chapter 2) when a protein is initiated from the
translational start site in exon 4. If translation was to occur from the putative
downstream translational start sites then protein would be produced. This protein
could rescue part of the Small eye phenotype in Pax6 Se>'Ed/Se>'Ed mice. However,
firstly the possible ATG sites have not been demonstrated to work in vivo yet and it
would have been too complicated to address all of these sites. To design the YAC so
that there is no possibility of PAX6 being produced would mean introducing many
translational stop sites. This would have made an already ambitious transgenic
project harder. It would have also meant changing the coding sequence to make the
stop sites and this would have had possible effect on Pax6 regulation. Secondly, it is
important to remember that all of the Pax6 reporter transgenic lines generated, apart
from the GFP, have a normal eye phenotype.
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New experimental avenues made available by the reporter mouse
The primary goal of this study, as set out in the aims section of Chapter 1, was to be
able to identify discrete Pax6 expressing cells in vivo that were able to express Pax6
irrespective of the status of the endogenous Pax6 gene and use these to identify Pax6
downstream targets. As a prerequisite I have generated a novel transgenic mouse, a
"Pax6 reporter" mouse that is designed to serve this purpose.
Aim 1: Demonstrate that using a 420kb YAC containing the human PAX6 contains
enough of the regulatory Pax6 elements to drive GFP expression to recapitulate the
Pax6 expression pattern in developing mouse embryos.
The GFP expression mostly matches the Pax6 mRNA and protein expression seen
before at this range of ages in both DTyl 123.54 and DTy374.001. The only
expression that needs further investigation is in the ganglionic eminence, and the
further work that I would suggest has been discussed above. Once I had identified a
suitable Pax6 reporter line I intended to study the characteristics of these cells, and in
the aims section of Chapter 1 I described a list of hypotheses based on these cells.
Flowever, due to time constraints I have been unable to address these hypotheses.
Some of the initial avenues now available have already been discussed above. With
regard to the aims set out in the introduction I will speculate what can now be
undertaken.
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Aim 2: Examine changes in target gene expression using micro arrays in discrete
FACS sorted populations of Pax6 expressing cells depending on changes to Pax6
status.
Initially I would cross the reporter mouse with Pax6SeyEd/+. Then I would
cross the combined (Pax6 Reporter: Pax6SeyEd/+) heterozygotes with
Pax6SeyEdand collect embryos over developmental stages. The reason for
not intercrossing the combined heterozygotes is it will increase the number of
reporter YACs. By having a range of number of YACs in each mouse this has
the possibility of interfering with the analysis. Primarily I am interested in
changes in gene expression in the central nervous system. This could be
approached by discretely dissecting parts of the central nervous tissue, e.g.
telencephalon, or using the whole central nervous system. Simultaneously I
would collect one of the limbs separately, this tissue will be used to isolate
DNA and confirm the genotype of the embryo. With the isolated tissue, e.g.
the whole central nervous system I would dissociate the cells, a potential
protocol is the Worthington Papain dissociation system (Lakewood, NJ,
USA). This system uses proteolytic enzymes to dissociate the tissue, this have
been widely used in cell dissociation previously(FIuettner and Baughman
1986). Once a solution of suspended cells has been isolated separately from
each embryo I would run it through a FACS to cell sort the cells into bins of
cells. The FACS machine will be optimised to generate two bins of cells. One
is GFP positive. The other is not. In the embryos that do not have the Pax6
reporter only one bin will be generated, GFP negative. The exact setting of
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the forward and reverse scatter and the gates on the FACS machine will have
to be optimised empirically. I would not fix the cells because I think the
fixing process could interfere with the GFP signal. Once a FACS protocol has
been established I would use it for the entire litter, and subsequent litters. A
cross of Pax6SeyEd/+:Pax6 Reporter with Pax6SeyEd/+ will yield embryos with














Not present Pax6 +/+ 12.5% 1.5
Not present Pax6 +A 25% 3
Not present *Pax6 "A 12.5% 1.5
One copy Pax6 +/+ 12.5% 1.5
One copy Pax6 +A 25% 3
One copy Pax6 "A 12.5% 1.5
Table 5.3. Table of the expected outcomes of a Pax6SeyEd/+: Pax6
Reporter cross with Pax6SeyEd/+. (* Analysis possible until near birth.)
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The Pax6 status of the embryo is established from DNA isolated from the
limb that is simultaneously isolated prior to papain dissociation. Once the
bins are isolated I would collect mRNA from them and use it to hybridise to
micro arrays to analyse changes in gene expression. Depending on the status
of Pax6 the gene expression is expected to change. A number of litters would
have to be collected to get statistically significant numbers. However, I would
run each embryo as a separate sample rather than pool embryos with the same
genotype, and then identify genes that have changes in expression in all of the
embryos with the same genotype. The embryos that do not have the Pax6
reporter are controls for the ones that do. If the initially dissections do not
yield significant results I would consider doing dissections of individual
tissues, parts of the cortex, etc.
The experiment I would first like to use these crosses for is to investigate the
general role of Pax6 in the developing cortex. I would dissect the cortex from
El 4.5 embryos and collect bins of cells as described in Table 5.4. Examining
the global changes of downstream gene expression by micro array between
1A, 2A, and 3 A will identify what are the downstream targets of Pax6 protein
in the El4.5 cortex. This will help to understand what the role of Pax6 is in
the developing cortex. It would also be interesting to collect the cortex from
earlier embryos and contrast the changes since it has already been shown that
in Pax6"/_ El 1 embryos there is already a dorsal to ventral transformation in











































Table5.4ofbinscellsintere tfr mhossPax6+~.Pax6ReportermiceandPax6+' .(*Analy isp s ibleu tila birth).
too difficult at the ages before El 1 then I will have to accept that a certain
amount of regionalisation has already taken place by El4.5.
Alternatively, this could also be used to examine a few specific down stream
targets of Pax6, for instance investigating the downstream targets in
determining neurogenic potential in the developing cortex. It has been
previously suggested that the neurogenic potential in Pax6 mutant cortices is
reduced and that cortical radial glial cells express fax^Heins et al. 2002). By
collecting the cortex from E14.5 embryos a change in the radial glial
"markers" such as RC2 and the astrocyte-specific glutamate transporter
(GLAST) verses neuron "specific" markers such as P-tubulin III could be
investigated. The bin la cells will have upstream signals activating Pax6
which in turn leads to the Pax6 protein potentially altering the expression of
RC2, GLAST, and P-tubulin III consistent with a cell lineage fate. The bin 3a
cells will have the upstream signals activating Pax6, however the Pax6
protein will not able to alter RC2, GLAST, and p-tubulin III gene expression
consistent with the lineage fate. Hence, this will enable me to investigate if
Pax6 has a role in neurogenic lineage fate determination in the developing
cortex.
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Aim 3: Demonstrate auto regulation in discrete isolated cells that are expressing
Pax6 using FACS to identify and sort the cells capable of Pax6 expression and to
quantify the number and amount of fluorescence.
I would use similar crosses that were designed for Aim 2, see Table 5.3.
Primarily I am interested in autoregulation in the central nervous system, but
autoregulation of Pax6 has only ever been previously reported in the eye so it
would be prudent to start with just the eye. Once 1 have established this
system works in the eye I could continue by discretely dissecting other tissue,
or using the whole head. For very early embryos the whole embryo could be
used. Similar to Aim 2 I would simultaneously collect unwanted tissue, such
as one of the limbs, separately to use to confirm the genotype of the embryo
and I would use the same dissociation system. However, once a solution of
suspended cells has been isolated I would run it through a FACS system to
analyse the cells but this time I wouldn't collect the cells I would just count
them. I would set the FACS machine to plot the forward scatter of the cells
against fluorescence intensity. Initially I would calibrate the machine to
subtract auto fluorescence, so the fluorescence measured is the GFP signal.
These exact setting of the forward and reverse scatter and the gates will have
to be optimised empirically. Again I would not fix the cells because I think
the fixing process could interfere with the GFP signal. Once a FACS protocol
has been established I would use it for the entire litter and subsequent litters.
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Again the embryos that do not have the Pax6 reporter are controls for the
ones that do. With this whole range of Pax6 status I will be able to establish:
a) If the absolute number of cells expressing Pax6 changes with Pax6 status.
b) If the same number of cells are expressing Pax6 but at a different expression
level.
If these dissections do not yield significant results I would consider doing
dissections of individual tissues, part of the forebrain, etc. In addition, I would
consider crossing the Pax6 reporter with PAX77. This transgenic line contains 5-
10 copies of the YAC Y593 containing human PAX6(Schedl et al. 1996). When
PAX77 transgenic mice were crossed with Small eye mice it rescued the eye
phenotype in mice that were heterozygous and homozygous mutants for
endogenous Pax6. In addition, analysis of the offspring of the cross that have the
genotype PAX77:Pax6+/+ demonstrated a similar eye phenotype to Small
eye(Schedl et al. 1996). This suggests the number of copies of Pax6, both a
minimum and a maximum, is important for correct eye development. Once I had
generated the mice with the genotype PAX77:Pax6 Reporter I would cross these
onto a Pax6+/" background. And finally once these were established I would cross
this PAX77: Pax6 ~:Pax6 Reporter with PAX77: Pax6 +~ this would give mice
with a complete range of different numbers of Pax6 and PAX77, Table 5.5 has a

















PAX7T/':Pax6 A One copy *Pax6 "A Not present 0
PAX7T/~:Pax6+/~ One copy Pax6 +/- Not present 1
PAX7T':Pax6+/+ One copy Pax6 +/+ Not present 2
PAX7T':Pax6 A One copy Pax6 v" PAX77 heterozygous 5
PAX77+,':Pax6+/' One copy Pax6 +A PAX77 heterozygous 6
PAX77+/:Pax6w+ One copy Pax6 +/+ PAX77 heterozygous 7
PAX77*/+:Pax "A One copy Pax6 A PAX77 homozygous 10
PAX77+/+:Pax6+/~ One copy Pax6 +A PAX77 homozygous 11
PAX77+/+:Pax6+/+ One copy Pax6 +/+ PAX77 homozygous 12
Table 5.5. Table of the number of copies of Pax6 and PAX77 from crosses of
PAX77: Pax6 +':Pax6 Reporter with PAX77: Pax6 +". For convenience only
the embryos that have the Pax6 reporter are given. The controls would have
identical genotypes but without the Pax6 reporter (* Analysis possible until
near birth.).
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Once these embryos were available I would investigate autoregulation for
each genotype and see how it fits with the number of functional Pax6 and
PAX6 genes. Again litter mates with identical genotypes except for the
presence of the Pax6 reporter would be identified and used as controls.
It is important to note that YAC Y593 was the starting point for the Pax6
reporter mouse so in order to genotype the crosses between PAX77 and the
Pax6 reporter I would design PCR primers that span where the reporter
cassette pDTl is inserted. I would use a second set of genotyping primers for
GFP. This should enable the genotypes of all the embryos to be identified. In
addition, the primers would be designed to produce a product of
approximately 250bp, thus they could be used with qPCR to genotyping the
number of copies of PAX77.
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Conclusion
Two of the nine transgenic lines generated (DTyl 123.54 and DTy374.001) have
incorporated the majority of the YAC and predominantly successfully report the
Pax6 expression pattern at the developmental stages investigated. Therefore, these
two lines can be used as 'Pax6 reporters' to investigate the function of Pax6.
Two of the lines (DTyl 123.22 and DTyl 123.42) incorporated part of the YAC. Both
of these incorporated a functional GFP reporter cassette and both express some GFP.
As discussed above it would be interesting to further investigate these lines and see
where the truncation in the YAC is and the chromosomal location of the incorporated
YAC.
Further analysis of the three remaining viable lines is still necessary (DTy3 74.028,
DTy374.226, and DTy374.227). It is anticipated that DTy374.226, which appears to
have incorporated the majority of the YAC, will have a GFP expression pattern
similar to DTyl 123.54 and DTy374.001.
A major difference was observed in GFP expression between DTyl 123.22 and
DTyl 123.42 which both have incorporated truncated YACs. Therefore, it seems
likely that the GFP expression in DTy374.028 and DTy374.227, which have both
incorporated truncated YACs, the GFP expression will be unpredictable. However, it
is none the less still very interesting. The mechanisms behind why some of these
transgenic lines that lack the majority of the YAC fail to fully report Pax6 expression
could give insights into the regulation of the Pax6 gene.
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Appendix A.
Molecular Biology Materials and Reagents.
General purpose molecular biology reagents were purchased from Sigma UK, Fisher
UK, and Merck UK.
Agarose for gel electrophoresis
Seakem LE Agarose Cambrex Bioscience, UK)
Bacterial culture media and antibiotics
LB tablets (Sigma UK)
Ampicillin (Roche UK)
50mg/ml dissolved in ddLLO and stored at -20°C. It was diluted 1000 fold to
working concentration of 50pg/ml in LB or LB-agar.
Enzymes for molecular biology
DNA Restriction enzymes
These were purchased from New England Biolabs (US), Roche UK, and
Amersham Pharmacia UK and used according to manufacturers guidelines.
DNA modifying enzymes
Cloned Pfu polymerase (Stratagene, La Jolla, CA, USA)





Plasmid mini prep kit (Qiagen, UK)
Plasmid midi prep kit (Qiagen)
Qiaex II gel extraction system (Qiagen)
High Prime DNA labelling kit (Roche)
Oligonucleotides
The oligonucleotides were designed using PRIMER3 software (Whitehead Institute















Primers to check PAX6 5' homology arm joins TauGFP correctly
FUSIONFOR ACTTTGTTTCAAGCCCCAAA
FUSIONREV CCCTGAGCATGATCTTCCAT




















Primers to confirm pDT1 has integrated correctly in YAC

































Tail tip lysis buffer (TTLB): 200mM Tris pH 8, 200mM NaCl, 5mM EDTA, 0.2%
SDS
Southern Blotting and hybridisation
32P-a-dCTP for radiolabeled probe preparation was purchased from ICN (Ohio US)
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Southern denaturing solution: 0.5M NaOH
Southern neutralising solution: 0.5M Tris, 3M NaCl, pH 7.0
20xSSC: 3M NaCl, 0.3M sodium citrate
Church Solution: 0.5M NaP04, 7% SDS, ImM EDTA, 1% BSA, pH7.2
Church Wash: 40mM NaP04, 1% SDS, ImM EDTA, pH7.2
Nylon membrane (positively charged) (Roche)
Yeast reagents
-AT drop out yeast medium














Make up to 1 litre, autoclave, and store protected from the light at 4°C.
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Appendix B.
YAC purification and isolation protocols.
Protocol 1: Preparation of High Density Plugs Protocol A
(Protocol from Dr Andreas Schedl, Institute of Human Genetics, University of
Newcastle upon Tyne)
1. 10ml of -AT drop out medium was inoculated with the frozen stock of the
yeast colony containing the YAC and incubated at 30°C for 16 hours in a
shaking incubator.
2. The 10ml starter culture was poured into 500ml of -AT drop out medium and
incubated for 2-3 days at 30°C in a shaking incubator.
3. A 2.5ml solution of 1% Seaplaque GTG LMP agarose in SE buffer was
prepared. SE buffer was 1M sorbitol, 20mM EDTA pH 8.0, 14mM P-
mercapto-ethanol was added. The agarose solution was kept at 42°C until use.
2mg/ml Zymolyase was added immediately before use.
4. The yeast culture was centrifuged at 3000g for 5 min to pellet the cells. The
supernatant was discarded and the pellet was resuspended in 50ml SE buffer.
This was repeated 3 times.
5. After the last washing step, the supernatant was discarded and all liquid was
carefully removed. The cell pellet was approximately 1 to 1.5 ml.
6. 200pl of SE buffer was added to the pellet and mixed.
7. The yeast cell suspension was heated to 37°C and added 50:50 to the LMP
agarose and mixed by pipetting up and down using a blue cut off tip. The
solution was kept at 42°C at all times to avoid setting of the agarose.
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8. The plug moulds were prepared and placed on ice.
9. Using a cut off yellow tip pipette 100 pi aliquots of the mixture was added to
the plug mould. The mixture was left for 30 mins to allow the agarose to set.
10. The plugs were transferred into SE buffer containing 14mM (3-mercapto-
ethanol and 1 mg/ml Zymolyase and incubated at 37°C for 4 to 6h.
11. The buffer was replaced with 0.2M EDTA, 0.1M Tris pH8.0, 0.5M NaCl, 1%
SDS, 0.5M (3-mercapto-ethanol and 1 mg/ml proteinase K using 0.5 ml/ plug
and incubated at 37°C overnight.
12. The following day the plugs were washed extensively in TE pH8.0 until no
more bubbles (from the SDS solution) could be seen. The plugs were stored
in 0.5 M EDTA at 4°C until needed.
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Protocol 2: Preparation of YAC DNA for Pronuclear Injection Protocol (4%
Concentrator Gel Method)
(Protocol from Dr Andreas Schedl, Institute of Human Genetics, University of
Newcastle upon Tyne)
1. A 1% agarose gel made in 0.5xTAE was poured with a long continuous slot
for a well.
2. The agarose plugs were loaded end-to-end in the well. Any trapped air
bubbles were released using a pipette tip.
3. The plugs were covered with 1% agarose made in 0.5% TAE.
4. Once the agarose had solidified the PFG was run. The optimal settings were
worked out by trial and error to separate the YAC from the endogenous
chromosomes. For the 426 kb Y1123 and Y374 YACs, the running buffer was
0.5% TAE, kept at 4°C, running at 200 V, with an initial pulse of 23 seconds
and a final pulse of 40 seconds. The gel was run for 24 hours.
5. Once the gel had finished. A small amount of the two edges of the gel were
removed and stained with 50pl of lOmg/ml Ethidium Bromide for 30 minutes
with very gentle agitation at room temperature.
6. Under UV light the precise location of the YAC chromosomal, upper, and
lower chromosome bands were marked with a blade.
7. The PFG was reassembled using the marks to identify the location of the
YAC, upper, and lower chromosomes. Three agarose slices containing the
three chromosomes were excised using a clean glass cover slip as a blade.
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8. The isolated gel slices containing the YAC, the upper and lower chromosomes
were turned through 90° and a 4% low melting point agarose gel cast around
them.
9. This concentrating gel was run overnight at 30 V in 0.5% TAE at 4°C with the
buffer re-circulated.
10. The gel was then cut into three longitudinal sections and the upper and lower
chromosomes stained with EtBr.
11. Visualisation with UV light showed the location of the compacted bands of
the upper and lower chromosomes.
12. Using these as markers the location of the compacted YAC DNA was
identified and the band excised.
13. The agarose slice was equilibrated in the following buffer for 2 hours at 4°C
(lOmM Tris-HCl pH7.5, ImM EDTA, lOOmM NaCl, 30pM spermine, 70pM
spermidine).
14. The buffer was removed and the gel slice weighed.
15. The slice was melted at 68°C for 5 minutes.
16. Then the gel slice was placed at 40°C for 5 minutes.
17. 2U agarase (NEB) per lOOmg of agarose slice was added.
18. The gel slice was incubated at 40°C for 3 hours.
19. The tube containing the digested agarose was placed at 4°C for several hours.
If the slice was not completely digested it was re-melted.
20. A Petri dish with 40 ml of Microinjection Buffer (lOmM Tris-HCl pH7.5,
O.lmM EDTA, lOOmM NaCl, 30pM spermine, 70pM spermidine) was
prepared.
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21. The YAC DNA solution was carefully pipetted into the centre of the filter by
transferring with a yellow cut off tip.
22. The solution was dialyzed for 1 hour at 4°C.
23. The YAC DNA solution was removed with a cut off yellow tip and stored at
4°C.
24. The integrity of the YAC DNA was verified by running an aliquot of the DNA
on a PFG alongside a yeast plug.
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Protocol 3: Preparation of High Density Plugs Protocol B
(Protocol from Dr Simon Fisher, Oxford University)
1. 10ml of -AT drop out medium was inoculated with the frozen stock of the
yeast colony containing the YAC and incubated at 30°C for 16 hours in a
shaking incubator.
2. The 10ml starter culture was poured into 500ml of -AT drop out medium and
incubated for 2-3 days at 30°C in a shaking incubator.
3. A 1.2% Seaplaque GTG LMP agarose solution was prepared in buffer
containing (1M sorbitol, 20mM EDTA, 14.4mM (3-mercaptoethanol) and kept
at 42°C until used.
4. The culture was centrifuged at 3000g for 5 min to pellet the cells. The
supernatant was discarded and the pellet was resuspend in 20ml of 50mM
EDTA pH8.0.
5. The cells were centrifuged again at 3000g for 5 min to pellet the cells and the
supernatant was discarded.
6. The cells were resuspended in 2ml buffer (1M sorbitol, 20mM EDTA,
14.4mM (3-mercaptoethanol, 2mg/ml Zymolyase).
7. The plug moulds were prepared and placed on ice.
8. The cell suspension solution was mixed 50:50 with the LMP agarose
solution.
9. This solution was transferred into the plug moulds and left on ice to allow the
agarose to set.
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10. The plugs were transferred into a buffer containing (1M sorbitol, 20mM
EDTA, 14.4mM (3-mercaptoethanol, lOmM Tris-Cl pH7.5, 2mg/ml
Zymolyase) and incubated at 37°C for 2h with gentle shaking.
11. The solution was replaced with 25ml of the buffer (lOOmM EDTA, lOmM
Tris-Cl pH8.0, 1% lithium dodecyl sulphate) and incubated at 37°C for 30-
60mins.
12. The solution was replaced with 25ml of fresh buffer (lOOmM EDTA, lOmM
Tris-Cl pH8.0, 1% lithium dodecyl sulphate) and incubated at 37°C
overnight.
13. The next day the solution was replaced with 25ml of the buffer (lOOmM
EDTA, lOmM Tris-Cl pH8.0, 1% lithium dodecyl sulphate) and stored at
room temperature until needed.
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Protocol 4: Preparation of High Density Plugs Protocol C
(Protocol from Dr Clare Huxley, Imperial College School of Medicine)
1. 10ml of -AT drop out medium was inoculated with the frozen stock of the
yeast colony containing the YAC and incubated at 30°C for 16 hours in a
shaking incubator.
2. The 10ml starter culture was poured into 500ml of -AT drop out medium and
incubated for 2-3 days at 30°C in a shaking incubator.
3. The culture was centrifuged at 1000 g for 5 minutes and the supernatant
discarded.
4. The cells were resuspended in 40 ml of 50 mM EDTA.
5. The cells were then again centrifuged at 1000 g for 5 minutes and the
supernatant discarded.
6. The pellet was resuspended in 100 ml of 1M sorbitol, 20 mM EDTA pH 8.0, 4
mM (3-mercaptoethanol.
7. The cells were centrifuged at 1000 g for 5 minutes and all the supernatant
carefully discarded.
8. Enzyme solution (1M sorbitol, 20 mM EDTA pH 8.0, 4 mM P-
mercaptoethanol, 2 mg/ml Zymolyase) was added. This was mixed well and
warmed briefly to 40°C.
9. Agarose Solution (2% SeaPlaque GTG LMP agarose in 1M sorbitol, 20 mM
EDTA pH 8.0 was prepared. 14mM p-mercaptoethanol was added to the
agarose solution once it was melted.
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10. The molten agarose solution was added to the yeast cell solution at a ratio of
40:60 and mixed.
11. The solution was poured into the pre-chilled plug mould.
12. The plugs were allowed to set for 1 hour on ice.
13. The plugs were transferred to 50ml 1 M sorbitol, 20 mM EDTA pH 8.0, 10
mM Tris pH 7.5, 14 mM P-mercaptoethanol, 2 mg/ml Zymolyase and
incubated at 37°C for 2 hours with agitation.
14. The solution was replaced with 50ml 1% lithium dodecyl sulphate, 100 mM
EDTA pH 8.0, 10 mM Tris pH 8.0 and incubated at 37°C for 1 hour with
agitation.
15. The solution was replaced with 1% lithium dodecyl sulphate, 100 mM EDTA
pH 8.0, 10 mM Tris pH 8.0 and incubated at 37°C overnight with agitation.
16. The next day the solution was replace with fresh 1% lithium dodecyl sulphate,
100 mM EDTA pH 8.0, 10 mM Tris pH 8.0for several hours, and incubated at
37°C with agitation.
17. The plugs were washed in 50 ml of NDS solution (lOOmM EDTA, 1.7mM
Tris-Base, 68mM N-laurylsarcosine (Sigma), pH 8.0) for 2 hrs at room
temperature with agitation.
18. This wash was repeated three times.
19. The plugs were stored at 4°C in NDS solution. Prior to use the plugs were
washed in lx for several hours.
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Protocol 5: Preparation of YAC DNA for Pronuclear Injection (Spin Column
method)
Dr Lluls Montoliu (Campus de la Universidad Autonoma de Madrid, Spain)
Part I: Preparation of high density plugs
1. 10ml of -AT drop out medium was inoculated with the frozen stock of the
yeast colony containing the YAC and incubated at 30°C for 16 hours in a
shaking incubator.
2. The 10ml starter culture was poured into 500ml of -AT drop out medium and
incubated for 2-3 days at 30°C in a shaking incubator.
3. The culture was centrifuged at 600 g for 5 minutes and the supernatant
discarded.
4. The cells were resuspended in 50 mM EDTA.
5. The cells were then again centrifuged at 600 g for 5 minutes and the
supernatant discarded. The pellet was resuspended again in 10 ml 50 mM of
EDTA.
6. The culture was centrifuged at 600 g for 5 minutes and the supernatant
discarded.
7. The pellet was warmed briefly to 37°C and enough prewarmed enzyme
solution (1M sorbitol, 20mM EDTA pH 8.0, 14 mM P-mercaptoethanol, 2
mg/ml Zymolyase) added to give a final concentration of 8x109 yeast cells/
ml. The cells were carefully resuspended.
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8. An equal volume of agarose solution (1M sorbitol, 20mM EDTA pH 8.0, 2%
SeaPlaque GTG LMP agarose, 14mM (3-mercaptoethanol) was added to give
a 50:50 ratio.
9. The solution was poured into prechilled plug moulds and allowed to set on
ice.
10. The plugs were transferred to wash solution (1M sorbitol, 20mM EDTA pEI
8.0, 10 mM Tris-HCl, 14mM (3-mercaptoethanol, 2 mg/ml Zymolyase and
incubated at 37°C for 2-3 hours with gentle agitation.
11. The solution was carefully poured off and 50ml 1% dodecyl lithium sulphate,
100 mM EDTA pH 8.0, 10 mM Tris-lTCl pH 8.0 added. The plugs were
incubated at 37°C with gentle agitation for at least 1 hour.
12. The buffer was poured off and replaced with fresh buffer and incubated
overnight at 37°C with gentle agitation.
13. The plugs were washed in 50 ml of NDS solution (lOOmM EDTA, 1.7mM
Tris-Base, 68mM N-laurylsarcosine (Sigma), pEI 8.0) for 2 hrs at room
temperature with agitation.
14. This wash was repeated three times.
15. The plugs were stored at 4°C in NDS solution. Prior to use the plugs were
washed in lxTAE for several hours.
Part II: Purification of YAC DNA for microinjection
16. A 1% SeaPlaque GTG (FMC) LMP PFGE gel was poured with a long
continuous slot for a well.
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17. Six plugs were loaded end-to-end in the well. Any trapped air bubbles were
released using a pipette tip.
18. The plugs were covered with 1% SeaPlaque GTG LMP agarose made in 1%
TAE.
19. Once the agarose had solidified the PFG was run. The optimal settings were
worked out by trial and error to separate the YAC from the endogenous
chromosomes. For the 426 kb Y1123 or Y374, the running buffer was 1%
TAE, 4°C, running at 200 V, with an initial pulse of 23 seconds and a final
pulse of 40 seconds. The gel was run for 26 hours.
20. Once the gel had finished, a small amount of the two edges of the gel were
removed and stained with 50pl of lOmg/ml Ethidium Bromide for 30 minutes
with very gentle agitation at room temperature.
21. Under UV light the precise location of the YAC chromosomal band was
marked with a blade.
22. The PFG was reassembled using the marks to identify the location of the
YAC chromosome. The YAC containing agarose slice was excised using a
clean glass cover slip as a blade.
23. The agarose slice was equilibrated in the following buffer for a minimum of 2
hours at 4°C: (10 m Bis-Tris-HCl pH 6.5, 0.1 mM EDTA, 100 mM NaCl
30pM Spermine, 70 pM Spermidine).
24. The buffer was removed and the gel slice weighed.
25. The slice was melted at 65°C for 10 minutes.
26. 1U agarase (NEB) per lOOmg of agarose slice was added.
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27. The gel slice was incubated at 40°C for 2 to 3 hours.
28. The tube was then centrifuged at 15,000g for 20 minutes to get rid of
undigested agarose bits.
29. 400 pi of the digested agarose with YAC DNA was carefully pipetted into the
upper reservoir of a Millipore ultrafiltration Unit (Millipore).
30. The column was centrifuged for two min at 3000g.
31. The centrifugation was repeated until 300-320 pi had passed through the
membrane.
32. The tube was left to stand at 4°C overnight.
33. Some of the YAC DNA was possibly still attached to the surface of the
membrane so it was removed by pipetting up and down with a cut-off yellow
tip once or twice very carefully. Then the entire solution was removed.
34. A Petri dish with 40 ml of Microinjection Buffer (10 mM Tris-HCl pH 7.5,
0.1 mM EDTA pH 8.0, 100 mM NaCl, 30pM Spermine, 70pM Spermidine)
was prepared.
35. A Millipore dialysis filter (Millipore) with a pore size of 0.05pm was floated
on the surface of the buffer.
36. The YAC DNA solution was carefully pipetted into the centre of the filter by
transferring with a yellow cut off tip.
37. The solution was dialyzed for two to three hours at 4°C.
38. The YAC DNA solution was removed with a cut off yellow tip and stored at
4°C.
39. The integrity of the YAC DNA was verified by running an aliquot of the
DNA on a PFG alongside a yeast plug.
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Protocol 6: Isolation of YAC DNA for Pronuclear Injection
(Protocol from Dr Clare Huxley, Imperial College School of Medicine, UK)
1. Agarose plugs were prepared as described previously, see Protocol 4:
Preparation of High Density Plugs Protocol C.
2. Six agarose plugs were equilibrated in lxTBE for several hours before use.
3. A 1% SeaPlaque GTG (FMC) LMP PFGE agarose gel made in lxTBE was
poured with a long continuous slot for a well.
4. The six equilibrated plugs were loaded end-to-end in the well. Any trapped air
bubbles were released using a pipette tip.
5. The plugs were covered with 1% SeaPlaque GTG LMP agarose made in 1%
TBE.
6. Once the agarose had solidified the PFG was run. The optimal settings were
worked out by trial and error to separate the YAC from the endogenous
chromosomes. For the 426 kb Y1123, the running buffer was 1% TBE, kept at
4°C, running at 200 V, with an initial pulse of 23 seconds and a final pulse of
40 seconds. The gel was run for 48 hours.
7. Once the gel had finished, a small amount of the two edges of the gel were
removed and stained with 50pl of lOmg/ml Ethidium Bromide for 30 minutes
with very gentle agitation at room temperature.
8. Under UV light the precise location of the YAC chromosomal band was
marked with a blade.
234
9. The PFG was reassembled using the marks to identify the location of the YAC
chromosome. The YAC containing agarose slice was excised using a clean
glass cover slip as a blade.
10. The agarose slice was equilibrated in the following buffer overnight at 4°C: 10
mM Bis-Tris-HCl pH 6.5, 0.2 mM EDTA, 100 mM NaCl made up in embryo
quality water (Sigma).
11. The buffer was removed and the gel slice weighed.
12. The slice was melted at 68°C for 10 minutes.
13. Then the gel slice was placed at 40°C for 5 minutes.
14. 1U agarase (NEB) per lOOmg of agarose slice was added.
15. The gel slice was incubated at 40°C for 2 hours.
16. The tube was then centrifuged at 6225g for 20 minutes to get rid of undigested
agarose bits.
17. 400 pi of embryo quality water was pipetted into the upper reservoir of a
Millipore Ultrafree-MC 30,000 NMWL Filter Unit (Millipore).
18. The column was centrifuged for five minutes at 3000g and the water
discarded. This was to prepare the column.
19. 400 pi of the digested agarose with YAC DNA was carefully pipetted into the
upper reservoir of the column and centrifuged for five minutes at 3000g.
20. The centrifugation was repeated until approximately 300 pi had passed
through the membrane.
21. The tube was left to stand at 4°C overnight.
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22. Some of the YAC DNA was possibly still attached to the surface of the
membrane so it was removed by pipetting up and down with a cut-off yellow
tip once or twice very carefully. Then the entire solution was removed.
23. A Petri dish with 40 ml of Microinjection Buffer (10 mM Tris-HCl pH 7.5,
0.2 mM EDTA pH 8.0, 100 mM NaCl) was prepared.
24. A Millipore dialysis filter (Millipore) with a pore size of 0.05pm was floated
on the surface of the buffer and left to equilibrate for several hours at 4°C.
25. The filters were carefully transferred to fresh microinjection buffer.
26. The YAC DNA solution was carefully pipetted into the centre of the filter by
transferring with a yellow cut off tip.
27. The solution was dialyzed overnight at 4°C.
28. The YAC DNA solution was removed with a cut off yellow tip and stored at
4°C.
The integrity of the YAC DNA was verified by running an aliquot of the DNA on a
PFG alongside a yeast plug.
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Appendix C
Modified Lithium Acetate Yeast Transformation
(Modified from Elble R (1992) Biotechniques 13(1): 18-20)
1. The culture is grown in yeast selective media at 30°C overnight.
2. The overnight culture was spun down, using 1ml of cells for each transformation.
3. The supernatant was poured away, leaving cells and 40-100pl of liquid.
4. 2pl of lOmg/ml carrier DNA (Salmon sperm) was added. The cells were then
resuspended with the pipette tip.
5. lpg of the plasmid was added (pDTl).
6. The solution was vortexd briefly.
7. 0.5 ml of PLATE mixture was added
8. The solution was then vortexed again briefly
9. 20pl of 1.0M DTT was added.
10. The solution was then vortexed briefly.
11. The solution was then incubated at room temperature overnight. (The number of
transformants increases linearly over time; where 24 hours gives 4-fold more than 6
hours. In practice 2 hours is sufficient.)
12. The cells were then heat shocked for 10 min at 42°C.
13. 50-1 OOpil of the cells in PLATE mixture were removed.
14. The cells were then plated (50pl and 5pl aliquots, using a drop of sterile ddEhO if
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In recent years, GFP has proven to
be a valuable tool in many biological
systems. Wild-type GFP has a major
absorption in the UV region at 398 nm
and a minor absorption in the blue re¬
gion at 475 nm (3). Recently, several
groups have independently carried out
amino acid modifications of the GFP
protein and have optimized these opti¬
cal characteristics (6). For a compre¬
hensive review on the photophysical
behavior of GFP and GFP mutants, see
Reference 7. Two widely used mutant
forms of GFP, eGFP (BD Biosciences
Clontech, Palo Alto, CA, USA) and
mmGFP6 (6), have greatly enhanced
absorbance at 475 nm, thus allowing
excitation with blue light alone.
Many lines of transgenic mice ex¬
pressing GFP and GFP fusion proteins
have been described. Commonly, such
mice are maintained by intercrossing of
heterozygotes. a breeding strategy that
necessitates the identi fication of trans¬
genic and non-transgenic progeny. In
animals that express GFP widely, this
can be done by examining tissue under
a suitable fluorescence microscope.
Small pieces of tissue removed from
animals during ear-notching (for identi¬
fication purposes) are suitable. Howev¬
er. this approach has several draw¬
backs. Ear-notching is an invasive
procedure that must be performed un¬
der appropriate animal husbandry prac¬
tise, is open to errors ofmisidentifying
from which mice biopsies have come,
and is a relatively time-consuming way
of screening large numbers of litters. In
addition, ears are not sufficiently devel¬
oped to allow ear-notching before
around three weeks of age.
Previously, a genotyping protocol
has been described that uses a UV light
source and filters to visualize GFP in ex¬
posed tissue (1). Using this as a starting
point, we investigated the possibility of
using blue light excitation of GFP as a
means to genotype GFP organisms. As a
model, we used the tauGFP expressing
transgenic line TgTP6.3 developed in
our laboratory (4). These animals ex¬
press a fusion protein in which GFP is
joined to the microtubule-binding pro¬
tein tau. The transgene is expressed at
high levels and in most tissues. We de¬
cided not to use UV light, since we
wanted to identify the GFP fluorescence
in living animals and UV light is a haz¬
ard to both the operator and the animals.
In addition, there were a number of oth¬
er criteria for our GFP visualization
equipment. We wanted it to be (i) nonin¬
vasive, (ii) easily brought in to the ani¬
mal care facility, (iii) amenable to disin¬
fection, (iv) quick to use (without
significant warm-up time), (v) to be
readily available, and (vi) inexpensive.
A survey of commercially avail¬
able macroscopic GFP visualization
equipment found that the cheapest
was more than $1100 for a system that
satisfies points i, ii, iii, and iv, and v.
However, these systems are designed
to high specifications that far exceed
our requirements.
Blue light GFP visualization works
by illuminating the tissue with light
with a peak intensity' at 475 nm and a
steep decline in intensity at other wave¬
lengths. Thus, the greatest possible
amount of light from extraneous wave¬
lengths is excluded. This is usually
achieved by using an appropriate filter.
The tissue is then visualized through a
second barrier filter that excludes the
blue light and passes only the emitted
green fluorescent light. This is typically
achieved using a filter that cuts out
light from wavelengths less than 500
nm. These filters should also help to re¬
duce the background autofluorescence.
A "homemade" system for GFP de¬
tection has been previously described
(5). This system used a single blue light
emitting diode (LED) to visualize GFP
in E. coh* transformed with a GFP con¬
taining plasm id. However, we consid¬
ered that a single blue LED would be
unlikely to generate enough light to ex¬
cite GFP to detectable levels in the
transgenic animals in vivo. In addition,
this system used a photomultiplier tube
(PMT) to convert photons to an electri¬
cal signal for computer analysis. PMTs
are sensitive detectors for low-intensity
applications such as fluorescence and
typically can create millions of elec¬
trons for each photoelectron detected.
This suggests that without the PMT am¬
plification the GFP signal would not be
strong enough from a single blue LED.
We have identified a commercially
available blue LED flashlight
(Inova X5 : Emissive Energy, War¬
wick, RI, USA) with an emission wave¬
length of 470 nm. However, there are
many available, and any blue LED
flashlight with a wavelength of 470 nm
would be suitable. The flashlight used
here has five blue LEDs. Blue LEDs are
also available from many semiconduc¬
tor suppliers and a homemade flashlight
could be produced. Several different
types of blue LED are available. The
compounds used in the LED manufac¬
ture govern the wavelength of the light.
The majority of gallium nitride and in¬
dium gallium nitride on AI2O3 LEDs
have a peak wavelength of around 470
nm: the exact wavelength is given in the
f igur e 1. Using a flashlight to visualize GFP in GFP-transgenic animals. (A) Schematic diagram of
the GFP visualization system. (B) Photograph ofa non-transgenic and transgenic newborn pup (top) tak¬
en using our system described here. The photograph was taken using a digital camera (Ricoh, Tokyo,
Japan) with type 12 filter (Eastman Kodak) placed in front of the camera. The room in which this was
done had no overhead illumination.
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Benchmarks
manufacturer's specifications.
Onto the front of the flashlight we
have attached a Kodak® Polymax Filter
PC3 (Eastman Kodak, Rochester, NY,
USA), and we observe mice through a
Kodak Wratten Gelatin Filter 12 (Sig¬
ma, Poole, UK). Details of the exact
specifications for the filters are avail¬
able from Eastman Kodak (2). Filter
PC'3 is no longer available on its own,
but an equivalent is available as part of
either the Kodak Polymax filter set or
the ILFORD Multigrade filter set IV
(ILFORD. Cheshire. UK). Any of the
higher-contrast filters in the sets will
work. Figure 1A illustrates the GFP vi¬
sualization setup. Filter PC3 restricts
the emitted light to around 475 nm, and
filter 12 cuts out light below about 500
nm. These filters are not of a high
enough quality for high-magnification
photoinicrographic work; however, for
the purpose of identifying GFP ex¬
pressing animals, they are acceptable.
Figure 1B demonstrates the readily vis¬
ible difference between transgenic and
non-transgenic littermates. Using this
system, we can identify transgenic ani¬
mals immediately after birth. Indeed,
the optimum time for identification of
many transgenic mice is in the first
week before hair grows. After the hair
has grown, GFP-expressing tissue is
still visible (e.g., parts of the nose and
feet), but the effect in these areas is not
as pronounced.
The system that we have described
here fulfills all of our criteria for a GFP
visualization system. It is noninvasive.
The system is portable and so can be
transported and used in an animal care
facility with little logistical difficulties.
The flashlight identified here is also
waterproof and so is easily disinfected.
The system requires no warm-up or
cool-down period. The components are
readily available, and it is relatively in¬
expensive. The setup described here
costs less than $160.
From ethical, time-saving, and fi¬
nancial points ofview, it is important to
optimize the efficiency of breeding
transgenic animals. As more and more
laboratories make use of existing GFP
transgenic animals, and more GFP
transgenics are made, the importance of
more effective screening will increase.
We feel that the system described here
will not be limited to genotyping wide¬
ly or ubiquitously expressing GFP-
transgenic mice but could probably be
used for any GFP transgenic organism
where the GFP protein is visible. The
protein could be expressed either some¬
where on the organism's surface or in
superficial internal organs visible
through the skin.
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Pax6 is a member of an evolutionary conserved family of
transcription factors. It is developmental^ regulated and is required
for the normal embryonic development of the central nervous
system, eye and pancreas. Pax6 mutations in the mouse result in the
Small eye {Sey) phenotype. Heterozygous mice have eye defects and
homozygotes die immediately after birth lacking eyes, nasal cavities
and with severe brain abnormalities, including a malformed cerebral
cortex. Recent work has established that there are changes in
expression of cell adhesion molecules and these may underlie at
least a part of the Pax6So,/Sey phenotype. Here we used cell trans¬
plants and explant cultures to investigate the role of Pax6 in cell
adhesion. Pax6Sev'Sey embryonic cortical cells transplanted into
wild-type embryonic cortex were observed to segregate from wild-
type cells and form dense clusters. Cells migrating from explants of
Pax6Sev:Sey embryonic cortex clustered to a greater extent than cells
migrating from wild-type controls. These new data support
the hypothesis that Pax6 exerts a cell-autonomous effect on the
adhesiveness of cortical cells.
Introduction
Pax6 is a member of a family of transcription factors charac¬
terized by the presence of an N-terminal 128 amino acid DNA
binding domain, the paired box. This domain is divided into two
helical sub-domains called PA1 and RED that can each bind DNA
independently (fun and Desplan, 1996). At least nine murine and
human paired box genes have been identified to date (Callaerts
et al., 1997). Separated from the paired box by a 78 amino acid
glycine-rich linker sequence is a second 60 amino acid DNA
binding domain, the homeobox. These two domains can interact
independently and cooperatively with DNA. At the G-terminal of
Pax6 is a 153 amino acid proline-serine-threonine rich domain
that is thought to be the transcriptional regulatory element.
Pax6 is expressed in the retina, lens and cornea of the
developing vertebrate eye (Walther and Gruss, 1991; Grindley et
al„ 1995). It is also expressed at a range of developmental stages
in regions of the forebrain, hindbrain, cerebellum, the ventral
neural tube and the pancreatic islet ceils (Walther and Gruss,
1991; Stoykova and Gruss, 1994; Grindley etal., 1995; St-Onge et
at.. 1997; Warren and Price, 1997; Kioussi et a!., 1999). Humans
heterozygous for mutations in PAX6 suffer from aniridia (iris
hypoplasia), which is associated with cataracts, lens dislocation,
foveal dysplasia, optic nerve hypoplasia and nystagmus (Jordan
et al., 1992; Glaser et al., 1994). The vast majority (92%) of
known PAX6 mutations in humans are nonsense mutations
(Hanson et a/., 1999). Interestingly, there are a few cases where
the mutation has been found several hundred kilobases away
from the PAX6 transcriptional start site (Fames el a/., 1995;
Lauderdale et at., 2000), demonstrating the presence of distant
regulatory domains. A rare case of an infant with a compound
heterozygous mutation in PAX6suffered severe craniofacial and
central nervous system defects, had no eyes, no adrenal glands,
and died neonatally, a phenotype similar to the homozygous null
mutation in mice (Glaser et a!., 1994).
Pax6 mutation in the mouse results in the Small eye (Sey)
phenotype. At least eight alleles of Pax6 have been identified in
the mouse so far and all are similar loss-of-function mutants
(Glaser etal., 1990; Hill et al., 1991; St-Onge et al., 1997; Lyon el
al., 2000). It is unclear whether these alleles are complete nulls
but they will be referred to here as Pax6~'~. A premature stop
codon in the linker domain generates the l'ax(?*ylM allele (Hill et
al., 1991) Heterozygous mice have a reduced eye size, iris hypo¬
plasia, corneal opacification, and cataracts. Homozygotes die
immediately after birth with no eyes, no nasal structures and
severe brain abnormalities, including malformed cerebral cortex
(Hogan etal., 1986; Hill et al., 1991; Schmahl et al., 1993; Caric
et a!., 1997). The diencephalic equivalent is reduced in size, is
not differentiated to a normal extent (Stoykova et a!., 1996;
Warren and Price, 1997), and fails to innervate the cortex (Pratt
et al., 2000). As in the human, distant regulatory modules have
been shown to be essential for the correct expression pattern of
Pax6 (Kleinjan etal., 2001).
A Rolefor Pax6 in Cortical Development
In normal development of the mouse, neurogenesis occurs from
embryonic day 12 (El2) to E18 (Gillies and Price, 1993; Levers et
a!., 2001). At these ages, the lateral ventricle is lined by a
population of cells in a region called the ventricular zone, which
gives rise to most neurones and glial cells of the mammalian
cortex. These cortical precursor cells are not a homogeneous
population and there is mounting evidence that different pre¬
cursor cells generate different differentiated cell types (Grove et
al.. 1993; Luskin et al., 1993; ReiAetal., 1995; Tan etal., 1998;
Ileins et a!., 2002). The mechanisms controlling the fates of
these precursor cells are not yet elucidated.
Nuclei of ventricular progenitor cells undergo dynamic intra¬
cellular migration during the cell cycle. Nuclei move away from
the apical surface during Gl, occupy the outer half of the
ventricular zone during S phase and return apical ty in G2 so that
mitosis occurs at the ventricular surface (Sidman et al., 1959;
Fujita, 1964). Neurons exit the cell cycle in contact with radial
glial fibres to migrate into more superficial positions. When
neurons reach the top of the cortical plate they detach and
associate into layers with cohorts of a similar birth date. This
results in the cortex being formed in an inside-out' laminar
fashion. After neural production has finished, astrocytes and
oligodendrocytes are produced in large numbers from pre¬
cursors in the subventricular zone (Gleeson and Walsh, 2000;
Morrison, 2000).
In Paxfr' mice both the cortical ventricular zone and the
subventricular zone are enlarged (Schmahl et a!.. 1993; Stoykova
et al., 1996; Caric et al.. 1997). In addition, the cortical plate is
thinner and within the intermediate zone (i.e. between the
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subventricular zone and cortical plate) there arc large collections
of cells characteristic of those in the subventricular zone.
Cumulative labelling with bromodeoxyuricline (Brdll) has
revealed that proliferative rates in the early Pax6 embryonic
cortex increase (Estivill-Torrus et at., 2002). In addition, pro¬
liferating cells in S phase are found scattered throughout the
ventricular zone, suggesting either a failure in interkinetic
nuclear migration or asynchronous cycling of precursor cells in
the mutant cortex (Gotz elal., 1998; Estivill-Torrus eta/., 2002).
Birthdating studies with Brdli in vivo show that many later-born
neurons fail to migrate to the cortical plate and accumulate in the
subventricular zone (Caric et al., 1997). Immunohistochemical
analysis of neuron-specific class III P-tubulin isotype (Tujl), an
early marker for postmitotic neurons (Lee et al., 1990), has
shown that cells in Pax6~!~ mutant cortices that fail to migrate do
begin neuronal differentiation (Caric et al., 1997). There is a
similar defect in Small eye rats (rSey): the E20 cortices have an
abnormal clustering of cells in the ventricular and intermediate
zones of the cortex (Fukuda et al., 2000).
Not all cells in the ventricular zone express Pax6; rather,
expression appears to be localized to a subset of radial glial cells
(Gotz etal., 1998). In Pax6~'~ embryos, the morphology of radial
glial cells is altered. At E15.5, wild-type radial glia have straight
processes running towards the pial surface whereas mutant
radial glial processes appear wavy and have frequent small
extrusions and branches (Gotz et al., 1998). Co-culture experi¬
ments mixing El 3.5 Pax6~ ~ cortical cells and wild-type cells
failed to rescue the phenotype of mutant radial glial cells,
suggesting that the defect may be cell-autonomous (Gcitz et al..
1998). Work over the past few years has shown that radial glial
cells are able to generate not only glial cells but also neurons
(Campbell and Gotz. 2002). In cultures of Pax6 radial glial
cells, less neural clones and more non-neural clones were
produced than in cultures of wild-type radial glial cells (Heins et
al., 2002). Furthermore, in vivo quantification showed a 50%
reduction of radial glial-derived neurons in the Pax6 cortex at
El4 and F.16 (Heitis et al., 2002). Infecting cells from E14
Pax6~'~ cortex with a retroviral vector containing full length
Pax6 cDNA increased the number of differentiated neurons and
appeared to reduce proliferation (Iieins et al., 2002). These
findings suggest that Pax6 may play a cell-autonomous role
driving radial glial cells to produce cells of a neuronal fate.
Some defects in the developing central nervous system of
Pax6~'~ embryos are not due to a direct cell-autonomous require¬
ment for Pax6 in the affected process. Transplantation of Pax6~'~
cortical precursors into a wild-type cortical environment can
rescue their migrational defect, suggesting that it may be
secondary to defects of other cells such as radial glia which
normally guide migration (Caric et al.. 1997). Abnormally
high levels of cell death among late-embryonic Pax6 ' dorsal
thalamic cells are most likely secondary to the inability of these
cells to obtain trophic support from the cerebral cortex, to
which they do not connect (Lotto etal., 2001).
Here, we present new data on experiments to test whether
Pax(> has a cell-autonomous role regulating cell adhesion in the
developing cortex. We examined the behaviour of Pax6~'~
cortical cells when they were either transplanted into wild-type
cortex or cultured as explants. The rationale behind the first
approach was that embedding the mutant cells in a wild-type
environment would reveal their cell-autonomous defects and
ameliorate any defects that might arise in mutant embryos as a
secondary consequence of abnormalities in other cells. The
explant approach provided a means of testing the adhesive
properties of mutant cortical cells in isolation from other cell
types or from wild-type cells.
Materials and Methods
Animals
All mouse embryos were derived from P«x6SlT'i'heterozygote crosses and
were genotyped as previously described (Hogan et at, 1986; Hill et at..
1991; Caric et at. 1997). Wild-type Long-Evans hooded rats were
obtained from external suppliers. The day of the vaginal plug following
mating was designated 1:0.5.
Transplants
Pax6~'~ and wild-type embryos were obtained from pregnant mice that
had been injected on E15.5 with BrdU (70 gg/g in sterile saline i.p.) 1 It
prior to death by cervical dislocation. The embryonic cerebral neo-
cortices were isolated and dissociated as described by Caric et al. (Caric
et at., 1997). Viabilities of dissociated ceils were assessed by trypan blue
exclusion and were -95%. E15.5 pregnant rats were anaesthetized with
ketamine (60 mg/kg i.m,) and xylazine (6 mg/kg i.m.), and dissociated
mouse cells were injected into the telencephalic vesicles using methods
described before (Caric etal., 1997). The rats recovered and gave birth as
normal. Their young were deeply anaesthetized with sodium pento¬
barbitone (1 mg i.p.) on postnatal day 7 (P7) and perfused transcardially
with 4% paraformaldehyde. Wax sections were cut and reacted to reveal
BrdlJ labelling, as described previously (Gillies and Price, 1993).
Explant Cultures
E13.5 or El5.5 wild-type and Pax6~" neocortex was obtained as
described above, sectioned parasagittal^" and divided into anterior,
middle and posterior thirds. Anterior (A) and posterior (P) thirds were
cut into pieces and placed in 9 * 9 mm wells on chambered eoverglass
slides coated with poiy(L)-lvsine and laminin in serum-free medium
(Lotto and Price, 1999). Wild-type and Pax(>~' diencephalon from brains
of the same age were dissected and added to the wells such that tissue was
co-cultured in the following combinations, (i) Both wild-type A and P
cortex were cultured with either wild-type or mutant diencephalon (four
combinations); (ii) both mutant A and P cortex were cultured with either
wild-type or mutant diencephalon (four combinations). Diencephalic
explains were included since it is known that factors from this tissue,
which interacts with the cortex in vivo, are required to ensure the
survival, growth and migration of cortical cells (Lotto and Price, 1996;
Price and Lotto, 1996; Lotto et al., 1999; Edgar and Price. 2001). Cortical
explants in contact with diencephalic tissue, or which became
innervated by processes that grew from die diencephalon, were excluded
from the analyses. For each age, the expiant cultures were set up using
three separate wild-type and Pax6 brains (in three independent experi¬
ments). After 24 h in culture, digital images of five randomly selected
explants in each culture well were recorded. Explants were fixed in 4%
paraformaldehyde and immunostained with antibodies using standard
techniques.
Analysis ofClumping In Vivo and In Vitro
We observed differences in the degree of clumping of mutant and
wild-type cells that had integrated into the wild-type cortex or migrated
out of cultured explants. These differences were analysed quantitatively.
For analysis of the distributions of transplanted cells in vivo, a series
of l-in-10 sections through die cortex were examined and every BrdU
labelled cell was scored for whether it had another BrdU labelled cell
within 1, 2, 3. 4 or >4 nuclear diameters of it. The percentages of cells
within each of the five categories were calculated from six transplants of
mutant or eight transplants of wild-type cells.
To quantify clumping of cells migrating from cortical explants in
culture, explant images were analysed using an IPLab script (Scanalytics
Inc., Fairfax, VA). Measurements were made by defining a series of
concentric rings of equal width surrounding the explant. calculating their
area and counting the numbers of touching and non-touching cells in
each ring. A measure of the degree to which cells clump together, fc.
independent of cell density, was obtained, /<: is calculated based on the
expected proportion of isolated cells (cells not touching another cell)
tinder the null hypothesis that cells are distributed randomly around an
Cerebral Cortex Jun 2003, V 13 N 6 613
100
□ +/+B -/-
<1 <2 <3 <4
Distance (nuclear diameters)
Figure 1. Results of transplants of E15.5 BrdU labelled wild-type or Pax6~h cortical cells into E15.5 rat brains, examined at P7. (A) Camera lucida drawings of three parasagittal
sections from brains that had received wild-type cells. The position of each labelled cell is marked with a small dot; broken lines mark the deep edge of layer 6. (S) Camera lucida
drawings of two parasagittal sections from brains that had received mutant cells. Labelled cells were found in a small number of dense clusters, such as that outlined with a box. (C)
Photomicrograph of the boxed area in 8: scale bar, 50pm. (0) Histogram showing the proportions of labelled ceils lying <1, <2, <3, <4 or >4 nuclear diameters from another
labelled eel! in sections through the P7 rat cortex. Labelled cells were either wild-type or mutant and values are means ± SEMs. Around 500 cells per brain from eight wild-type and
six mutant transplants were counted. Abbreviations: Ant, anterior; Lat, lateral; Med, medial; Post, posterior; ctx, cortex.
explant. A scale of clumping is produced where A = 0 if all cells are
isolated (not touching another cell), /<: = «<= if all cells are touching one or
more other cells, and A; ■ 1 if the proportion of isolated cells is equal to
that expected under the null hypothesis that cells are randomly
distributed. Tile model was subjected to tests for validity and shown to
produce a measure of clumping that fulfilled the criteria for analysis of
variance [ANOVA; A. Carothers, described by Pearson (Pearson, 1999)].
Results
Transplants
Figure XA-C shows examples of the distributions of wild type
and Pax6~" BrdU labelled (on E15.5) cortical cells in P7 wild-
type cortex following transplants at E15.5. As shown before,
both mutant and wild-type cells migrated preferentially to the
superficial layers of the cortex, a location that was appropriate
for their birthdate (Caric et a/., 1997). Genotype had a cleat-
effect on their tangential distribution. Wild-type cells were
scattered throughout the cortex (Fig. 1 A) whereas mutant cells
were found in a small number of very dense clusters (Fig. 1 B.O-
These clusters were found throughout the rostrocaudal extent of
the cortex. Combining quantitative data from eight wild-type
and six mutant transplants showed that the vast majority of
mutant, cells were found within a single nuclear diameter
of another mutant cell, whereas most transplanted wild-type
cells were separated by much greater distances from other
transplanted wild-type cells (Fig. ID). The total numbers of
transplanted mutant and wild-type cells identified in the analysis
were comparable and represented tiny proportions of the overall
numbers of cells in the recipient cortices. Analysis of trans¬
planted wild-type and Pax6~'~ cells labelled with fluorescent
dyes revealed that they adopted neuronal morphologies and
appeared viable (Caric et a/., 1997).
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Figure 2. Results of explant cultures of E13.5 and El 5.5 cerebral cortex. |A, 8) Expiants of wild-type and mutant explants at E13.5. Arrows in S point to clusters of cells that had
migrated away from the explant. Scale bar, 50p.m. (C, D) Average/c values ! • SEMsi frqm wild-type and mutant expiants at E13.5 and E15.5, co-cultured with either wild-type or
mutant diencephalon.
Explant Cultures
After 24 h in culture, both wild-type and Pax6~~ cortical ex-
plants had extended numerous processes and cells had migrated
out from the explain body (Fig. 2A,S). A striking difference in
behaviour between cells from the wild-type and mutant tissue
was observed. Whereas wild type cells migrated individually or
in association with one or two other cells (Fig. 2,4). many mutant
cells migrated together in streams and formed distinct clusters
away from the body of the explant (Fig. 2B). ANOVA on values
of/c revealed that, at both E13.5 and E 15.5, clumping was
significantly greater in ceils migrating from mutant than from
wild-type cortical expiants (P < 0.001) (Fig. 2C.D). The analysis
revealed no significant difference between co-culturing El3.5 or
E15.5 expiants (whether wild-type or mutant) with wild-type or
mutant diencephalic tissue (Fig. 2C..D). This indicates that the
clumping phenotype of Pax6~'~ cortical cells is regulated in¬
dependently of thalamic factors. Cellular clumping was not
significantly different between anterior and posterior cortical
expiants at either age examined (data were combined for Fig.
2C,D). There were no differences in rates of cell death in
expiants of different genotypes (counts of dead cells were made
on the basis of nuclear morphology after staining with fluores¬
cent nuclear stains).
Immunostaining of cells migrating from the expiants was
performed to evaluate the cell types involved. Antibody Tujl
stains the earliest born postmitotic neurons. Its use revealed
that many cells migrating from both wild-type and mutant
expiants were neuronal and that some, but not all, cellular
clumps contained neurons (Fig. 3.4,/>). Staining with an antibody
against phosphorylated histone H3 marks metaphase cells
(Estivill-Torrus el al., 2002). This antibody revealed that most
cell division occurred in the body of both wild-type and Pax6'1
expiants and very rarely within clumped cells, indicating that
the clumps were not due to cell division after migration (Fig.
3C.D). Finally, RC2 antibody revealed radial glial cells extending
front both wild-type and mutant expiants and, in both strains,
some cells appeared to be migrating along them (Fig. 3E,F).
Discussion
The new data presented here indicate that Pax6 regulates the
adhesive properties of cortical neurons. The transplant experi¬
ments show that cortical cells lacking Pax6 segregate from
wild-type cells and form dense clusters, pointing to a difference
in the cell surface properties of mutant and wild-type cells. The
in vitro experiments indicate that Pax6~'~ cortical cells have an
increased tendency to aggregate with each other even in the
absence of wild-type cells. This suggests that the cell-surface
molecules whose expression is affected by Pax6 include cell
adhesion molecules that regulate the absolute adhesiveness of
cortical cells. The role of Pax6 in controlling these cellular
properties appears to be cell-autonomous. Given the funda¬
mental importance of cell adhesion in developmental processes,
a defect of cell adhesion in Pax6~'~ cells is likely to underlie
many of the defective processes in mutant embryos.
Regulation ofCell Adhesion by Pax6
Other studies have indicated abnormalities in the adhesive
properties of Pax&' cortical cells. Cortical cells express Pax6
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Figure 3. Cultures of El 3.5 wild-type and mutant cortex stained with TuJ1 (A, B), phosphorylated histone H3 [C. 0) and RC2 If, F). Arrows in A and B indicate individual TuJ1 -labelled
cells; arrowhead indicates a cluster of such cells. Scale bar: A and 8,15 gm; C-F, 30 jim.
whereas striatal cells do not and when cells from El2.5 to El4.5
wild-type cortex and striatum are co-cultured in a short-term
assay they segregate strongly from eaeh other (Stoykova et al.,
1997; Gotz el al.. 1996). Pax6~ ~ cortical and striatal cells,
however, segregate only weak ly from eaeh other (Stoykova et al.,
1997). Pax6~'~ cortical cells segregate from wild-type cortical
cells but Pax6'h striatal ceils mix with wild-type striatal cells
(Stoykova et al., 1997). These results suggest that Pax6 regulates
the adhesive properties of cells in the telencephalic region
where it is expressed, i.e. the cerebral cortex.
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The expression patterns of some adhesion molecules are
altered in Pax6~'~ forebrains. Expression of the extracellular
matrix molecule tenascin-C (TN-Q at the cortico-striatal
boundary is abolished and the expression of calcium dependent
adhesion molecules, cadherins, is altered in the cortex (Stoykova
el al., 1997; Bishop et al., 2000). The expression domain of the
homophilic adhesion molecule R-cadherin and that of Pax6 have
some overlap (Ganzler and Redies, 1995; Matsunami and
Takeichi, 1995) and, in the absence of functional Pax6, ex¬
pression of R-cadherin mRNA is reduced considerably in areas
that normally show co-expression (Stoykova et al., 1997).
Loss of Pax6 also seems to have an effect on the cell surface in
E12.5-E135 mouse hindbrain. The migration of post mitotic
cells from the rhombic lip seems to be controlled in part by
Pax6, whose actions may be mediated by regulation of the netrin
receptor Unc5h3 (Engelkamp et a!., 1999), although alterations
in the polarity of cytoskeletal components may also be involved
(Yamasaki et al., 2001). In small eye rats there is impaired
migration of midbrain neural crest cells (Matsuo et at.. 1993;
Nagase et al., 2001). These cells use the frontonasal epithelium
as a scaffold for their migration and frontonasal epithelial cells
are known to express Pax6 (Matsuo et al., 1993). Within this
region the cell surface molecule HNK-1 carbohydrate epitope
and the gene encoding an enzyme for the synthesis of the HNK-1
epitope are expressed ectopically in small eye rats (Nagase el at.,
2001). This suggests that the impairment of migration may be
due in part to the inhibitory effect of the ectopically expressed
HNK-1 epitope.
Changes in the adhesive properties of other cell types that
express Pax6 have also been observed. Transgenic mice with an
altered ratio of expression of different splice variants of Pax6 in
the lens show a change in the expression of cell adhesion
molecules (Duncan et at., 2000). Expression of Pi20 catenin
(pl20"n), a member of the armadillo family of proteins
implicated in cell-cell adhesion and signal transduction, and
Paxillin, a focal adhesion adapter protein implicated in integrin
mediated signalling pathways, are highly elevated. Expression of
N cadherin and a-catenin are both slightly elevated, a5-integrin
and (31-integrin accumulate in lens although E cadherin and
(x6-integrin expression appears normal (Duncan et at., 2000).
Studies using microarravs of eye mRNA from various Pax6
over-expressing and null mutant cells have shown changes in the
expression of-400genes (Chauhan eta/., 2002). These included
Paralemmin and Tangerin A (Chauhan el at., 2002), which are
two putative ceil surface molecules thought to be important in
plasma membrane dynamics and cell process formation (Kutzleb
et at., 1998; Agassandian et al., 2000; Chauhan et al., 2002).
Changes in these cell surface molecules could also contribute to
the altered adhesion seen in Pax6 mutant cells.
Some experiments have suggested that Pax6 protein may
directly interact with the regulatory elements of genes encoding
adhesion molecules. The gene for neural cell adhesion molecule
(N-CAM) has a Pax6 paired-domain binding region within its
promoter (Hoist, et a!., 1997). In addition, Pax6 activates the
expression ofLl-luciferase reporter constructs in neuroblastoma
cells (Meech et al., 1999). Although this and other studies
suggests an interaction between Pax6 and the cell adhesion
molecule LI, which regulates axonal guidance and fasciculation
during development (Cbalepakis eta!., 1994; Meech et al., 1999;
Honig el at., 2002), the interaction is likely to be complex. For
example, the expression domains of Pax6 and LI only partially
overlap and it has been shown that there is no change in 1.1
expression in the intermediate, ventricular and subventricular
zones of E19 I'axO mice (Caric et al., 1997).
The expression pattern of Pax6 in the developing mouse eye
closely parallels that of the retinoic acid-responsive transcription
factor (AP-2«) (Koroma et al., 1997). Genes involved in cell-cell
and cell matrix adhesion have been shown to be regulated by
AP-2(x in vitro (Chalepakis et al., 1994; Fini etal., 1994; Chen et
at.. 1997; Hoist et al., 1997). For example, AP-2a is required for
activation of the E-cadherin promoter in epithelial cell cultures
(Behrens et al., 1991: Hennig eta!., 1996). Loss of AP-2w leads to
a change in Pax6 expression in the developing eye (West-Mays et
a!., 1999). The discovery of a number of possible binding sites
for AP-2a in the Pax6 promoter has generated the suggestion
that Pax6 may be a required intermediary step for AP-2a
controlled cell adhesion (Plaza et al., 1995).
Overall, our results and those of others provide compelling
evidence that a central role of Pax6 is to regulate cell-cell
interactions and adhesion at many sites in the developing
embryo, including the cerebral cortex. Further work is required
to elucidate the molecular pathways by which its influence on
the cell surface is mediated.
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